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GENERAl INTRODUCTION
IntroduCtIon
History of the Pancreas and Pancreatitis
The pancreas was apparently first described by Herophilus, a Greek anatomist and 
surgeon, who was born in 336 BC. Four hundred years later, Ruphos, in the 1st or 
2nd Century AD, an anatomist – surgeon of Ephesus, proposed the name “pancreas”. 
In Greek, the word means “all flesh”. Scientific study of the pancreas began in 1642, 
when Johann Georg Wirsüng, discovered the pancreatic duct in the San Francisco 
Monastery in Padua, Italy (Figure 1.). Wirsüng was murdered by a student the year 
after the discovery1. 
The history of “acute pancreatitis” probably starts with the fatal illness of Alexander 
the  Great  (323 BC)2. The first systematic analysis of acute pancreatitis was performed 
by Reginald Huber Fitz (1843-1913), a pathologistat the Massachusetts General 
Hospital. He published a landmark paper on acute pancreatitis in the Boston Medical 
and Surgical Journal in 18893. This study described the clinical characteristics of 53 
patients, distinguishing between the haemorrhagic, suppurative and gangrenous 
forms of the disease. He believed that acute pancreatitis was a complication of 
Figure 1  Imprint by Wirsung from a copper plate (1642)
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gastroduodenitis and ‘originates by the extension of a gastroduodenal inflammation 
along the pancreative duct’. It was Chiari who, in 1896, postulated that the underlying 
pathophysiological mechanism of the disease was pancreatic autodigestion-i.e. 
that the pancreas ‘succumbs to its own digestive properties’4.
definition and cause of pancreatitis
In this thesis, acute pancreatitis is defined as proposed in the 1992 Atlanta classification: 
“An acute inflammatory process of the pancreas with variable involvement of other 
regional tissues or remote organ systems, associated with raised pancreatic enzyme 
levels in blood and/or urine”5. Chronic pancreatitis is defined as a continuing 
inflammatory disease of the pancreas characterized by irreversible morphologic 
changes that typically cause pain and/or permanent loss of endo/exocrine function28.
epidemiology and etiology of acute pancreatitis
Worldwide the annual incidence rate of acute pancreatitis ranges from 5 to 80 per 
100.000 and tends to increase over time, with a reported case-fatality rate ranging 
from 3% to 10.7%6. In the Netherlands, the annual incidence is 19.2 per 1000007.
Sex is strongly associated with the risk of acute pancreatitis: the incidence of 
alcoholic pancreatitis is higher in men and the incidence of gallstone pancreatitis is 
higher in women6. The two major etiological factors responsible for acute pancreatitis 
are alcohol and cholelithiasis (gallstones) accounting for 70-80% of all cases6. 
Other etiologies are: abdominal injury, ischemia, surgery, ERCP +/- endoscopical 
sphincterotomy (ES), exacerbation of chronic pancreatitis, pancreatic cancer, 
anatomical variants of the pancreas/biliary system, autoimmune diseases, hyper-
lipidemia, hypocalcaemia, drugs, toxins, infections, genetic and idiopathic6.
new insights regarding acute pancreatitis
Recent papers report a higher incidence of non-biliary acute pancreatitis and an 
increased transition from acute pancreatitis to chronic pancreatitis in cigarette 
smokers8-16. More and more evidence is accumulating, regarding the influence of 
obesity on the incidence and course of the disease17-22. Therefore, smoking and 
obesity are important in patient’s management and pancreatitis research.
outlIne of tHe tHesIs
This thesis deals with two focus areas in pancreatology.
1. Clinical studies on acute biliary- and drug induced pancreatitis.
2. Clinico-morfological studies on pancreatic steatosis and pancreatic inflammation/ 
fibrosis.
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Part 1: Clinical studies: acute biliary pancreatitis and drug 
induced pancreatitis
A biliary origin is prevalent in the majority of cases presenting with acute pancreatitis. 
Unlike alcohol induced acute pancreatitis (the second most common cause of 
pancreatitis), biliary or gallstone pancreatitis can possible be treated by means of 
an endoscopical intervention: Endoscopic Retrograde Cholangiography- (ERC). 
The merits of this treatment are still debated in several studies, symposia and 
guidelines. In the first part, a review of the etiology, diagnosis, treatment and 
recurrence of ABP is presented (Chapter 1, 2 and 4). The opinion of Dutch gastro-
enterologists regarding the role of an early ERC and Endoscopic Sphincterotomy 
(ES) in acute biliary pancreatitis was studied by means of a national survey (Chapter 3). 
These studies combined with a prospective trial from the Dutch Acute Pancreatitis 
Group23 form the basis of the APEC-trial, a large nationwide prospective randomized 
trial comparing an emergency ERCP versus conservative treatment in ABP starting 
in 2013. This study will hopefully provide a definite answer regarding the role of 
early ERC in biliary pancreatitis.
Reports of drug-induced acute pancreatitis (AP) have been published since the 
1950s, and each year the list of drugs associated with AP expands. The etiology of 
drug-induced acute pancreatitis remains unclear. Even when a definite association 
has been demonstrated it is often impossible to determine whether only drug 
exposure or interaction with the underlying condition is the cause of pancreatitis 
(e.g. azathioprine and Crohns disease or pentamidine and HIV). Results from 
several reports point to a higher incidence of thiopurine induced acute pancreatitis 
in Crohn’s disease compared to ulcerative colitis or other disease24,25. The overall 
incidence probably ranges from between 1.2% and 1.4% of pancreatitis cases6,26. 
The drugs reported to be associated with the highest incidence of acute pancreatitis 
are: mesalazine (HR 3.5) azathioprine (HR 2.5), simvastatine (HR 1.8) and 
didanosine6. 
In a gastroenterology-liver patient population, thiopurines are used in various 
disease including Crohn’s disease, ulcerative colitis, undifferentiated colitis, micro- 
scopical colitis, refractory celiac disease, auto-immune hepatitis and pancreatitis. 
In chapter 5 we investigate the association proclaimed “disease associated 
sensitivity” to develop thiopurine induced acute pancreatitis in patients with Crohn’s 
disease compared to ulcerative colitis and vasculitis.
The interval between drug administration and the onset of acute pancreatitis differs 
depending on the drug, and therefore may be helpful in establishing a causal 
relation between drug and onset of pancreatitis. Certain drugs, such as paracetamol 
(acetaminophen), can cause pancreatitis after a single dose. Others, such as 
azathioprine, 6-mercaptopurine, metronidazole, aminosalicylates, and sulfonamides, 
14
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characteristically can cause acute pancreatitis within a month after exposure, while 
still others, such as pentamidine, valproic acid, and didanosine, appear to cause 
injury weeks or months after exposure, possibly through the accumulation of a toxic 
metabolite27. The interval time between starting thiopurines and the development of 
acute pancreatitis (latency-time) is studied in chapter 5.
Part 2: Clinicomorfological studies on pancreatic steatosis and 
inflammation/fibrosis
Pancreatic steatosis
Pancreatic steatosis was first described by Ogilvie in 193329. He observed an 
association between fatty infiltration of the pancreas and obesity: obese cadavers 
had 17% pancreatic fat, while lean cadavers had only 9% fat29. Other associations 
with pancreatic steatosis include: age, impaired glucose in tolerance / type 2 
diabetes mellitus,  hepatic steatosis and alcohol use30-32. In chapter 7 a review of 
the clinical associations/ impact and nomenclature of pancreatic fatty infiltration is 
given. 
Pitt postulated that central obesity leads to organ steatosis33. Like pancreatic 
steatosis, hepatic steatosis is related to obesity34. A more severe form of fatty 
infiltration of the liver is nonalcoholic steatohepatitis (NASH) which leads to cirrhosis 
in 20% of the patients34. In analogy of NASH, the identity “non-alcoholic steatopan-
creatitis (NASP)” could excist33. In chapter 6 the relation between NAFLD/ NASH 
and obesity versus the development of pancreatic steatosis (or NASP) is studied in 
a post-mortum histological study of both organs.
Obesity is associated with an increased risk of acute pancreatitis and an aggravated 
course of pancreatitis17-22. The mechanisms by which obesity increases the severity 
of acute pancreatitis are unclear. Several hypotheses have been suggested: 
(1) central obesity leads to organ steatosis and altered serum adipokines including 
reduced adiponectin and markedly elevated leptin. This abnormal adipokine milieu 
results in increased tissue infiltration of monocytes and macrophages which produce 
proinflammatory cytokines that alter organ function33; (2) Pancreatic injury leads to 
a massive release of pancreatic lipase that causes digestion of (peri)pancreatic 
adipose tissue, which becomes infiltrated by significant quantities of monocytes 
(inflamed and necrotic adipose tissue). Because adipocytes synthesize and secrete 
adipose-specific proteins (adipocytokines), such as adiponectin, leptin, and resistin, 
have potent immunomodulatory and metabolic activities, the metabolic and pro-
inflammatory changes seen in acute pancreatitis might be – at least in part – caused 
by these proteins35; (3) obese patients have an increased accumulation of fat within 
and around the pancreas where necrosis is often located36.
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It must be kept in mind that the incidence of (predicted severe) acute pancreatitis is 
increased in obese patients17-22. The observational studies and meta-analyses did 
not stratify for the predicted severity, which leads to an overrepresentation of obese 
patients with a predicted severe disease. This will eventually lead to a more severe 
course of acute pancreatitis in obese patients. In Chapter 8 we study the unselected 
true effect of obesity and several anthropometric parameters on the morbidity of 
acute pancreatitis in patients with a predicted severe acute pancreatitis.  
Pancreatic inflammation/ fibrosis
There is strong epidemiological evidence for cigarette smoking as a risk factor for 
pancreatic cancer. Smokers have a two- to three-fold risk compared to nonsmokers 
and the risk remains elevated up to two decades after cessation of smoking and 
lower the age of pancreatic cancer presentation37-40. Cigarette smoking is also an 
independent risk factor in the development of acute and chronic pancreatitis41,42. 
Furthermore, smoking accelerates the progression of chronic pancreatitis43,44. 
Malfertheiner contrived a theory that the risk of smoking for pancreatic cancer and 
chronic pancreatitis development can be reconciled by the fact that chronic 
pancreatitis independent of its etiology represents a pre-cancerous condition45. 
Hence, it is assumable that tobacco smoke induces chronic inflammation as a trigger 
for cancer development. His theory is confirmed by two observations on rat pancreata 
exposed to cigarette smoke. Both studies revealed clear signs  of inflammation 
after cigarette smoke exposition46,47.  Malfertheiner’s theory is tested in chapter 9, 
a post-mortum study, in which the extent of fibrosis was scored on the pancreata of 
smokers and non-smokers.  
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CHAPTER 1
ABstrACt
Establishing a biliary etiology in acute pancreatitis is clinically important because of 
the potential need for invasive treatment, such as endoscopic retrograde cholangio-
pancreatography.
The etiology of acute biliary pancreatitis (ABP) is multifactorial and complex. 
Passage of small gallbladder stones or biliary sludge through the ampulla of Vater 
seems to be important in the pathogenesis of ABP. Other factors, such as anatomical 
variations associated with an increased biliopancreatic reflux, bile and pancreatic 
juice exclusion from the duodenum, and genetic factors might contribute to the 
development of ABP.
A diagnosis of a biliary etiology in acute pancreatitis is supported by both laboratory 
and imaging investigations. An increased serum level of alanine aminotransferase 
(>1.0 μkat/l) is associated with a high probability of gallstone pancreatitis (positive 
predictive value 80–90%). Confirmation of choledocholithiasis is most accurately 
obtained using endoscopic ultrasonography (EUS) or magnetic resonance cholangio- 
pancreatography (MRCP). 
This Review discusses the pathogenesis of ABP and the clinical techniques used 
to predict and establish a biliary origin in patients with suspected ABP.
25
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Gallstones are present in 35–60% of patients with acute pancreatitis in the USA and 
Western Europe (1-3). Most cases of acute pancreatitis are mild and self-limiting; 
however, approximately  25% of patients with acute pancreatitis develop multiple 
organ failure and severe biliary pancreatitis, such as necrotizing pancreatitis (1-4). 
The overall worldwide mortality rate for acute pancreatitis ranges between 2% 
and 10% and has decreased since the 1970s and 1980s, presumably because 
of advances in intensive care support, the use of broad-spectrum antibiotics, 
percutaneous  drainage of infected peri-pancreatic collections and a decrease in 
the indiscriminate use of surgical procedures during the acute phase of the disease 
(1,5). 
The yearly incidence of acute biliary pancreatitis (ABP) is estimated to be 4.9–80.0 
cases per 100,000 people with distinct variation in people from different ethnic 
backgrounds—predominantly affecting white individuals and individuals with a 
Hispanic back- ground (5). Over the past decade, the incidence of ABP has 
increased by 35% in countries such as the Netherlands and the USA (5). The 
incidence of ABP is higher in women than in men (69% versus 31%), and increases 
with age (a greater than threefold increase in the incidence of ABP is observed at 
75 years of age compared with 20 years of age (5). 
Biliary pancreatitis is the first manifestation of gallstone disease in up to 40% of 
patients who do not have a preceding ‘warning’ episode of biliary colic (5). Between 
4% and 8% of patients with gallstones eventually develop biliary pancreatitis secondary 
to migratory gallstones (6). ABP potentially requires invasive treatment (that is, 
endoscopic retrograde  cholangiopancreato- graphy [ERCP]), demonstrating the clinical 
importance of establishing a biliary origin of acute pancreatitis. The controversial 
role of an emergency ERCP in ABP means that clear etiopathological insight and 
diagnosis of ABP are crucial for future intervention  studies on this disease. 
This review discusses the pathogenesis of ABP, including the role of genetics, ductal 
anatomy and ampullary obstruction in development of the disease. In addition, 
methods that predict and establish a biliary etiology in patients with suspected ABP 
(such as evaluations of serum biochemistry and imaging) will also be discussed.
revIew CrIterIA
This Review is based on the personal experience of the authors and literature 
accumulated over their years working on acute biliary pancreatitis. The authors 
compiled their literature lists independently, and searched the PubMed database 
for articles published between 1970 and 2009 using the terms “(gallstone OR 
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biliary) AND pancreatitis AND (prediction OR origin OR algorithm) NOT (chronic OR 
carcinoma OR autoimmune OR case report)”, which resulted in 407 hits, and 
“(gallstone OR biliary) AND pancreatitis AND (etiology OR etiology OR pathogenesis) 
NOT (carcinoma OR autoimmune OR case report)”, which resulted in 196 hits. The 
PubMed title and abstract results were scanned manually resulting in a possible 
120 articles of potential interest. Only full text papers in English, German and Dutch 
were reviewed. The reference lists of selected papers were examined for leads to 
relevant older literature.
PAtHoGenesIs
Investigations over the past 100 years have shown that the pathogenesis of ABP 
is multifaceted (Figure 1). The first association between gallstones and acute 
pancreatitis, was proposed by Bernard in 1856 (7). This hypothesis was supported 
by observations published in 1901 by Opie; he observed an impacted gallstone at 
the papilla of Vater (also known as the major duodenal papilla) in two patients with 
severe pancreatitis (8). In the same year, Halstead suggested that reflux of bile into 
the pancreatic duct caused pancreatitis in patients with cholelithiasis (9).
Figure 1  Pathogenesis of acute biliary pancreatitis
The pathogenesis of acute biliary pancreatitis is multifaceted. Anatomical, genetic and stone-related 
factors are all involved in the development of the disease. Passage of gallstones through the ampulla of 
Vater and the presence of mainly small gallstones can lead to ampullary spasm, fibrosis and obstruction 
of the hepatopancreatic ampulla. This obstruction can lead to biliopancreatic reflux and the exclusion of 
bile and pancreatic juices (which is further exacerbated by abnormal anatomy). Ultimately, elevated levels 
of bile and pancreatic juices and activation of pancreatic enzymes lead to pancreatitis. Abbreviation: BPJ, 
bile–pancreatic juice.
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Subsequently, in 1980, Acosta and colleagues proposed that pancreatic inflammation 
is aggravated by persistent ampullary obstruction  by gallstones (10). Additionally, 
a ‘multihit model’ was proposed by Neoptolemos, who postulated that repeated 
episodes of ampullary obstruction  by gallstones contribute to initiation of ABP (11).
Pancreatic duct obstruction
Gallstone impaction usually causes a transient obstruction; most of the offending 
stones migrate rapidly and can be found in the stool of patients with ABP (12,13). 
Studies in opossums have indicated that multiple changes to the pancreas, biliary 
tract and small intestine occur after biliary obstruction, including: acinar cell 
necrosis and pancreatic edema, increased pancreatic secretion (from the exocrine 
glands), increased levels of bile acid in the pancreatic juice, reduced myoelectric 
activity of the sphincter of Oddi and the duodenum, increased levels of bacterial 
trans location from the gut to the intestinal lymph nodes, endotoxemia, and 
blockade of the reticuloendothelial system (14–20). Interestingly, in animal models 
of pancreatitis, the above mentioned factors, did not cause severe necrotizing 
pancreatitis when experimentally combined with pancreatic duct obstruction. 
Experimental (15,21) and clinical (10,22–24) evidence demonstrates that ampullary 
obstruction by gallstones not only initiates, but also sustains and aggravates biliary 
pancreatitis. Gallstones in the common bile duct have been found in many patients 
who died from biliary necrotizing pancreatitis (25,26).  The exact mechanisms by 
which gallstones passage through the ampulla of Vater and then initiate pancreatic 
inflammation remains elusive. Biliary sludge containing minute calculi seem to 
cause no clinical harm as they pass the ampulla of vater, but both biliary sludge 
and microscopic granules have been shown to initiate acute idiopathic pancreatitis 
(27,28). However, only 2% of patients who have undergone extracorporeal lithotripsy 
of gallstones develop mild pancreatitis, irrespective of the initial size of the gallstone 
before therapy despite the fact that countless parts of fragmented gallstones pass 
the ampulla of Vater (29). even if the hepato-pancreatic ampulla is not obstructed 
by a sizable stone, the passage of sludge or small stones may induce local edema 
or a transient spasm of the ampulla of Vater that leads to temporary obstruction of 
the pancreatic duct. the causative role of transient obstruction by gallstones or 
biliary sludge in pancreatitis is supported by the observation that attacks of 
recurrent biliary pancreatitis are prevented or largely reduced by endoscopic 
sphincterotomy (29,30). These studies also demonstrate that endoscopic 
sphincterotomy can be used as an alternative to cholecystectomy in patients with 
biliary pancreatitis (30,31).
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duodenal exclusion of bile and pancreatic juice
In 1991, murayama et al (32). first reported a relationship between duodenal bile 
exclusion and exacerbation of acute pancreatitis as a result of their experiments in 
rats that had temporary obstruction of both the main pancreatic duct and the 
common bile duct (32).  The researchers observed increased serum levels of 
circulating cholecystokinin in rats with obstructions in both the main pancreatic 
duct and common bile duct compared to rats with an obstruction in the common 
bile duct alone. Only a combination of main pancreatic duct and common bile duct 
obstruction induced acute pancreatitis (33). In rats, cholecystokinin-releasing 
peptide is secreted into the duodenum and degraded by trypsin (34). A lack of 
trypsin (induced by ligation or obstruction of the main pancreatic duct) will cause 
an increased amount of cholecystokinin-releasing peptide and subsequent 
increased cholecystokinin production (34). Cholecystokinin acts on the CCKA- 
receptors and induces exocrine pancreatic juice production (35). Previously, 
discussions about the translation of the above mentioned physiological pathways 
to humans were questioned by the lack of evidence of direct cholecystokinin-in-
duced stimulation of human pancreatic acinar cells (36). However, in 2008, murphy 
et al.37 discovered that cholecystokinin has a direct effect on human pancreatic 
acinar cells and activates calcium signaling and stimulates enzyme secretion in 
these cells (37). Additionally, in experimental studies in rats, duodenal bile and 
pancreatic juice depletion combined with ampulla of vater obstruction causes 
stress on the acinar cell and results in an increased production of activated stress 
kinases (such as p38 mitogen- activate protein kinases and extracellular signal-
regulated kinases), which aggravates ABP (35,38–40).
Gallstone-related factors
Stone-related features have been identified as potential risk factors for the 
development of ABP, including small size (<2–5 mm), multiplicity, mulberry shape 
and irregular surface (41–48). Observations in humans indicate that small gallstones, 
excess cholesterol crystals in the gallbladder and good emptying of the gallbladder 
are particularly associated with an increased risk of pancreatitis (5,49). In a 
multivariate analysis of 143 patients with gallstones (43 patients with ABP; 100 
control patients without ABP), small gallstone diameter (that is, a diameter of ≤5 
mm), cystic duct width (that is, a diameter of >5 mm) and gallstone number (that is, 
≥20 gallstones) were shown to be substantial risk factors for ABP (50). All these 
factors relate to the ease by which gallstones are able to migrate from the gallbladder 
to the common bile duct and the number of stones that pass through the ampulla.
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Biliopancreatic reflux
In addition to obstruction causing an increase in intra-pancreatic pressure, reflux of 
infected bile (infected with bacteria such as Escherichia coli) into the pancreatic 
duct has been proposed to be a plausible mechanism through which pancreatitis 
is initiated (51).  Under physiological circumstances, the pressure in the pancreatic 
duct is threefold higher than in the common bile duct (52), thereby preventing reflux 
of bile into the pancreatic duct. During times of ampullary obstruction the pressure 
gradient between the biliary tree and the pancreatic duct may reverse (as 
demonstrated in rabbits) (53). The causative role of the composition of the refluxate 
has been investigated in animal studies (54,55) and in patients with pancreatic 
disorders (56,57). Sterile refluxate caused an increase in the permeability of the 
pancreatic ductal system via activation of pancreatic enzymes (54–56), whereas 
only infected bile (infected with Escherichia coli) or a mixture of pancreatic juice 
and bile caused pancreatitis (52).
ductal anatomy
The relationship between ductal anatomy, biliary origin, and severity of pancreatitis 
has not been studied extensively. Several anatomical factors have been linked to an 
increased incidence of ABP, including an enlarged common bile duct (>1.3 mm) 
and a wide angle between the bile duct and the pancreatic duct (37° versus 24° in 
patients with non-ABP choledocystolithiasis)(41).  Jones and colleagues found that 
67% of patients with aBP had a common pancreaticobiliary channel as opposed to 
32% of patients with cholelithiasis or choledocholithiasis without biliary pancreatitis 
(57). This finding was confirmed by Kamisawa et al.(58). in a prospective study of 
354 patients who underwent ERCP a common pancreaticobiliary channel was 
observed in 11.5% of patients with ABP, which was significantly more frequent than 
n patients without pancreatitis (4.9%, P <0.05)(58). Even in patients with totally 
separate orifices of the common bile duct and pancreatic duct, gallstone pancreatitis 
can occur (57). Obviously, in this case, reflux of bile into the pancreatic duct is 
excluded as a contributing factor. In such cases, in our experience, obstruction of 
the pancreatic duct might occur if a stone is wedged at the level of the ampulla of 
vater, in much the same way as a cystic duct stone can cause obstruction of the 
common bile duct in Mirrizzi syndrome. One may question whether drainage of 
pancreatic juice via the minor pancreatic (or santorini) duct serves as a pivotal 
escape route and overflow protection mechanism in case of obstruction of the 
major pancreatic (or Wirsung) duct at the level of the major duodenal papilla. Uomo 
and co-workers studied the morphology of the pancreatico–choledochal junction 
and the pancreatic ductal system by comparing the findings from ERCP in 62 
patients with ABP and 62 patients as controls (59). Of note, more abnormalities of 
the ampulla of Vater were observed in the ABP group (that is, edema, hemorrhagic 
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lesions, lacerations, and impacted stones) than in the controls (66% versus 33.5%, 
P = 0.001). Papillary diverticula were found in 19% of patients with ABP and in 6.4% 
of the control group (59). In this series, no substantial differences were observed 
between the length of the common pancreaticobiliary channel, the angle between 
the common bile duct and the main pancreatic duct and the patency of the Santorini 
duct. Furthermore, noappreciable difference in Santorini duct patency was found 
between edematous and necrotizing cases of ABP. Contradictory results were, 
however, reported by Nowak and colleagues (60) and Kamisawa et al.(61) these 
investigators observed a markedly lower frequency of Santorini duct patency in 
patients with ABP (17% and 8%) than in the control group (69% and 43%, P <0.001 
and P <0.01, respectively); patients with other causes of acute pancreatitis also 
had low frequency of Santorini duct patency. The control group in both studies was 
comprised of patients with suspected biliary disease in whom a pancreaticogram 
was obtained during ERCP. Based on a study in rabbits, Arendt postulated that a 
patent Santorini duct might protect the pancreas from the harmful consequences 
(increased intraductal and, hence, increased parenchymal pressure) of obstruction 
of the main pancreatic duct, but it might also promote biliary pancreatic reflux 
during obstruction of the common channel and lead to subsequent development of 
pancreatitis caused by infected choledochal secretions(62).
Genetics
Over the past 10 years variations or mutations in the genes that encode pancreatic 
enzymes have been suggested as potential risk factors for the development of 
acute pancreatitis (including ABP). The common pathological event in acute 
pancreatitis is the early activation of zymogens within the pancreatic parenchyma. 
In this regard, the activation of trypsinogen by enteric peptidases to trypsin is 
important, as trypsin is capable of converting all proteolytic precursor enzymes 
(phospholipase, chymotrypsin and elastase) to their active form and activates other 
cascades (including complement, kinin–kallikrein, coagulation and fibrinolysis 
signaling cascades)(63). Several trypsinogen mutations have been identified in 
patients with chronic, hereditary pancreatitis (64). A number of mechanisms exist to 
protect the pancreas from autodigestion. One of these mechanisms is the synthesis 
of pancreatic secretory trypsin inhibitor (also known as serine protease inhibitor 
Kazal-type 1), which is a potent inhibitor of the trypsin activity within the pancreas 
and is encoded by SPINK1. research into the genetics of ABP is limited. one study 
reported a higher incidence of SPINK1 mutations (101a>G, which results in a 
Asn34Ser variant in the protein) in patients with acute pancreatitis (all causes) 
compared with a healthy control group (24 out of 936 versus 18 out of 2234, odds 
ratio 3.240, P <0.001) (65). A second study reported a case of recurrent ABP 
associated with a mutation in ABCB4 (the genetic defect was a heterozygous 
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3,683–3,688 del within exon 28 of ABCB4) (66). ABCB4 encodes multidrug resistance 
protein 3, a protein involved in the transport of phosphatidylcholine across the 
canalicular membrane of the hepatocyte. Gene defects in ABCB4 have been 
associated with progressive familial intrahepatic cholestasis type 3, intra- hepatic 
cholestasis of pregnancy, adult biliary cirrhosis and the newly described low phos-
pholipid-associated cholelithiasis syndrome (66). Mutations in the cystic fibrosis 
transmembrane regulator (CFTR) gene have been extensively described in patients 
with chronic pancreatitis (mainly alcoholic origin) and in recurrent idiopathic acute 
pancreatitis (64,67–69. CFTR is located in the proximal ductal system of the 
pancreas and regulates bicarbonate secretion (64) Disturbances in the secretion of 
bicarbonates can theoretically lead to enhanced viscosity of pancreatic secretions, 
possibly resulting in protein plugs that might contribute to the progression of 
chronic pancreatitis (64). However, an increased prevalence of mutations in CFTR 
have not been reported in patients with ABP.
dIAGnosIs
Acute pancreatitis is most reliably diagnosed using the classification proposed by 
the Atlanta Pancreatitis Classification working Group in 2008 (70). These criteria 
include: acute abdominal pain and rebound tenderness in the upper abdomen, 
increased pancreatic enzyme levels (amylase or lipase) in blood, urine or ascitic 
fluid (at least threefold greater than normal limits), and abnormalities characteristic 
of acute pancreatitis as determined by radiological findings. To establish a diagnosis 
of acute pancreatitis, two or more of the above criteria must be fulfilled while other 
causes of acute abdominal pain are excluded, such as: gastric perforation, acute 
cholecystitis, acute cholecystolithiasis and an acute myocardial infarction. Distinguishing 
biliary pancreatitis from other forms of acute pancreatitis can be difficult and 
requires biochemical and radiological evaluations (Figure 2). Additionally, the presence 
of gallstones alone might suggest a biliary origin, although this finding is not conclusive.
BIoCHemIstrY
diagnostic criteria
Determination of serum levels of amylase or lipase are used in the diagnosis of 
acute pancreatitis. serum lipase and amylase concentration rise within 4–8 h after 
the onset of an attack of acute pancreatitis, peak after 24 h and return to normal 
levels after 2–4 days (amylase) or 8–14 days (lipase) (71). in most studies, diagnosis 
of acute pancreatitis is based on high levels (threefold higher than the upper limit of 
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normal) of amylase (normal range 0.46–2.23 μkat/l) and lipase (0.5–3.2 μkat/l) (72). 
In fact, Lankisch and co-workers found that 21.9% of the patients who were 
eventually diagnosed with ABP had amylase levels less than three times the upper 
limit of normal at admission to the clinic (72). For lipase, 15.8% of patients who were 
later diagnosed with ABP had increased serum levels of the enzyme (72). For 
patients presenting with acute alcoholic pancreatitis, 41% and 15.7% had increased 
serum levels of amylase and lipase, respectively (lower than the recommended 
diagnostic criteria for the diagnosis of acute pancreatitis) (72). These findings 
indicate that tests for serum amylase and lipase must be repeated in cases where 
acute pancreatitis is suspected. Determination of the serum levels for lipase is 
preferred for the diagnosis of acute pancreatitis because of the high sensitivity and 
specificity, and long half-life of lipase in serum (7–13 h compared with the 2 h 
half-life of amylase), especially in patients with acute alcoholic pancreatitis (72). 
Serum amylase levels are generally higher in patients with ABP than in patients with 
other forms of acute pancreatitis(73). Serum pancreatic enzymes are often slightly 
increased during chronic kidney disease (74) and serum amylase is increased in 
patients with diseases of the liver, salivary gland, lung and genitalia (75).
Figure 2  Predicting the biliary origin of acute pancreatitis
Biochemical and radiological evaluations can help to establish a biliary cause of acute pancreatitis. 
Confirmation of  gallstones or biliary sludge using radiological imaging (including EUS, AUS, CT and 
MRCP), elevated serum levels of ALT (>60 IU/l) and a BMI <30 kg/m2 indicates an episode of acute 
pancreatitis with a biliary origin. If these findings are negative another cause of acute pancreatitis should 
be considered. 
Abbreviations: ALT, alanine aminotransferase; AUS, abdominal ultrasonagraphy; EUS, endoscopic ultra-
sonagraphy; MRCP, magnetic resonance cholangiopancreatography.
Gray arrow = yes, orange arrow = no
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Predicting a biliary etiology
Mc Mahon and Pickford were the first to suggest that a rise in plasma levels of 
hepatic transaminases on the day of admission for pancreatitis was associated 
with a biliary origin (76). However, 10–15% of patients with ABP present with normal 
serum liver enzymes (bilirubin and alkaline aminotransferase [ALT]) (77). Davidson 
and Neoptolemos developed a test that measured serum levels of three liver 
enzymes, diagnostic for ABP (alkalinephosphatase >3.76 μkat/l, alt >1.25 μkat/l 
and bilirubin >40 μmol/l) (78). This three-factor test had similar sensitivity and 
specificity in predicting the biliary origin of acute pancreatitis as a single-marker 
test that measured ALT alone (>1.0 μkat/l) (78). Furthermore, Stimac and co-workers 
retrospectively analyzed 145 patients with acute pancreatitis and developed a 
score to differentiate between alcoholic and biliary pancreatitis (79). The score was 
based on six serum markers (amylase, alt, alkaline phosphatase, aspartate 
transaminase, lipase:amylase ratio, and mean corpuscular volume) and one urine 
marker (amylase) with one point being scored per item over a specific threshold 
value. The Stimac score was reported to have a positive predictive value (PPV) of 
98% and a negative predictive value (NPV) of 77% in correctly distinguishing biliary 
pancreatitis from alcoholic pancreatitis, when a patient has scored four or more 
points (79). This scoring system was easy to use and has promising predictive 
values, but has not been re-evaluated in other series. Tenner and colleagues 
performed a meta-analysis of studies that used liver enzymes (bilirubin, alkaline 
phosphatase, alt and aspartate transaminase) in the prediction of a biliary origin of 
an attack of acute pancreatitis (80). The researchers deduced that a threefold or 
greater elevation in ALT levels had a PPV of 95% in diagnosing ABP (80), which was 
confirmed in subsequent Studies (81,82). In a series by Ammori et al.(83), a single 
test for ALT (>1.34 μkat/l) had a high sensitivity (91%), specificity (100%), PPV 
(100%) and NPV (86%) for the identification of a biliary cause of an acute pancreatitis 
attack (83). Combining abdominal ultrasonography (AUS) with evaluations of alt 
level (>1.34 μkat/l) improved results, albeit not substantially (98% sensitivity, 100% 
specificity,100% PPV and 96% NPV) (83). Interestingly, one patient who presented 
with an elevated ALT level, but negative results from both AUS and endoscopic 
 ultrasonography (EUS), was confirmed to have cholelithiasis at postmortem 
examination. In two subsequent studies that used EUS as a reference examination, 
the value of elevated alt levels in the diagnosis of ABP was once again confirmed 
(84,85). A French prospective study included 213 patients with a first episode of 
acute pancreatitis (62% of whom had confirmed pancreatitis with a biliary origin) to 
examine the effectiveness of bioclinical markers in predicting ABP(84). ALT levels 
more than twofold the upper normal limit were set as the diagnostic criteria for the 
prediction of ABP, resulting in a sensitivity, specificity, PPV and NPV of 74%, 84%, 
88% and 66%, respectively (84). For ALT levels more than threefold higher than the 
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upper normal limit, the sensitivity, specificity, PPV and NPV were 61%, 91%, 92% 
and 59%, respectively (84). A study from Hong Kong showed that female sex, age 
>58 years and an ALT level >2.50 μkat/l had a high sensitivity (93%) and accuracy 
(85%) in predicting a biliary cause of pancreatitis (85). We must stress that an elevated 
alt level also has many alternative diagnoses (mainly alcoholism, nonalcoholic 
 steatohepatitis and viral hepatitis). For instance, in western europe and the usa the 
prevalence of obesity and their related liver diseases (that is, nonalcoholic fatty liver 
disease and nonalcoholic steatohepatitis) are increasing (86). Thus, when ALT level 
is used as a diagnostic marker for ABP, BMI must be accounted for when predicting 
a biliary origin to rule out any alternative diagnoses (Figure 2).
ImAGInG studIes
diagnostic criteria
In our experience, a diagnosis of acute pancreatitis is supported by distinct 
radiological features found on AUS, CT or MRI. The use of AUS is often limited by the 
presence of air-filled and fluid-filled loops of bowel that overlie the pancreas. AUSis 
well-suited to show (and follow) peripancreatic fluid collections. the most widely used 
method to establish and confirm a diagnosis of acute pancreatitis is Ct. Findings from 
CT in acute pancreatitis can be classified into pancreatic and peripancreatic changes 
(87). Pancreatic changes include parenchymal enlargement (either diffuse or localized), 
parenchymal edema and necrosis. Peripancreatic changes consist of blurring of 
fat planes, thickening of the facial planes and the presence of fluid collections. 
Contrast-enhanced mri and contrast-enhanced CT are of comparable diagnostic 
and prognostic value in acute pancreatitis (88,89). MRI and magnetic resonance 
cholangio pancreatography (MRCP) are more accurate than CT in detecting bile 
duct lithiasis, pancreatic hemorrhage, pancreatic ductal anatomy, necrosis in 
peripancreatic fluid collections, duodenitis and duodenal narrowing (88–91). MRI is 
inferior to CT in the detection of small gas bubbles and calcifications (90). EUS is a 
very sensitive technique for the visualization of pancreatic lesions, pseudocysts, 
stones of the common bile duct and pancreatic duct anatomy (92). Furthermore, a 
radiological evaluation can be useful in the prediction of the severity of an attack of 
acute pancreatitis. For example, the Balthazar score on abdominal CT (93) and the 
extrapancreatic inflammation on CT score on abdominal MRI (94) can be used to 
estimate the severity of an acute pancreatitis.
Predicting biliary etiology
A biliary origin of an acute pancreatitis attack may be suspected in the case of 
cholecystolithiasis or dilation of the biliary tree with or without choledocholithiasis. 
35
etiology and diagnosis of acute biliary pancreatitis
1
A summary of the performances of various diagnostic modalities in the detection of 
choledocolithiasis in ABP is listed in table 1. AUS has a high specificity and relatively 
high sensitivity for the evaluation of cholecystolithiasis in acute pancreatitis 
(93,95,96); however, this technique has a low sensitivity for the detection of 
gallstones in the common bile duct in patients with ABP(97–100) EUS is regarded 
as the most sensitive and specific procedure (with high PPV and NPV) for the 
detection of choledocholithiasis and cholecystolithiasis in patients with or without 
ABP (99,101–104) and, like AUS, is an operator-dependent procedure (101). 
Additionally, ERCP is highly sensitive for confirming the diagnosis of cholelithiasis 
in patients with ABP (98,99,102) while MRCP has been shown to be highly sensitive 
and specific for gallstone detection. Abdominal CtThas a low sensitivity (40%) in 
predicting common bile duct stones in patients with ABP, which makes it a less 
accurate tool in differentiating biliary pancreatitis from the other origins (99). More 
promising results for the use of CT in diagnosing ABP were reported by Tse et al. 
(105). The researchers analyzed six prospective trials in which common bile duct 
stones were detected with high- resolution helical scans (hCTCs) combined with 
intra venously administered contrast agents (105) with a sensitivity of 87% and 
specificity of 97% in detecting common bile duct stones, which results in an 
accuracy of 96%, hCTCs could have equivalent accuracy as MRCP in the detection 
of choledocholithiasis. However, the studies included in the meta-analysis by Tse et 
al.(105) were performed in patients with suspected common bile duct stones 
scheduled for a cholecystectomy. A head-to-head comparison of MRCP and 
hCTCs is, therefore, needed to draw a definitive conclusion as to whether mrCP is 
equivalent or superior to hCTCs in detecting choledocholithiasis. Only one 
Table 1  Detection of gallstones in patients with acute biliary pancreatitis
Technique  
(location of gallstone) 
sensitivity  
(%)
Specificity 
(%)
PPV 
(%)
NPV 
(%)
references
AUS (gallbladder) 67–87 93 100 75–80 83, 95, 96
AUS (CBD) 20–50 83 67 38.5 97–100
Abdominal CT (CBD) 40 92 89 48 99
MRCP (CBD) 80–100 83–98 89 71–100 99, 100
ERCP (CBD) 90–100 92 95 85 85, 97–99, 103, 111
EUS (CBD) 91–100 85–100 92–98 88–92 85, 97–99, 103, 111
Abbreviations: AUS, abdominalultrasonography; CBD, common bile duct; ERCP, endoscopic retrograde 
cholangiopancreatography; EUS, endoscopicultrasonography; MRCP, magnetic resonance cholangio-
pancreatography; NPV, negative predictive value; PPV, positive predictive value.
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prospective head-to-head study has directly compared multiple imaging modalities 
and evaluated their sensitivity and specificity for detecting choledocholithiasis (99). 
Using endoscopic extraction of a biliary stone as the reference standard, the 
relative sensitivity of AUS, CT, MRCP, ERCP and intra ductal endosonography for 
detecting bile duct stones was 20%, 40%, 80%, 90% and 95%, respectively.99 
mrCP in patients with ABP (with intraoperative cholangiogram or ERCP as the 
golden standard for common bile duct stone detection) was found to have high 
sensitivity (94–100%) and specificity (91–98%) for the detection of choledocolithia-
sis (100,106).  The American Gastroenterological Association, Japanese and Dutch 
guidelines advise an initial AUS or EUS in every patient who presents with an attack 
of acute pancreatitis (107–109). If the initial ultrasound images are inadequate or if 
a suspicion of gallstone pancreatitis remains, repeat AUS after recovery should be 
performed (as per the American Gastroenterological Association guideline) (109).
This guideline also states that endoscopic ultrasonography can be used as an 
accurate alternative approach to screen for cholecystolithiasis and choledocholi-
thiasis, either at admission to the clinic or thereafter (109). The Dutch and UK 
guidelines recommend MRCP in cases of persistent suspicion of a biliary origin of 
acute pancreatitis (108,110).
ConClusIons
The etiology of ABP is complex and involves multiple contributory factors. The 
passage of numerous small gallstones or biliary sludge (which contains microscopic 
particulates) through the ampulla of Vater seems to be a major factor in the 
pathogenesis of ABP. Anatomical variations, such as the presence of a common 
pancreatico-biliary channel and the absence of a patent Santorini duct, raise the 
risk of pancreatic duct obstruction and increased intrapancreatic pressure, and 
Santorini ducts are less prevalent in patients with ABP. Refluxate of pancreatic and 
bile juices increases the permeability of the pancreatic ducts and, if infected, adds 
to the risk of developing ABP. Additionally, exclusion of bile and pancreatic juices, 
and genetic mutations in genes that encode pancreatic enzymes result in elevated 
levels of activated pancreatic enzymes in the pancreas. Combinations of these 
features probably render an individual more prone to the development of ABP. A 
possible biliary origin in patients presenting with an acute pancreatitis should be 
investigated using laboratory tests and imaging techniques. an increased ALT level 
above normal (>1.0 μkat/l on admittance to the clinic is associated with a high 
probability (PPV 80–90%) of gallstone ABP. Additional confirmation of choledocho-
lithiasis is most accurately obtained using EUS or MRCP.
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ABstrACt 
Objectives. Several randomized controlled trials studied the role of endoscopic 
retrograde cholangio pancreaticography (ERCP) and endoscopic sphincterotomy 
(ES) in acute biliary pancreatitis (ABP). No study assessed whether these trials 
resulted in international consensus in published meta-analyses and treatment 
guidelines.
Methods. A systematic review, according to the PRISMA-guidelines, of meta-analyses 
and guidelines on ERCP in ABP was performed in PubMed until August 2011.  
The methodological quality of the meta-analysis and guidelines was assessed by a 
validated quality assessment tool.
Results. Eight meta-analyses and 12 guidelines fulfilled the inclusion criteria. There 
is consensus that ERCP is indicated in case of ABP with coexistent cholangitis and/
or persistent cholestasis. By exception of the first meta-analysis, all included 
studies disapproved early ERCP in predicted mild ABP. Consensus is lacking 
regarding the role of early ERCP in predicted severe ABP, as 3 meta-analyses and 
1 guidelines do not advice this strategy. Routine early ERCP in predicted severe 
ABP is recommend in 7 of the 11 guidelines. 
Conclusions. There is consensus in guidelines and meta-analyses that ERCP/ES 
is indicated in patients with ABP and co-existing cholangitis and/or persistent 
cholestasis. Consensus is lacking on the role of routine early ERCP/ ES in patients 
with predicted severe ABP. 
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IntroduCtIon
Acute pancreatitis is a common disease with an estimated incidence of 30/100.000/
year1-3. The leading etiology is gallstones/sludge, which accounts for 35-60% of 
acute pancreatitis cases in the United States and Western Europe1-3. Biliary 
pancreatitis is mostly mild and self- limited1-3. Some 15-20% of patients will develop 
severe acute biliary pancreatitis (ABP) including necrotizing pancreatitis and/or 
multiple organ failure1-3. 
In the Western world, the incidence of ABP has increased during the last decade by 
35%4-6. Although mortality decreased by 35%, it still ranges from 2-14%, depending 
on patient age and decade of presentation4,5,7,8. Expedited triage of moderate to 
severe cases for more aggressive fluid resuscitation on admission and aggressive 
management in intensive care units (ICUs) are possible explanations for the 
declining mortality rates6,9. Keeping in mind that mortality does not differ between 
the various etiologies of acute pancreatitis 6,10-12, the outcome of treatment of ABP 
has probably truly improved over the last decades.
A treatment which might have contributed to better outcomes of ABP is emergency 
endoscopic retrograde cholangiopancreatography (ERCP) with endoscopic spinctero- 
tomy (ES), inspired by a landmark study of Neoptolemos et al in 198813. The rationale 
for performing this study was based on several prevailing theories hypothesizing 
the merits of biliary decompression to ameliorate the severity of the pancreatitis, 
which include treatment and prevention of (ongoing) increased pressure in the 
pancreatic duct, (infected) bile reflux into the pancreatic duct, and stimulation of 
pancreatic enzyme production/activation by duodenal bile exclusion14-19. 
Based on the ampullary obstruction and reflux theory of Opie and Bernard, two 
surgical trials preceded the study of Neoptolomos20,21. In the years that followed, 
six randomized trials studied the effect of (early) biliary decompression versus 
conservative management on the course and outcome of patients with ABP13,22-28. 
These studies formed the basis for several meta-analyses and national guidelines. 
In the light of the somewhat confusing and partly conflicting outcomes of the 
various randomized trials we performed a systematic review to determine whether 
there is consensus in published meta-analyses and  guidelines on the role of an 
(emergency) ERCP and ES in the early management of biliary pancreatitis.
metHods
We conducted a systematic review of published English, German and French 
literature according to the PRISMA (Preferred Reporting Items for Systematic 
reviews and Meta-Analyses) guidelines29,30. The PRISMA Statement consists of a 
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27-item checklist and a four-phase flow diagram. The checklist includes items 
deemed essential for transparent reporting of a systematic review. The PRISMA 
flow diagram is shown in Figure1. Two PubMed searches were performed: 1. Meta- 
analysis; Emergency ERCP in ABP and 2. Guidelines: Emergency ERCP in ABP. 
One author (E.J.M.v.G.) performed the selection and reviewed all full text papers. 
The included and excluded studies were discussed with two other authors (H.C.v.S 
and M.J.B). Cross references were carefully reviewed.
search for meta-analyses
For meta-analysis the subsequent search terms were used: “Pancreatitis AND 
(biliary OR gallstone OR gallstones OR cholelithiasis OR cholecystolithiasis)”. The 
results were limited to articles published in the English language, and meta-analyses.
Figure 1  PRISMA Flow Diagram
# of records identified
through database
searching    
# of additional records
identified through other
sources    
# of records after duplicates removed  
# of records screened  
# of full-text articles
assessed for eligibility
 
 
# of studies included in
qualitative synthesis   
# of studies included in
quantitative
synthesis(meta-analysis)   
# of records excluded  
# of full-text articles
excluded, with reasons  
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2
search and quality assessment for / of guidelines
Since the first meta-analysis was published in 199931, the electronic searches of 
PubMed were limited from the 1st of January 2000 to the 15th of August 2011. The 
following search terms were used: “pancreatitis AND (guideline OR guidelines OR 
practice guideline OR practice guidelines OR consensus)”. The results were limited 
to articles published in the English, German and French language. Furthermore, 
only guidelines endorsed by a professional body and their latest updates were 
included. The Dutch guideline was added to the results although it is not indexed in 
PubMed32. 
The quality of the guidelines was assessed with the Grilli score33 (Figure 2.) and 
AGREE (Appraisal of Guidelines for Research and Evaluation) Collaboration (http://
www.agreetrust.org). The Grilli-score is an easy applicable quality assessment tool 
addressing 3 topic’s: description of the involved professionals, description of the 
sources of information and explicit grading of evidence. The AGREE instrument 
provides a framework to assess the quality of guidelines by using 6 domains, with 
a total of 23 items. Every item can be scored, with a 1-7 point range. The domains 
Description of the type of professionals involved in developing the guideline:
Yes If there was a description of the type of professionals and other 
stakeholders involved in the development process
2 points
Partially If only a list of names with institutional affiliation was
provided
1 point
No If only names were reported, without further information 0 points
Description of the sources of information used to retrieve the relevant evidence:
Yes If it was explicitly stated that searches were undertaken, at least 
through MEDLINE
1 point
No If no information was reported. 0 points
Explicit grading of the evidence in support of the main recommendations:
Yes If any form of explicit grading of the quality of the supporting
evidence was reported
1 point
No If otherwise 0 points
Figure 2   Checklist for quality assessment of guidelines endorsed by specialty societies
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of AGREE are: scope and purpose, stakeholder involvement, rigour of development, 
clarity of presentation, applicability and editorial independence.
statistical analysis
The 2010 journal impact factors were noted and quality assessment of the guidelines 
calculated by the Grilli-score (Box 1). The relation between the Grilli-score and 
impact factor was calculated with SPSS Pearson 2-tailed test (SPSS version 17).
results
meta-analyses: erCP versus conservative management of ABP
The initial PubMed search identified 24 articles for further review. Eight meta-analyses 
met the inclusion criteria and are presented in Table 1. Sixteen articles were 
excluded because they addressed other topics or were reviews. Impact factors 
ranged from 0.9 to 6.1. The number of included randomized trials varied from 2 to 
5. Only 2 of 8 meta-analyses included the same studies.
Only the first meta-analysis concluded that an emergency ERCP/ES was beneficial 
in all patients with ABP (regardless of cholestasis/cholangitis), resulting in a 
significant reduction of morbidity and mortality (p<0.001 and p<0.05), particularly 
in predicted severe cases (Table 1)31. The remaining seven meta-analyses reported 
no beneficial effect of an emergency ERCP in patients with predicted mild ABP and 
did not specify the indication of an ES in predicted severe case. 
In case of predicted severe ABP,  the meta-analysis of Steinberg and Heinrich34 
concluded that an emergency ERCP ± ES resulted in a significant reduction of 
complications and mortality, but only in predicted severe cases of ABP (Table 1)35. 
The meta-analyses of Ayub36 and Moretti37 reported a significant reduction in 
morbidity but not mortality, in the emergency ERCP group with predicted severe 
ABP, regardless of cholestasis/ cholangitis (Table 1). Whereas the meta-analyses of 
Petrov38, Uy39, and Petrov40 concluded that a an early ERCP in ABP was not 
associated with a significant reduction in morbidity and mortality in predicted 
severe cases (Table 1).  
Guidelines: erCP versus conservative management of ABP
The initial database search regarding “guidelines” identified 299 articles for further 
review. After reading the abstracts 22 potential guidelines were retrieved. Six papers 
were excluded because they lacked an official endorsement. Two older Japanese 
guidelines (200241 and 200642-44) and one older Italian guideline45 were excluded, 
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and were represented by the latest 2010 guidelines. The Dutch guideline was added 
to the search64. Two guidelines were excluded, because they did not mention a 
policy regarding the endoscopic treatment of ABP46,47. This resulted in 12 guidelines, 
which are reported in Table 2. The reported impact factor of the guidelines varied 
between not specified to 12.9. Regarding the quality of the guidelines, there was no 
significant correlation between the Grilli factor (0-3: low and 4: high quality) and 
AGREE-score versus the journal impact factor (p=0.996 and p=0.573). The Grilli 
factor was significant correlated to the AGREE-score (R=0.762, p=0.004).
Clinical trials and meta-analyses formed the basis of most guidelines (Table 2). 
However, guidelines of the Societé Nationale Française de Gastroenterologie48 and 
American Gastroenterological Association23 (AGA) did not report the references. 
All guidelines recommend an emergency ERCP in patients with ABP with co-existing 
cholangitis and/or biliary obstruction (Table 2). According to the included guidelines 
there is no indication for an emergency ERCP in patients with predicted mild ABP, 
without cholangitis and/or biliary obstruction. In case of a predicted severe ABP the 
guidelines are controversial.
The Japanese 2010 Guidelines49 50-52 (Table 2) included the most clinical trials and 
meta-analyses and had a maximum Grilli score of 4. This is the only guideline that 
does not recommend an emergency ERCP in severe ABP. Four guidelines question 
the usefulness of an emergency ERCP in patients with predicted severe ABP: the 
French48, International Association of Pancreatology53, AGA, and Italian-guide-
line54 (Table 2). The Grilli score of these guidelines varies between 2 and 4 and the 
number of studies (i.e., clinical trials or meta-analyses) that were included are low. 
Six guidelines recommend an emergency ERCP in patients with predicted severe 
ABP:  the Dutch64, Chinese55,  German56, World Congress of Gastroenterology 
(WCG) 57, American thoracic society (ATS)58, British59, and American college of 
gastroenterology (ACG)-guidelines60. The optimal time period for ERCP differed 
among the guidelines: within 72 hours after onset of symptoms (WCG, ATS, British, 
Dutch) or within 24 hours after hospital admission (German and ACG).
The guidelines have several recommendations concerning the use of an early ES, 
whenever an early ERCP is performed. Six guidelines advise an ES, whenever 
emergency ERCP is performed (Table 2). In two guidelines an ES is advocated in 
case of biliary obstruction and/or cholangitis. (Table 2). However, the indication of 
an early ES is not specified in 4 guidelines. 
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Table 1   Meta-analyses on the use of routine emergency ERCP in acute biliary 
pancreatitis
Impact factor 
journal
Studies  
included
Excluded  
studies
Reason  
exclusion
Morbidity  
(ERCP versus 
Conservative)
Mortality ERCP  
in Mild  
ABP
ERCP  
in Severe 
ABP
ERCP in
co-existent 
Cholangitis
Suspected 
Obstruction
Meta-analysis 1 
(Sharma et al, 1999)31
6.12 Neoptolemos13
Fan24, Nowak25
Fölsch23
None - Overall: 25.0% vs 38.2% 
(p<0.001)
Overall: 5.2% vs 9.1% 
(p<0.05)
Yes Yes Yes Yes
Meta-analysis 2
(Steinberg et al, 2001) 
35.
2.61 Neoptolemos13
Fan24,
Nowak25 Fölsch23 Abstract/ timing ERCP
Excluding the non-biliary 
pancreatitis cases from the 
Hong Kong study24. 
Mild : 16% vs 16% (ns)
Severe: 54% vs 15% 
(p<0.01)
Mild: 0% vs 0% (ns)
Severe: 15% vs 2% 
(p<0.05)
No Yes Yes N.S.
Meta-analysis 3
(Ayub et al, 2004)36 
5.65 Neoptolemos13
Fan24
Fölsch23
Nowak25 No conservative group Mild ABP: OR=0.89 (ns)
Severe ABP:OR=0.27 
(95%CI 0.14-0.53)
Overall, mild and  
severe ABP (ns)
No Yes Yes N.S.
Meta-analysis 4
(Heinrich et al, 2006)34
7.9 Neoptolemos13
Fan24, Fölsch23
Nowak25 Abstract Overall: 31.3% vs 41.8% 
(p=0.03)
Mild ABP (ns)
Severe ABP: 18.2% vs 
57.1% (p<0.0001)
Mild ABP (ns)
Severe ABP: 3.6%  
vs 17.9% (p=.0.03)
No Yes Yes N.S.
Meta-analysis 5
(Petrov et al, 2008)38 
7.9 Neoptolemos13
Fölsch23
Oria26
Fan24
Nowak25
Acosta22
ERCP in all acute 
pancreatitis
No conservative group
Treatment group: only 47% 
ERCP
Overall: ns
Mild and severe ABP (ns)
Overall, mild and  
severe ABP (ns)
No No Excluded N.S.
Meta-analysis 6
(Moretti et al, 2008)37 
2.97 Neoptolemos13
Fan24, Fölsch23
Zhou27, Oria26
Nowak25
Acosta22
Abstract, different control 
group
Different treatment group
Overall: 27% vs 36% 
(p=0.01)
Mild ABP (ns)
Severe: rate difference 
38.5% (p=<0.0001)
Overall, mild and  
severe ABP (ns)
No Yes N.S. N.S.
Meta-analysis 7
(Petrov et al, 2008)40
3.31 Neoptolomos13
Fan24, Folsch23
Oria26,Acosta22
Nowak25 Abstract Limited to local 
complications:
Overall, mild and severe 
ABP (ns)
Overall, mild and  
severe ABP (ns)
No No N.S. N.S.
Meta-analysis 8
(Uy et al, 2009)39 
0.89  
(estimated 
2007)71
Fölsch23
Oria26 
Fan24
Nowak25
 Zhou27
 Acosta22
Neoptolomos13
All AP, cholangitis not 
excluded
No information on 
cholangitis
Did not exclude cholangitis.
 Excluded only severe 
cholangitis. 
Did not exclude cholangitis.
Overall: ns
Mild and severe ABP (ns)
Overall, mild and  
severe ABP (ns)
No No Excluded N.S.
Abbreviations:
Ns not significant
N.S. Not specified
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Different treatment group
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Mild ABP (ns)
Severe: rate difference 
38.5% (p=<0.0001)
Overall, mild and  
severe ABP (ns)
No Yes N.S. N.S.
Meta-analysis 7
(Petrov et al, 2008)40
3.31 Neoptolomos13
Fan24, Folsch23
Oria26,Acosta22
Nowak25 Abstract Limited to local 
complications:
Overall, mild and severe 
ABP (ns)
Overall, mild and  
severe ABP (ns)
No No N.S. N.S.
Meta-analysis 8
(Uy et al, 2009)39 
0.89  
(estimated 
2007)71
Fölsch23
Oria26 
Fan24
Nowak25
 Zhou27
 Acosta22
Neoptolomos13
All AP, cholangitis not 
excluded
No information on 
cholangitis
Did not exclude cholangitis.
 Excluded only severe 
cholangitis. 
Did not exclude cholangitis.
Overall: ns
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Overall, mild and  
severe ABP (ns)
No No Excluded N.S.
Abbreviations:
Ns not significant
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Table 2   Guidelines addressing the use of routine emergency ERCP/ES in acute 
biliary pancreatitis
Guidelines year Impact 
factor 
journal
Grilli 
Score
AGREE Studies/ Meta-analysis Mild 
biliary 
pancreatitis
Severe biliary 
pancreatitis
Cholangitis ERCP advised 
in Suspected 
Obstruction
Endoscopic
Sphincterotomy
Societé Nationale 
Française de 
Gastroenterologie48 
(French)
2001 1.7 2 51 N.S. No Debate Yes Yes When ERCP is
 indicated
International Association 
of Pancreatology53 (IAP)
2002 1.4 3 76 Neoptolomos, Fan,  
Folsch
No Debate Yes Yes When ERCP is 
indicated
World Congress of 
Gastroenterology57 
(WCG)
2002 2.3 3 65 Neoptolomos, Fan,  
Nowak, Folsch
No Yes Yes Yes When ERCP is
indicated
Chinese society of 
Gastroenterology55
2004 1.6 0 23 N.S. No Yes Yes Yes When ERCP is 
indicated
American Thoracic 
Society58 (ATS)
2004 6.4 4 69 Neoptolomos, Fan,  
Nowak, Folsch, Sharma
No <72h onset 
symptoms
Yes Yes N.S
British Society of 
Gastroenterology59 
(British)
2005 9.4 3 84 Neoptolomos, Fan,  
Folsch, Nowak
No <72h onset 
symptoms
Yes Yes When ERCP is
 indicated
Dutch Society of Internal 
Medicine32 (Dutch)
2005 N.S. 4 80 Neoptolomos, Fan,  
Nowak, Folsch
- < 72h (N.S.) Yes (<24h) Yes (<24h) Obstruction
Cholangitis, CBDS
American College of 
Gastroenterology60 (ACG)
2006 6.1 4 73 Neoptolomos, Fan, Nowak, 
Folsch, Sharma, Ayub
<24h 
admission
Yes Elective ERCP 
in persistent 
obstruction
N.S. 
American 
Gastroenterological 
Association23 (AGA)
2007 12.9 2 70 N.S. No controversial Yes (<24h) Yes (<72h) N.S.
German Society for 
Digestive Diseases and 
Metabolic Diseases56 
(German)
2007 1.2 4 85 Neoptolomos, Fan,  
Folsch, Oria, Ayub
No Yes (<24h 
Admission)
Yes (<24h) Yes (<24h) Cholangitis,
Jaundice,
Cholestasis
Italian Association for the 
Study of the Pancreas54 
(Italian)
2010 3.0 4 54 Petrov, Moretti No controversial Yes Yes When ERCP is
indicated
Japanese Guidelines49 
50-52
2010 1.9 4 82 Neoptolomos, Fan, Nowak, 
Folsch, Zhou, Acosta, Oria, 
Sharma, Ayub, Heinrich
No No Yes Yes N.S.
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dIsCussIon
At present, according to published meta-analyses and national guidelines, two 
statements about early ERCP/ES in ABP seem un-debated: 1. ERCP/ES does not 
have a clear advantage in patients with predicted mild ABP and 2. co-existing 
cholangitis is an indication for emergency ERCP/ES (within 24 hours of admission). 
However, consensus is lacking on the role of routine early ERCP/ES in all patients 
with predicted severe ABP, regardless of cholestasis.
How is it possible that meta-analyses on the same subject reach such different 
conclusions? There are two likely explanations for this to happen. The first possible 
explanation is time of publication. More recent meta-analyses or guidelines might 
reach different conclusions as new data has come available over time. However, 
this argument is contradicted by the observation that the latest meta-analyses 
(2006-2009: Table 1) are not concurrent in which of the most recent (randomized) 
clinical trials were included in their analysis: Acosta22(2006), Oria26(2007) and van 
Santvoort61 ( 2009), which results in conflicting outcomes (like the older meta-
analyses). The second likely explanation is what has just been alluded to that is 
selection of which studies to include in the meta-analysis. For example, in contrast 
to all other meta-analyses only Sharma et al31 included the study of Nowak et al25, 
although only published in abstract. This already provides ample explanation why 
only this meta-analysis recommends early ERCP in predicted mild ABP. For the use of 
ERCP in predicted severe cases of ABP the outcome of the 8 meta-analyses depend 
on the in27,34,36,62 or exclusion38,39, of the study of Neoptolomos13 and/or Fan et al24. 
In the light of contradictory recommendations of clinical trials, meta-analyses and 
guidelines we recently surveyed the daily clinical practice among Dutch gastroen-
terologists63. Of the 97% responders who would consider performing an early 
(<72h) ERCP in ABP, 14% stated that they always perform ERCP regardless of the 
presence of any condition or symptom. The remainder of the respondents considers 
ERCP only if a concomitant condition is present such as a dilated CBD (95%), 
co-existent cholangitis (87%), common bile duct stone(s) (CBDS) (72%), jaundice 
(59%), ampullary stone (68%) or (predicted) severe-ABP (35%). Accordingly, the 
study of Van Santvoort et al. demonstrated that in daily clinical practice in the 
Netherlands the use of ERCP in predicted severe ABP varied from 0 to 100% in 15 
of the largest Dutch hospitals64. Similar defiance of the national guidelines were 
reported in an Italian and British surveys.65-67 In a British survey amongst surgeons 
(n=583), 35% advocated early ERCP /ES in patients with predicted severe biliary 
pancreatitis and a further 14% ERCP/ES for all patients with biliary pancreatitis 
regardless of the predicted severity68.   
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Interestingly, apart from the first meta-analysis, none specified the indication for 
early ES in patients with ABP. Furthermore, the indication for ES is also not specified 
in the American and Japanese guidelines. Literature concerning this topic is 
remarkably scarce. Only one randomized clinical trial addressed this issue and 
reported a significantly decreased morbidity and mortality in patients with an early 
ERCP with ES compared to ERCP alone25. These results were partly confirmed by 
an univariate analysis in a prospective clinical trial of Van Santvoort et al61. In this 
study, ES was associated with a significant reduction in overall complication rate 
(adjusted OR 0.24; 95% CI 0.06-0.93; P = 0.04) albeit without a significant effect on 
mortality (adjusted OR 1.38; 95% CI 0.13-14.44; P = 0.79). 
The present systematic review clearly demonstrates that despite numerous 
randomized trials, there is an obvious lack of consensus on the indications, the 
timing, and procedural techniques (ES or not) in meta-analyses and nationwide 
guidelines. Three strategies might possibly improve consensus.  First, uniform 
criteria for inclusion of studies in meta-analyses and guidelines would increase the 
likelihood of reaching consensus. Future versions of the PRISMA guidelines for 
systematic reviews and meta-analyses could provide such criteria.  Second, rather 
than performing meta-analyses of literature reports, future meta-analyses should 
aim to aggregate and analyze individual patient data. It has been shown that 
individual patient data meta-analyses (IPDMA)  provide more reliable outcomes 
than regular meta-analyses69. Third, an obvious strategy would be to perform new 
high quality randomized trials on relevant questions reflecting patient management 
in daily clinical practice, for example about the role of (early) ERCP in patients with 
predicted severe acute biliary pancreatitis. Such a study should be adequately 
powered, using practical inclusion criteria, clear crossing-over criteria, a cannulation 
failure scenario, and end-points that are clinical relevant in terms of patient outcome. 
ES should be an integral part of ERCP treatment70. The preparation of such a trial 
has started and will be carried out by the Dutch Pancreatitis Study Group. In this 
APEC-trial (Acute biliary Pancreatitis: early ERC plus ES versus Conservative 
treatment: APEC), a randomized, superiority, assessor-blinded multicenter trial, 
patients with ABP are randomized within 24h admission between a conservative 
and ERC/ ES group.
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ABstrACt
Objective. Based on the ampullary obstruction and reflux theory, six endoscopic 
retrograde cholangiopancreatography (ERCP) studies have investigated the effect 
of (early) biliary decompression versus conservative management on the course 
and outcome of patients with acute biliary pancreatitis (ABP) showing inconsistent 
and contradictory outcomes. We investigated the opinion and attitude of Dutch 
gastroenterologists regarding the application of (early) ERCP in the clinical 
management of ABP by means of a nationwide survey. 
Material and methods. An anonymous questionnaire was sent to all registered 
consultant gastroenterologists (n = 283) across the Netherlands. Results. The response 
rate was 52%. The vast majority of consulting gastroenterologists declared that 
early ERCP may be indicated in ABP (96.6%). Fourteen percent stated that they
always perform ERCP in ABP. The remainder of the respondents consider ERCP 
only if a concomitant condition is present such as a dilated CBD (95%), co-existent 
cholangitis (87%), common bile duct stone(s) (CBDS) (72%), jaundice (59%), 
ampullary stone (68%) or (predicted) severe ABP (35%). About half of the consultant 
gastroenterologists (51.4%) consider the optimal time point for ERCP in ABP to be 
within 24 h after admission or symptom onset. If ERCP is performed for suspected 
APB, 55% of the respondents perform an endoscopic sphincterotomy (ES), 
regardless of the findings on cholangiography.
Conclusions. The vast majority of Dutch gastroenterologists attest to a role for 
ERCP in ABP, but indications when to perform ERCP, its timing, and the application 
of ES vary greatly and are not always in line with the Dutch or other published 
national guidelines. The results of this survey highlight the need for additional 
comparative randomized studies to define the role of (early) ERCP in ABP.
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IntroduCtIon
Gallstones account for 35–60% of acute pancreatitis cases in the United States and 
Western Europe [1–3]. Approximately 25% of patients develop severe acute biliary 
pancreatitis (ABP) including necrotizing pancreatitis and multiple organ failure. The 
overall mortality ranges between 2 and 10% [1,2]. The incidence of ABP has 
increased during the last decade by 35% in the western countries [4]. Several 
theories have been put forward about the etiology of ABP including ampullary 
obstruction, (infected) bile reflux into the pancreatic duct, and an increase in 
pancreatic enzyme production/activation by duodenal bile exclusion [5–10]. Based 
on the ampullary obstruction and reflux theory of Opie and Bernard, two surgical 
trials [11,12] and six prospective randomized endoscopic retrograde cholangiopan-
creatography (ERCP) studies have investigated the effect of (early) biliary 
decompression versus conservative management on the course and outcome of 
patients with ABP [13–18]. These studies form the basis for several meta-analyses 
and national guidelines. The first meta-analysis (1999, n = 834) recommended 
ERCP and endoscopic sphincterotomy (ES) in all patients with ABP, particularly in 
predicted severe cases [19]. The second meta-analysis (2004, n = 511) made a 
clear distinction between patients with and without acute cholangitis and showed 
that early ERCP decreases complications in all patients with predicted severe ABP 
[20]. The third meta-analysis (2008, n = 450) [21] that included the new Argentinean 
study [18] indicated that ERCP in patients with both predicted mild and severe ABP 
without cholangitis does not lead to a significant reduction of overall complications 
and mortality. The UK guideline (2005) states that all patients with predicted severe 
ABP should undergo early ERCP [22]. The American Gastroenterology Association 
(2007) states that early ERCP in predicted severe ABP without signs of cholangitis 
is controversial [23] and the American College of Gastroenterology (2006) 
recommends that early ERCP is to be performed only in patients with severe ABP 
and acute cholangitis [24]. The Japanese guidelines (2006) recommend an urgent 
ERCP in patients in whom biliary duct obstruction is suspected and in patients with
cholangitis [25]. The Dutch guidelines published by the Dutch internal medicine 
association (2005) state that ERCP is warranted within 24 h in patients with predicted 
severe ABP with cholangitis or biliary obstruction and within 72 h in cases with 
predicted severe ABP without signs of cholangitis or obstruction [26]. All guidelines 
state that an emergency ERCP in predicted mild ABP is not indicated. In the light of 
the somewhat confusing and in part conflicting recommendations we investigated 
the opinion and attitude of Dutch gastroenterologists toward the application of 
(early) ERCP in the clinical management of ABP by means of a nationwide survey.
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metHods
A questionnaire was sent by mail to all registered gastroenterologists across the 
whole of the Netherlands in May 2008 (registry source: Dutch Association of 
 Gastroenterologists). In total 283 consultant gastroenterologists were invited to 
participate in this anonymous survey. The questionnaire consisted of nine questions. 
Five questions dealt with demographic issues including age, gender, type of 
hospital (academic, community hospital), total years of ERCP experience, and 
number of ERCPs performed yearly. The remaining questions focused on the 
endoscopic management of ABP: Is there an indication for early ERCP (multiple 
conditions listed, more than one could be selected)? In what time frame in relation 
Table 1  Questionnaire
1. Function Gastroenterologist
Other
2. Age ……years
3. Gender M / W
4. Hospital General / academic
5. ERCP’s/year and years of experience
6.  Indication for early ERCP in ABP  
(< 24 till 72 hours after admission)
Yes
No: Not enough evidence/ experience/ expert 
based/ I don’t no
7. When is an early ERCP indicated a. Always
b. Cholangitis
c. Predicted severe pancreatitis:……..
d.  Increased bilirubine:……..uM
e.  Common bile duct (CBD)stones
f.   Distended CBD…………mm (age, CC)
g.  Papillary stone
h.  other reason;………..
8. When do you perform an ERCP in ABP? a.  < 24h after onset symptoms / admission
b.  <48h after onset symptoms / admission
c.  < 72h after onset symptoms / admission
d.  Other timing:…….
9.  When do you perform an endoscopic 
sphincterotomy (ES), when an ERCP is 
carried out
a.  Always
b.  CBD stones (CBDS)
c.  Distended CBD on cholangiography
d.  Ampullary stone
e.  Increased bilirubine without CBDS
f.  Cholangitis
g.  Other;……….
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to start of symptoms or admission is an early ERCP indicated (within 24, 48, or 72 h)?; 
when is an early ERCP indicated? (multiple conditions listed, more than one could 
be selected); in what circumstances/ conditions do you perform a sphincterotomy? 
(multiple conditions listed, more than one could be selected). Questions had 
additional space for free text (Table I). Closure date for receiving the questionnaires 
was August 2008. Descriptive statistics were applied to summarize results.
results
Two hundred eighty-three questionnaires were sent to consultant gastroenterolo-
gists and responses were received from 148, a response rate of 52%. 
Characteristics of responders 
Eighty-three percent of the responders were men, with an average age of 47 years 
(SD 8). Twentythree percent were employed in an academic hospital. The vast 
majority (92%) performed ERCP in daily practice, with an average practice time of 
nearly 12 years and an average of 70 ERCP yearly. 
Indication for erCP 
The vast majority of gastroenterologists (n = 144, 96.6%) stated that they would 
considerer performing early ERCP, within 72 h of admission, in patients with 
suspected ABP. Of these 144 gastroenterologists, only 10 did not routinely perform 
ERCPs as they did not master this technique themselves. Four gastroenterologists
disapproved of any indication for early ERCP in ABP, three because of insufficient 
scientific evidence to support its application and one based on “gut-feeling”. Of the 
96.6% responders who would consider performing ERCP in ABP, 14% stated that
they always perform ERCP. The remainder of the respondents considers ERCP only 
if a concomitant condition is present such as a dilated CBD (95%), coexistent 
cholangitis (87%), common bile duct stone (s) (CBDS) (72%), jaundice (59%), 
ampullary stone (68%) or (predicted) severe ABP (35%).
timing of erCP
More than half of the consultant gastroenterologists (51.4%) consider the optimal 
time point to perform ERCP in ABP to within 24h of admission or after first symptoms 
(Table II).Timing  of ERCP within 48 h after admission or start of symptoms was still 
considered appropriateby72.3%ofgastroenterologists.The timing in 6.1% was 
determined by clinical signs of the patient with ABP. The mean age of responders 
did not differ between the different time intervals (data not shown). Application of 
endoscopic sphincterotomy Fifty-eight percent of the consultant gastroenterolo-
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gists always perform an ES whenever they carry out an ERCP for suspected ABP, 
regardless of the presence or absence of specific features. The percentage of 
responders who would perform ES in the presence of a particular feature was: 
CBDS 98%, distended CBD 77%, cholangitis 75%, ampullary stone 76.5%, and 
increased bilirubin 41%.
dIsCussIon
The response rate of our nationwide questionnaire was 52%, which is well in line 
with other surveys [27–29]. With 92% of responders performing ERCPs, with an 
average procedural experience of 11.7 years and an average yearly case load of 70 
procedures, this survey gives an interesting insight into the opinion and attitude of 
experienced endoscopists with regard to the indication of ERCP in suspected ABP 
in the Netherlands. Several guidelines exist with regard to the endoscopic treatment 
in suspected ABP (Table III). These guidelines are based on conflicting data from a 
few clinical randomized trials comparing ERCP with or without ES with conservative 
management in ABP [13–16,18,30] and have non-uniform outcomes and recom-
mendations (Table III). Nevertheless, two statements about early ERCP in APB 
seem undebated at present: (1) ERCP does not seem to have a clear advantage in 
patients with predicted mild ABP and (2) co-existing cholangitis is an indication for 
Table 2  Timing of ERCP
Timing of ERCP(N = 148) Cumulative
< 24h after first complaints (9) 6.1%
< 24h after admission (29) 19.6%
< 24h after first complaints or admission (34) 23%
< 24h after first complaints or admission: in SABP (4) 2.7% 51.4%
< 48h after first complaints (13) 8.8%
< 48h after admission (6) 4.0%
< 48h after first complaints or admission (12) 8.1% 72.3%
< 72h after first complaints (18) 12.1%
< 72h after admission (2) 1.3%
< 72h after first complaints or admission (10) 6.8% 89.1%
Depending on clinical sign’s (9) 6.1% 98.6
Never (2) 1.4% 100%
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an emergency ERCP (within 24 h of admission). The aim of the present study was 
to assess the opinion and attitude of Dutch gastroenterologists on early ERCP in 
ABP compared with published studies and national guidelines. The vast majority of 
consultant gastroenterologists (96.6%) attest to a potential role for (early) ERCP in 
ABP. In this regard it should be noted that in the Netherlands, like in most parts of 
Europe, ERCPs are carried out by gastroenterologists. In the United Kingdom, 
however, many surgeons perform ERCP. It would be interesting to know whether 
their opinions differ from those of gastroenterologists. Seven percent of Dutch gas-
troenterologists claim that ERCP is always indicated in ABP, regardless of the 
presence or absence of any additional sign or symptom. This would indicate that 
those colleagues also perform ERCP in uncomplicated cases without a predicted 
severe disease course. In line with the outcome of the meta-analyses and the 
majority of published guidelines, the vast majority of responders (87%) consider 
ERCP a legitimate procedure in case of cholangitis. Thirteen percent does not 
recognize the potential benefits of early ERCP in case of cholangitis and probably 
rely on antibiotics, judging against all guidelines. Remarkably, a predicted course 
of severe AP was a reason to perform an ERCP for only 35% of responders, which 
is in sharp contrast to the national Dutch, US, and UK guidelines. These results 
might be explained by the lack of guideline knowledge, a disbelief in the guidelines, 
or the impact of the recent meta-analysis of Petrov et al. [21], which indicates hat 
ERCP in patients ABP without cholangitis does not lead to a significant reduction of 
overall complications and mortality. In case of suspected or proven biliary 
obstruction depending on which additional sign or symptom is present including 
jaundice, dilated CBD, CBDS, or ampullary stones, 60–95% of the responders 
perform an ERCP in ABP. This is in line with Dutch and Japanese guidelines. 
However, only for a dilated CBD there is near consensus with 95% of responders 
performing ERCP. In case of jaundice, CBDS, or an ampullary stone less than 
two-thirds of responders consider ERCP. The small majority of responders (54%) 
perform ERCP within 24 h after the onset of symptoms or hospital admission. This 
is in accordance with the Dutch guidelines in patients with predicted severe ABP 
with cholangitis or biliary obstruction. The remainder still performs ERCP within 72 
h, which in accordance to the guidelines would be appropriate in cases with 
predicted severe ABP without signs of cholangitis. Nearly 60% of endoscopists 
always perform an ES in case of suspected ABP. Ninety-eight percent performs an 
ES whenever CBDS are detected. Other indications to carry out an ES range from 
40 to 77%, indicating a liberal application, but not uniform consensus in the 
application of ES. Importantly, studies have not systematically addressed this 
important aspect of ERCP in ABP. National guidelines do not specify if and when an 
ES should be performed. This survey reflects the current opinion of Dutch gastro-
enterologists regarding the application of early ERCP in ABP in the Netherlands 
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and to what extent ollowed. There is no apparent reason to assume that in other 
European countries in which primarily gastroenterologists perform ERCP, results 
would be different. Despite published studies and national guidelines, the 
indications to perform ERCP and its timing vary greatly. There is also no uniformity 
as to if and when ES is done. One could argue if this is due to ignorance about 
studies results and published guidelines. However, in recent years substantial 
attention has been drawn to this issue, especially in relation to the recently published 
Dutch guidelines. It therefore seems more likely that many Dutch endoscopists are 
not convinced by the existing literature evidence and proposed guidelines and still 
follow their “gut” feeling. The results of this survey highlight the need for additional 
clinical trials. For such studies to have a true impact on practicing physicians, they 
should reflect patient management in daily clinical practice. This would require a 
comparative trial with a sufficient number of patients using practical inclusion 
criteria, clear crossing-over criteria, a cannulation failure scenario, and end-points 
that are clinically relevant in terms of patient outcome. In such a study ES should be 
an integral part of ERCP treatment.
Declaration of interest: The authors report no CONFLICTS OF INTEREST. 
The authors alone are responsible for the content and writing of the paper.
Table 3   Indication of ERCP in treatment of ABP: the guidelines and meta-analysis
National guideline/meta-analysis Mild Severe Cholangitis Suspected 
Obstruction
UK22 - + + -
USA / AGA23 - +/- + -
USA / ACG24 - + + -
Japan25 - - + +
Netherlands26 - + + +
Meta-analysis 1 
(Sharma et al, 1999)19
+ + + +
Meta-analysis 2
(Ayub et al, 2004)20
- + + -
Meta-analysis 3
(Petrov et al, 2008)21 
- - + -
UK  United Kingdom
AGA  American Gastro Association
ACG  American College of Gastroenterologists
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ABstrACt
Background. Recurrent attacks of acute biliary pancreatitis (RABP) are prevented 
by (laparoscopic) cholecystectomy. Since the introduction of endoscopic retrograde 
cholangiopancreaticography (ERCP), several series have described a similar 
reduction of RABP after endoscopic sphincterotomy (ES). This report discusses the
different treatment options for preventing RABP including conservative treatment, 
cholecystectomy, ES, and combinations of these options as well as their respective 
timing.
Methods. A search in PubMed for observational studies and clinical (comparative) 
trials published in the English language was performed on the subject of recurrent 
acute biliary pancreatitis and other gallstone complications after an initial attack of 
acute pancreatitis.
Result. Cholecystectomy and ES both are superior to conservative treatment in 
reducing the incidence of RABP. Cholecystectomy provides additional protection 
for gallstone- related complications and mortality. Observational studies indicate 
that cholecystectomy combined with ES is the most effective treatment for reducing 
the incidence of RABP attacks.
Conclusion. From the literature data it can be concluded that ES is as effective in 
reducing RABP as cholecystectomy but inferior in reducing mortality and overall 
morbidity. The combination of ES and cholecystectomy seems superior to either of 
the treatment methods alone. A prospective randomized clinical trial comparing ES 
plus cholecystectomy with cholecystectomy alone is needed.
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IntroduCtIon
Acute biliary or gallstone pancreatitis (ABP) is an inflammatory condition of the 
pancreas induced by gallstones [1]. The initial treatment of ABP can be either 
conservative or interventional. The coexistence of cholangitis is an accepted 
indication for the performance of endoscopic retrograde cholangiopancreaticogra-
phy (ERCP). However, whether this procedure is performed for patients with ABP 
depends on local expertise and guidelines, as is the decision to perform an 
endoscopic sphincterotomy (ES) [2–5]. After patients have recovered from their first 
attack of ABP, most guidelines advocate a cholecystectomy to prevent a recurrent 
attack or other gallstone-related disorders such as symptomatic choledocholithia-
sis, cholecystitis, gallstone ileus, jaundice, and cholangitis [2–5]. ‘‘Recurrent’’ 
symptomatic choledocholithiasis after an initial attack of ABP may be preexisting 
common bile duct (CBD) stones not detected at the time of the primo episode or 
stones that migrated from the gallbladder into the CBD after initial stone clearance. 
Choledocholithiasis also may have developed newly within the bile duct after chole-
cystectomy. The incidence of recurrent acute biliary pancreatitis varies widely, from 
0% to 57%, depending on the population studied, the initial treatment, and the 
follow-up time (Table 1). Recently, observational studies point toward a reduction in 
recurrent ABP attacks and other gallstone complications when ES is performed for 
selected groups of patients [6–10]. Based on whether a patient has undergone ES, 
cholecystectomy, or both, the post-ABP-status of a patient can be classified into 
four categories: 1 (no ES and no cholecystectomy), 2 (no ES with cholecystectomy), 
3 (ES without cholecystectomy), or 4 (ES with cholecystectomy). To date, no studies 
have compared any combination of these conditions (Table 1). The current report 
reviews additional medical interventions to determine which are most effective for 
preventing recurrent medical problems after an attack of ABP.
Cholecystectomy versus conservative treatment
Evidence that a cholecystectomy actually reduces the incidence of recurrent ABP 
is scarce. The evidence that does exist originates mainly from older retrospective 
studies that observed no recurrent ABP after a cholecystectomy compared with a 
25% to 61% rate of ABP recurrence with conservative management [11–17]. From a
retrospective population-based cohort study, it was concluded that a cholecystec-
tomy reduces the risk of a recurrent or de novo ABP almost to the same level as 
found in the general population [18]. The overall age- and sex-adjusted incidence 
of acute pancreatitis before cholecystectomy was 6.3 to 14.8 per 1,000 patient 
years. Cholecystectomy for patients without a prior ABP attack reduced the relative 
risk for the development of acute pancreatitis to 2 (0.65 per 1,000 person years). 
The recurrence rate for acute pancreatitis of cholecystectomized patients was 2.7 
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per 1,000 patient years. However, none of these had a biliary origin. Importantly, 
13% to 14% of all patients presenting with ABP have a history of a prior cholecystec-
tomy without having undergone ERCP and ES [19, 20].
endoscopic sphincterotomy versus conservative management
Uomo et al. [6] prospectively investigated the effect of ES on patients after a first 
attack of ABP who were considered unfit for surgery. In the ES group, the observed 
rate of recurrent ABP was 5% compared with 57% in the conservative group after a 
mean follow-up period of 30 and 23.8 months, respectively. Paloyan et al. [21] 
confirmed this rate of ABP recurrence after conservative treatment with their rate of 
48%. However, Hammarstrom et al. [8] observed a 12.5% rate of ABP recurrence in 
noncholecystectomized patients during a median follow-up period of 79 months. 
Other prospective observational studies with various follow-up times showed ABP 
recurrence rates of 0.9% to 6.4% for patients treated with ES alone [7, 8, 22–24]. 
Intraoperative choledocholithiasis is present in 13% to 24% of patients undergoing 
cholecystectomy and bile duct exploration for symptomatic gallstone disease 
[25–29], including ABP [29, 30]. In 3% to 6% of the patients in whom CBD stones 
were detected, the stones were asymptomatic without preoperative indicators, 
negative abdominal ultrasound findings, or laboratory parameters [25, 29, 31]. It is 
believed that about 15% of these asymptomatic patients eventually will become 
symptomatic and require further interventional treatment [32]. Evaluation of the 
CBD for a planned cholecystectomy to decide on CBD exploration should be 
scheduled with a tight interval because the prevalence of CBD stones may change 
in time. In fact, multiple studies have shown that the prevalence of CBD stones in 
relation to admission time decreases because of spontaneous stone migration 
[33–37] (Table 2). Conversely, when a CBD is found to be free of stones at 
admission, this might be not representative for the time of surgery because 
migration of gallbladder stones into the CBD may have occurred just before the 
operation. From a clinical management point of view, patients referred to the 
surgeon for a laparoscopic cholecystectomy after an attack of ABP can be classified 
as follows according to what is known about the presence of CBD stones: 1 (cleared 
CBD after ERCP/ES), 2 (no CBD stones on previous imaging investigations including 
ultrasound, magnetic resonance cholangiopancreatography [MRCP], endoscopic 
ultrasound [EUS], and ERCP), or 3 (unknown CBD stone status). Hence, 
perioperative CBD stone clearance is of great importance. Clayton et al. [38] 
performed a meta-analysis to compare endoscopic removal of CBD stones and 
cholecystectomy with cholecystectomy and intraoperative removal of CBD stones 
in terms of morbidity and mortality. They concluded that both approaches had 
similar outcomes and that treatment should be determined by local resources and 
expertise. Laparoscopic CBD duct exploration seems to be an ideal approach, but 
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most surgeons still are uncomfortable and untrained with this technique. The 
potential drawback of finding CBD stones intra-operatively is that conversion to an 
open procedure sacrifices the advantage of the laparoscopic approach. However, 
a postoperative ERCP may be unsuccessful in clearing the CBD, necessitating a 
second surgical procedure. Adopting a wait-and-see policy is associated with 
additional interventions and increased morbidity [32, 39–41]. On the other hand, a 
‘‘diagnostic’’ ERCP for detection and potential clearance of CBD stones before 
surgery is not justified because 76% to 87% of patients have no CBD stones, and 
the costs and potential complications of such an invasive approach are considerable 
[25–29].
In light of these considerations, preoperative assessment of CBD stones by means 
of noninvasive and cost-effective procedures such as laboratory values, multi-item 
scores, and imaging methods is of great clinical relevance. A wide variety of 
multi-item scores are suggested to be useful, but no two studies have identified the 
same variables. Factors thought to be discriminative by some are found to be of 
little use by others [41–63]. Recently, two studies assessed the value of 
gammaglutamyl- transferase (gGT) as a potential predictor for the presence of 
CBD stones. Peng et al. [64] investigated patients presenting with cholecystitis and 
found that there was a 33% chance of concomitant CBD stones with a gGT higher 
than 90 U/l and less than a 2% chance with a gGT lower than 90 U/l. In 1,002 
patients undergoing laparoscopic cholecystectomy for any reason, Yang et al. [65] 
observed that abnormal gGT values had a sensitivity of 84.1%, a specificity of 72%, 
a positive predictive value of 22.4%, and a negative predictive value of 97.9% for 
detecting concomitant CBD stones before surgery. Radiologic imaging techniques 
also can be used to detect CBD stones. Abdominal ultrasound is the safest, 
Table 2   Incidence of common bile duct (CBD) stones in acute biliary pancreatitis 
(ABP) in relation to time [33–37]
Time from admission CBD stones (%)
Admission 50-70%
< 24h 27
< 48h 23.1
2-3 days 25
4-5 days 12.5
>7 days 8
ACG  American College of Gastroenterologists
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cheapest, and least invasive imaging method available for visualizing the biliary 
tree. Unfortunately, its performance in detecting CBD stones is disappointing, with 
a reported sensitivity of only 25% to 58% and a specificity of 68% to 91% [66]. The 
sensitivity of the CT scan for detecting CBD stones is about 40%, which is too low 
for it to be of clinical use [67]. However, MRCP is a very accurate method detecting 
CBD stones, with a reported sensitivity of 82% to 95%, a specificity of 97.5% to100%, 
a positive predictive value of 95% to100%, and a negative predictive value of 90% 
to 98% [33, 68–73]. In a systematic review of seven prospective trails, Ledro- Cano 
[74] compared the performance between MRCP (n = 411) and endoscopic ultraso-
nography (n = 411) in detecting choledocholithiasis. They concluded that both 
imaging methods had a comparable and very high accuracy in detecting CBD 
stones. Some individual studies suggest that MRCP has a slightly lower sensitivity 
for detecting stones than EUS because the sensitivity of MRCP decreases as 
follows when stones become smaller: 67% to 100% for stones larger than 10 mm, 
89% to 94% for stones measuring 6 to 100 mm, and 33% to 71% for CBD stones 
smaller than 6 mm [69–72] Endoscopic sphincterotomy and cholecystectomy 
Hammarstrom et al. [8] followed 96 patients after an initial ABP event in an 
observational non randomized study for a median of 79 months (range, 33–168 
months). From this potentially biased study, it was concluded that ES without a 
cholecystectomy reduced the overall incidence of recurrent pancreatitis event 
(4.7% vs 9.4%; p = 0.02). Of those patients initially treated using ES, 35% required 
an additional cholecystectomy during the follow-up period. It is reported that 2% to 
33% of patients with symptomatic choledocholithiasis require an additional chole-
cystectomy, suggesting that patients with ABP are at greater risk for late gallstone-
related complications [75– 77]. This also is supported by the observation that 15% 
of the patients from the Hammarstrom study required an emergency cholecystec-
tomy after ES, compared with only 4% to 6% of patients presenting with symptomatic 
gallstone disease but not ABP [8, 75]. Higher cholecystectomy rates probably are 
due to the risk of acute cholecystitis after ES, which alone does not have a clear 
etiology [8, 78]. In a prospective non- randomized trial, Kahaleh et al. [79] 
investigated the rate of ABP recurrence after ES (n = 96) compared with ES and 
cholecystectomy (n = 66). The mean follow-up period was 1091 days. The observed 
rate of ABP recurrence was 2.1% compared with 3% (p = 0.278). Evidently, because 
of the nonrandomized study design, selection bias cannot be ruled out. Furthermore, 
this study has been published only in abstract form and other recurrent gallstone 
complications, for example, are not discussed. From the literature, the picture 
emerges that ES reduces the number of recurrent ABP events more than a chole-
cystectomy. Does this mean that we can skip performing a cholecystectomy after 
ABP? The answer is not straightforward. McAlister et al. performed a meta-analysis 
that included five prospective randomized trials [9, 80–83] showing the benefit of 
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an additional cholecystectomy after ES in case of symptomatic gallstone diseases, 
including ABP [84]. An additional cholecystectomy resulted in a lower death rate 
(7.9% vs 14.1%; p = 0.01) even in studies that included patients from higher-risk 
American Society of Anesthesiology (ASA) classes. In the patients for whom a 
wait-and-see policy was adopted, 16% experienced the development of biliary type 
pain or cholecystitis (relative risk [RR], 14.56; confidence interval [CI], 4.95–42.78), 
and more patients experienced recurrent jaundice or cholangitis (RR, 2.53; CI, 
1.09–5.87; p = 0.03), but no significant difference in recurrent ABP rates was 
observed (0.3% vs 1.3%; p = 0.39). Eventually, for 35% of the patients subjected to 
a wait-and-see policy, an additional cholecystectomy was performed, with median 
follow-up times ranging from 30 to 80 months. From these data, it seems apparent 
that a cholecystectomy after an ABP event is beneficial and indicated. What about 
the timing of the operation? No scientific data exist to guide the timing of surgery. 
Expert opinion guidelines are based on sound and practical reasoning. Windsor 
[17] proposed that a cholecystectomy should be performed within 1 month after the 
first episode of ABP because most recurrent ABP events occur within 1 month (if no 
additional ES was performed). When the initial episode of ABP is severe and 
accompanied by peripancreatic fluid collections or pseudocysts, cholecystectomy 
should be delayed until the pseudocysts have either resolved or persisted beyond 
6 weeks, at which time pseudocyst drainage can safely be combined with chole-
cystectomy [85]. Hammarstrom et al. [8] investigated the effect of an additional ES 
after an initial cholecystectomy in preventing recurrent ABP events. Their data 
showed a 0% rate for recurrent ABP events after cholecystectomy plus ES compared 
with a 19% rate for recurrent ABP events after cholecystectomy alone and 2% after 
ES alone. These data were not confirmed by Kahaleh et al. [79], who observed no 
difference between ES and ES plus cholecystectomy in preventing recurrent ABP 
(2.1% vs 3.0%). Furthermore, the high rates of ABP recurrence after cholecystecto-
my in the Hammarstrom et al. [8] study were not confirmed by Kaw et al. [7], who 
reported a rate of 2.4%. Boerma et al. [80] investigated the outcome of a cholecys-
tectomy for patients whose symptomatic CBD stones, ABP, or both were treated by 
an ERCP and ES. The patients were randomized into two groups: group 1 (ERCP 
and ES plus cholecystectomy) and group 2 (ERCP and ES plus a wait-and-see 
policy). They observed significantly higher rates of conversion from laparoscopic to 
open procedure in the wait-and-see group than in the cholecystectomy group (55% 
vs 20%; p = 0,01). This also was observed by Allen et al. [86] in a prospectively 
collected database (25% vs 4%; p\0.01). However, these observations were not 
confirmed in the meta-analysis by McAlister et al. described earlier.
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ConClusIon
Endoscopic sphincterotomy with or without an additional cholecystectomy offers 
better protection than cholecystectomy alone in terms of reducing the number of 
recurrent ABP events. An additional cholecystectomy after ES is indicated because 
studies suggest an added reduction in mortality and morbidity. The proper timing 
of the cholecystectomy has not been studied and is based on expert opinion. The 
current consensus is that surgery should be used for mild cases during the same 
hospital admission and severe cases after 6 weeks. To prevent recurrent ABP 
events or other gallstone-related disease, CBD stone clearance is an important 
issue. Therefore, diagnosing CBD stones to establish the proper indication for 
ERCP with ES and stone removal is an important and clinically relevant item. For 
this, MRCP and EUS are instrumental. Randomized clinical trials comparing the 
long-term effects of cholecystectomy and ES versus cholecystectomy alone for 
APB are indicated.
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ABstrACt
Background. Several reports suggest an increased rate of adverse reactions to 
azathioprine (AZA) in patients with Crohn’s disease (CD).
Aim. To compare the incidence of thiopurine-induced acute pancreatitis (TIAP) in 
patients with IBD with that in patients with vasculitis. 
Methods. This retrospective analysis was performed using data collected in three 
databases by two university hospitals (241 patients with IBD and 108 patients with 
vasculitis) and one general district hospital (72 patients with IBD). 
Results. The cumulative incidence of TIAP in CD equalled that of ulcerative colitis 
(UC) (2.6% vs. 3.7%), and this did not differ from vasculitis patients (2.6% vs.1.9%). 
Additionally, the cumulative incidence of TIAP in UC-patients was not different from 
vasculitis patients. In the IBD group, 100% of TIAP-patients were female , whereas 
in the vasculitis group the two observed TIAP cases (n=2 out of 2) concerned 
males (p=0.012). 
Conclusions. In this study, the alleged higher cumulative incidence of TIAP in CD 
compared to vasculitis or UC patients was not confirmed. Female gender appears 
to be a risk factor for developing TIAP in IBD patients.
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IntroduCtIon 
Drugs are thought to be a relatively rare cause of acute pancreatitis, with an 
estimated incidence between 1:1000 to 1:501, 2. The true incidence of drug related 
pancreatitis is hampered by underreporting of cases by clinicians to the appropriate 
authorities. Nevertheless, many drugs have been suspected of causing pancreatitis 
with evidence mainly derived from case reports and small cohort studies. Diagnosis 
of drug-induced pancreatitis may be cumbersome as in cases with mild to moderate 
severity abdominal complaints may not stand out against regular symptoms of the 
underlying disease. Diagnosis and subsequent identification of the culprit 
pathogenic drugs is pivotal since disease course may worsen if the causative drug 
is not withdrawn2. Few data exist on the mechanisms causing drug-induced 
pancreatitis. Clinically, certain subpopulations such as children, women, the elderly, 
and patients with inflammatory bowel disease appear to be at higher risk1, 2. 
The thiopurine bases 6-mercaptopurine (MP) and azathioprine (AZA) are widely 
used in the treatment of patients with inflammatory bowel disease (IBD) and 
vasculitis. These immunosuppressives, usually intended for maintenance treatment, 
reduce the need for corticosteroids in about 75% of patients. Median response time 
of effectiveness is three to four months3-6. Remarkably, several reports suggest an 
increased rate of AZA induced pancreatitis in patients with Crohn’s disease (CD) 
compared to other patients groups also suffering from idiopathic, chronic 
inflammatory conditions with auto-immune characteristics7, 8. Thiopurine use is 
known to induce adverse events in a fairly high percentage ranging from 10 to 
29%9, 10. Apparently, adverse events are not only drug-class specific, but may be 
disease-related as well7, 8. In this study we investigate whether the incidence of 
thiopurine induced acute pancreatitis (TIAP) is increased in patients with IBD, and 
CD in particular, in comparison with patients with autoimmune vasculitis. 
metHods
Patient selection and data collection
The study was performed with data enclosed in three databases from two university 
hospitals and one general hospital in the Netherlands. The IBD patients were 
treated at the VU University Medical Centre (VUMC) in Amsterdam and St-Anna-
Hospital (SAH) in Geldrop. The vasculitis patients were treated at the University 
Medical Centre of Groningen (UMCG). In all three databases (VUMC, UMCG and 
SAH) information was collected regarding patient characteristics, dosage of 
thiopurines, side effects, co-medication, duration of thiopurine use, and reason for 
discontinuation of AZA/MP. In the VUMC-IBD database, patients with IBD were 
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studied in an interception cohort from 01-01-2000 till 01-01-2007. The database is 
maintained daily to monitor IBD patients and their treatment. Diagnosis of IBD was 
established and classified by an experienced IBD-gastroenterologist (AvB). 
Azathioprine or MP was started in a therapeutic step-up approach similar to 
guidelines that recently have been advocated in the ECCO guidelines of IBD11-13. 
Information of IBD patients from the St Anna Hospital, a general hospital in Geldrop, 
was extracted from an IBD-database dating back to January 2000. Diagnosis of 
IBD was established by two gastroenterologists (RL and his colleague). Both were 
trained to manage thiopurine therapy similar to that at the VUMC. 
ANCA-positive-vasculitis patients who were treated at the UMCG with AZA were 
retrieved from the hospital records from the period January 1995 to February 2006. 
Patients were classified using the Chapel Hill Consensus Conference definitions14. 
All patients were initially treated with oral cyclophosphamide 1.5-2.0 mg/kg/d, in 
combination with corticosteroids. When remission induction was achieved for a 
three-month period, patients switched to AZA 1.5-2.0 mg/kg/d. A complete blood 
count was performed at week 2 and 4 after baseline to adjust the dose of AZA to 
maintain white blood cell count above 4.0 109/l. From twelve months onwards, the 
daily dose of AZA was tapered by 25 mg every three months to 1.5mg/kg 
bodyweight. 
Of all patients, thiopurine dosage, duration of therapy, laboratory results, body 
mass index, smoking habits, time to develop TIAP, and co-medication were 
collected. TIAP was defined as serum amylase or lipase equal or more than two 
times the upper reference limit of normal (200IU/l), combined with compatible 
clinical signs, such as chronic or acute epigastric pain with or without radiation to 
the back. Other aetiologies of acute pancreatitis (hypertriglycaemia, excessive 
alcohol use: ≥5 units per day, biliary causes and hypercalcaemia) had to be 
excluded. 
Cumulative incidence was defined as the number of new cases within a specified 
time period divided by the size of the population initially at risk. The time period 
used is the mean time that thiopurines were used by a specific cohort. The incidence 
rate was defined as the number of new cases per unit of person-time at risk, 
correcting for possible differences in mean follow-up time (thiopurine use in this 
study) between different studies. In this study, we defined the incidence rate as the 
number of new cases of acute pancreatitis or TIAP/100000/year.
statistical analysis
To compare proportions of TIAP in different treatment groups, an independent 
samples t-test, chi-square test and Fischer-exact test were used with a p < 0.05 
considered as significant (SPSS version 14, Chicago, U.S.). 
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results
Between 2000 and 2007, 1002 patients were collected in the VUMC database. 
Twenty-eight patients were excluded because they eventually proved to have no 
IBD, leaving 974 patients. Of these, 733 patients did not use thiopurines in the 
studied intercept. Consequently, 241 patients were available for analysis. Crohn’s 
disease was diagnosed in 162 patients, ulcerative colitis (UC) in 76 patients, and 
colitis of undetermined origin (IBD-U) in 3 patients (table 1). In the SAH database 
424 patients with IBD were collected. Seventy-two IBD patients used AZA or MP. 
Table 1   Patient characteristics VUMC, SAH and UMCG
VUMC SAH UMCG IBD versus 
Vasculitis
Total on AZA/MP 241 72 108
MP (N (%)) 48  (20%) 5 (7%) - P=0.0023
AZA (N (%)) 192 (80%) 67 (93%) 108 (100%) P<0.0001**
Gender: male (%) 38.6 52.8 59.3 P<0.0001*
Average age in yrs (SD) 42.6 (13.1) 46.3 (14.3 ) 51.9 (14.7  ) P<0.0001**
CD (N (%)) 162 (67%) 34  (47%) -
UC (N (%)) 76 (33%) 32  (44%) -
IBD-U (N (%)) 3  (1%) 6  (8%) -
PSC 11 (3.5%) 0 (0%)
Mean BMI in kg/m*m (SD) 23.8  (4.5) 24.2 (3.7) 27.0 (4.7) P<0.0001*
Mean dose AZA mg/kg (SD) 1.87 (0.60) 1.82 (0.65) 1.43 (0.49 ) P<0.0001*
Mean dose MP in mg/kg (SD) 1.15 (0.42) 0.89 (0.30) -
Mean age at diagnosis  
in years  (SD)
27.0 (13.5) 35 (14.6) 51.1 (17.0) P<0.0001*
Mean age at start  thiopurines  
in years (SD)
34.8 (12.1) 40.25 (14.3) 51.1 (17.0) P<0.0001*
Mean thiopurine use  
in months (SD)
35.8 (43.3) 27.2 (30.9) 38.8 (28.8) P<0.0001*
ANCA+-vasculitis
MPA (n)
NCGN (n)
WGD (n)
- - 108
14
10
84
* Independent samples t-test  ** Chi-square test
CD=Crohn’s disease;UC=Ulcerative colitis; IBD-U=Colitis of undetermined origin; BMI=Body mass 
index; AZA=Azathioprine; MP=Mercaptopurine; MPA=Microscopic polyangiitis; NCGN=Non-classified 
glomerulonefritis; WGD=Wegener’s disease; PSC= primary sclerosing cholangitis
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Crohn’s disease was diagnosed in 34 patients, UC in 32 patients and IBD-U in 6 
patients (table 1). All of the 108 ANCA-positive-vasculitis patients in the UMCG 
database received AZA. Fourteen patients were diagnosed with microscopic 
polyangiitis, 84 with Wegener’s disease and ten with non-classified glomerulone-
phritis (table 1). 
differences between academic and general district hospital in  
IBd patients
A higher percentage of the IBD patients received thiopurine therapy in the academic 
hospital (VUMC) when compared to patients treated in the general district hospital 
(SAH) (24% versus 17%, P<0.001). In the academic hospital, a higher percentage 
of IBD patients had CD (67% versus 47%, p=0.012), a longer duration of IBD (96 
versus 24 months, p=0.012) and a younger age at diagnosis (27 versus 35 years, 
p=0.03, see table 1). Azathioprine, next to MP use, was more commonly used in 
the general hospital when compared to the cohort of the university hospital (93 
versus 80%, p=0.0023).
demographic and clinical differences between IBd and  
vasculitis patients
Patients with IBD were significantly younger than vasculitis patients (42.6 and 46.3 
years versus 51.9 years, p<0.0001). Average BMI, age at first use of a thiopurine 
derivative (baseline) and percentage of men were lower in the IBD group (p<0.0001). 
Azathioprine mean dosage was higher in the IBD group (1.87 and 1.82 mg/kg 
versus 1.43 mg/kg, p<0.0001, table 1). The mean duration of thiopurine use was 
longer in the vasculitis cohort than the IBD cohort (3.23 year versus 2.73 year, 
p<0.00001)
 
Cumulative incidence of acute pancreatitis
Overall, acute pancreatitis was diagnosed in 10 IBD patients on thiopurines. One 
patient was diagnosed with an alternative aetiology of acute pancreatitis, being a 
post-double-balloon-enteroscopy-pancreatitis. Therefore, nine patients with acute 
pancreatitis met the inclusion criteria for having a possible TIAP (9/313 = 2.9%) in 
the IBD population (VUMC plus SAH). Two patients with IBD, who were diagnosed 
with TIAP (normal liver functions and absence of choledocholithiasis on abdominal 
ultrasound), had a history of acute biliary pancreatitis for which they underwent an 
endoscopic retrograde cholangiopancreaticography (ERCP) with endoscopic 
sphincterotomy and subsequent laparoscopic cholecystectomy. In the UMCG 
vasculitis database (n=108), 2 patients with vasculitis developed TIAP, which 
resulted in a 1.9% cumulative incidence of TIAP (table 2). Both patients lacked a 
history of alcohol abuses, cholecystectomy or endoscopic sphincterotomy.
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In the IBD group TIAP was equally often observed in CD-patients and UC-patients 
(2.6% and 3.7%, p=0.79). This was not statistically significantly higher in comparison 
with the cumulative incidence in the vasculitis group (2.9% vs. 1.9%, p = 0.735). 
Cumulative incidences of patients with CD, UC and vasculitis were equal (2.6% and 
3.7% vs. 1.9%, p= 0.443 and p=1.00, respectively). The incidence of TIAP in IBD 
was higher in women than in men (5.1% vs 0%, p=0.012). No difference in TIAP 
cumulative incidence was observed between patients in the university hospital 
(VUMC) and patients from the general district hospital (SAH: p=0.79). Another 
difference between the IBD and vasculitis patients was the time lag between 
initiation of AZA/MP therapy and the development of TIAP. All IBD cases developed 
TIAP within 1 month, whereas in vasculitis patients this time interval was more than 
8 months (see table 2, p<0.0001). The cumulative incidence of TIAP in patients on 
MP compared to AZA was similar, respectively: 1.9% vs 3.0% (p=0.58).
Incidence rate of acute pancreatitis
The incidence rate of acute pancreatitis (due to any cause) in this IBD-cohort was 
calculated by approximation: ten patients with acute pancreatitis divided by a total 
of 313 IBD patients divided by 2.73 years of follow up, times 100.000, resulting in an 
incidence rate of 1070/100.000/year. The incidence rate of TIAP in the IBD cohort 
(thus, related to thiopurine use) was calculated to be: nine cases in 313 patients in 
an average 2.73 year, resulting in 1053/100.000/year. In the vasculitis group a 
similar calculation was performed: two patients with acute pancreatitis divided by a 
total of 108 patients with vasculitis divided by 3.23 years of follow-up, times 100.000, 
which resulted in an incidence rate of 573/100.000/year. 
Incidence rate of TIAP in patients with IBD not using thiopurines was calculated 
using the university database. Of the 733 patients with IBD, not using thiopurines, 
the follow-up of 658 patients could be retrieved, which resulted in a mean follow-up 
of 7.7 years. In this IBD-cohort, 4 patients with acute pancreatitis were retrieved 
(two patients with acute pancreatitis without identifiable cause, one mesalazine-
Table 3   Cumulative incidence of thiopurine induced acute pancreatitis (TIAP)
Diagnosis CD UC IBD-U Vasculitis Total
Male  / Female (n)
TIAP: M / F (n)
70 / 126
0 / 5
59 / 49
0 / 4
6 / 3
0 / 0
64 / 44
2 / 0
199 / 222
2/ 9
Total (n)
%TIAP Total
196
2.6%
108
3.7%
9
0%
108
1.9%
421
2.6%
M = male; F = Female; TIAP = Thiopurine induced acute pancreatitis; CD = Crohn’s disease; UC = 
Ulcerative Colitis; IBD-U = IBD Unclassified
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induced acute pancreatitis and one following double-balloon-enteroscopy), 
resulting in a cumulative incidence of 0.6%.  The incidence rate in this group was 
4/658/ 7,7 times a 100000 or 79 cases of acute pancreatitis/100.000/ year. Since 
these calculations represent a rough approximation of the true incidence rate, 
additional analytical statistical elaboration was not performed.
dIsCussIon
In this study we assessed the cumulative incidence of TIAP in 313 patients with IBD 
and 108 patients with vasculitis. The cumulative incidence of acute pancreatitis in 
all patients was 2.4%, irrespective of the causative factor. The overall cumulative 
incidence of TIAP was 2.1%. The cumulative incidence of TIAP was not statistically 
significant different between patients with CD (2.6%), UC (3.7%) or IBD (2.9%), 
when compared to patients with vasculitis (1.9%). Therefore, TIAP seemed not to be 
a disease specific phenomenon. 
The cumulative incidence of TIAP in IBD patients varies in literature between 1% to 
6%7, 8, 15-18, which is in line with our findings (2.9 %). Incidence of TIAP in patients 
with vasculitis is not widely reported. Apart from a few case reports, only one 
retrospective study reported no occurrence of TIAP in vasculitis (n=85, Wegener’s 
disease) 7. In our series; the cumulative incidence of TIAP in patients with vasculitis 
was relatively low (1.9%), but in the range of TIAP in IBD patients. Intriguingly, TIAP 
developed in one patient with Wegener’s disease (n=1/84; 1.2%). 
Previous series reported an increased cumulative incidence of TIAP in CD-patients 
compared to UC, autoimmune hepatitis and autoimmune vasculitis-patients7, 8. 
Several theories have been put forward to explain this observation: 1) a higher 
percentage of smokers (Relative Risk 3.59)19, 2) duodenal involvement of CD 
(5-12%)8, and 3) a higher prevalence of choledocholithiasis or sludge8. In our 
series, however, UC and vasculitis patients who developed TIAP did not smoke, 
and duodenal involvement of CD was not present. Additionally, the cumulative 
incidence of TIAP did not differ between CD and UC patients (2.6 vs. 3.7%). 
The two patients with vasculitis developed TIAP after an eight month period which 
is a much longer interval when compared to patients with IBD in whom TIAP 
occurred within 30 days (p<0.0001). In IBD patients an ”idiosyncratic” reaction 
appears to be the cause of TIAP, and this 30 days interval of developing TIAP is also 
reported by others8, 20. Thiopurines are usually initiated in patients already using 
corticosteroids, suggesting a direct toxic component in the development of TIAP. 
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Corticosteroids were simultaneously used in 4 out of 9 patients of this series 
(prednisone). A female predominance in patients with TIAP has been described 
before in patient series suffering from IBD, but not as stern as in this cohort of IBD 
patients7, 8. It is unclear what this observed susceptibility to TIAP caused in female 
IBD patients. Both vasculitis patients who developed TIAP were man.
Regarding the aetiology of adverse effects of thiopurines several pharmacodynam-
ic and metabolic options have been suggested in literature 21-23. Conflicting data 
have been published concerning the role of the thiopurine metabolizing enzyme 
inosine triphosphate pyrophosphatase (ITPase) in developing TIAP22-24 . Patients 
with diminished ITPase may be at an increased risk of developing TIAP. Whether 
TIAP is a drug class (thus thiopurine) induced phenomenon is recently challenged 
by reviews on the use of the non-conventional thiopurine 6-tioguanine25 .6-Tiogua-
nine-induced pancreatitis is rare and has been reported to occur in only 1% of IBD 
patients previously intolerant to the classical thiopurines  AZA and/or MP. 
Remarkably, 10% of this 6-tioguanine-using group had developed TIAP when using 
AZA before 26.
An average annual incidence rate of a first attack of acute pancreatitis of 
approximately 12.4-15.9/100.000/year has been reported in a reference Dutch 
population (1988-2003)27. The incidence rate in these cohorts of vasculitis and 
IBD-patients on thiopurines is approximately 38 (573/15) and 75 (1070/15) times 
higher than the observed yearly incidence rate in the Netherlands. This increased 
relative risk (allegedly well above 10) strongly corroborates the association between 
thiopurine use and acute pancreatitis. A much lower incidence of acute pancreatitis 
of 79/100.000/year in the IBD patients not using thiopurines compared to the above 
mentioned cumulative incidences of acute pancreatitis in IBD patients using 
thiopurines corroborates an association between thiopurines and acute pancreatitis.
On a statistical level the cumulative incidences did not differ between patient 
groups, but the absolute incidence rates for IBD 1053/100.000/year was twice that 
of the vasculitis group, which was within the range of the results reported by 
Weersma et al and Baja et al, both reporting an increased incidence rate of TIAP in 
CD if compared to other autoimmune diseases7, 8. In the study of Baja, the definition 
of TIAP was restricted to a one-month follow-up, which potentially excluded late 
onset TIAP8. Therefore, the results of our study should be compared prudently with 
this study, as TIAP in (our) non-IBD patients developed in general much later. 
However, implying their inclusion criteria and definitions, the TIAP percentage 
would be 0% in the vasculitis group in our series, which nearly equals their findings. 
The study by Weersma and colleagues only calculated the incidence rate, which is 
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not corrected by the follow-up time7. Consequently, a comparison with our findings 
would probably be biased by this difference in duration of follow-up. 
The incidence of acute pancreatitis is increased in IBD patients, compared with the 
general population28. An acute pancreatitis incidence of respectively 1,4% and 
1,6% has been reported in cohorts of 852 and 5073 IBD-patients, respectively 29, 30. 
This is in line with our observations in non-thiopurine-using IBD patients (79/100.000/
year) plus thiopurine-using IBD-patients (1070/100.000/year) resulting in a total of 
1.1% acute pancreatitis per year in this IBD cohort.
In addition, chronic pancreatitis (CP) is associated with IBD with an estimated 250 
times higher incidence in patients with IBD (1.2%) compared to the average risk in 
the general population31. Finally, a recent report by Ravi and colleagues documented 
a substantial, relatively increased, proportion of IBD patients in a cohort of patients 
suffering from autoimmune pancreatitis (AIP) 32. 
Primary sclerosing cholangitis (PSC) ,which is more prevalent in patients with IBD 
(2-10%)33, is associated with an increased incidence of acute pancreatitis34, 35. PSC 
in patients on thiopurines was diagnosed in 11 patients of the university database 
(4.6%%). No cases of PSC were reported in the district hospital (0%). Resulting in a 
overall PSC incidence of 3.5% in IBD patients, which is in line with the reported 
findings. However, none of the patients with acute pancreatitis in our databases 
were diagnosed with PSC.
In this study, neither ALT increase was observed nor alcoholic abuse was reported 
in relation with the attacks of acute pancreatitis. Clinical features of chronic 
pancreatitis were not present in our TIAP cases. Since thiopurine use is a well-known 
risk factor for acute pancreatitis, it cannot be excluded that clinicians refrained from 
a full scaled diagnostic run, including MRI or CT-scan, assessment of all known 
metabolic risk factors and exclusion of rare pathogenetic causes of pancreatitis. 
This potential flaw probably applies more to IBD-patients as TIAP is uncommon in 
vasculitis patients, and therefore more extensively investigated by treating 
physicians. Rechallenge with thiopurines to corroborate or ascertain the diagnosis 
TIAP is unusual in clinical practice due to the high risk of inducing a potentially 
severe and life threatening disease such as TIAP is.
The duration of thiopurine use in the vasculitis patient cohort was longer than in the 
IBD cohort (3.23 years versus 2.72 years, p<0.0001). However, since TIAP in 
IBD-patients developed within 30 days of thiopurine use, a longer follow-up time 
was not likely to increase the number of TIAP cases.
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Differentiation between vasculitis induced acute pancreatitis and drug induced 
pancreatitis is difficult, because vasculitis may induce pancreatitis itself36. The 
diagnostic accuracy of TIAP in these autoimmune vasculitis patients may therefore 
be hampered, in particular since our patients had no re-challenge with AZA, and, 
hence, vasculitis-induced pancreatitis, although an uncommon finding, cannot be 
ruled out. Consequently, the true cumulative incidence of TIAP in autoimmune 
vasculitis patients might be (slightly) lower.
In conclusion, contrary to existing literature data, we observed a statistically 
comparable cumulative incidence of TIAP in patients with IBD and vasculitis. In IBD 
patients, a female gender is associated with the risk for developing TIAP. In vasculitis 
patients, TIAP tends to develop later than in IBD-patients, which may point towards 
a different aetiology.
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ABstrACt
Objectives: Obesity and insulin resistance cause fatty infiltration of many organs, 
including the pancreas (pancreatic steatosis [PS]) and the liver (nonalcoholic fatty 
liver disease [NAFLD]). In contrast to NAFLD, patho-physiological mechanisms 
and clinical relevance of PS remain unknown. This study aimed to identify a possible 
relation between PS and NAFLD.
Methods: In this study including postmortem collected material of 80 patients, 
clinical and histological data were collected and revised. Patients with hepatic or 
pancreatic disease and alcohol abuse were excluded. Nonalcoholic fatty liver 
disease activity score was used for grading the histology of the liver, whereas 
pancreatic lipomatosis score assessed PS. Ordinal logistic regression was used to 
analyze correlations.
Results: Interlobular and total pancreatic fat were both related to NAFLD activity 
score in patients without steatogenic medication (P = 0.02 and P = 0.03, 
respectively). When corrected for body mass index, no relation could be found. 
Total pancreatic fat was a significant predictor for the presence of NAFLD (P = 
0.02). Presence of intralobular pancreatic fat was related to nonalcoholic steato-
hepatitis; however, total fat was not.
Conclusions: This study demonstrates that NAFLD and PS are related. This 
relationship seems to be mediated by general obesity. Intralobular pancreatic fat is 
associated with nonalcoholic steatohepatitis.
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IntroduCtIon
Obesity is becoming an endemic problem with tremendous prevalence numbers 
(1). In the period of 1981 till 2006, the prevalence of obesity among adults in the 
Netherlands increased from 5.1% to 11.3% (2). Obesity is related to a variety of 
diseases, such as cancer, metabolic syndrome, and cardiovascular disease (1,3,4). 
In humans, obesity and associated insulin resistance can cause fat infiltration of 
striated muscle, the heart, the liver, and the pancreas (5). Excessive storage of fat 
in pancreatic tissue has been termed pancreatic lipomatosis (PL), first described by
Ogilvie (6). The term lipomatosis is old and is now replaced by steatosis. Literature 
regarding pancreatic steatosis (PS) is scarce, and its pathophysiological 
mechanisms and clinical relevance are largely unknown. The degree of PS is 
correlated with age and BMI (7,8). Moreover, Stamm (8) demonstrated a significant 
association of severe generalized atherosclerosis, adult-onset diabetes, and 
pancreatic fibrosis with PS. Recently, Tushuizen et al. (9) observed increased 
pancreatic lipid content, measured by 1H magnetic resonance (MR) spectroscopy, 
in a prospective study of 36 patients with A-cell dysfunction, a finding that was not 
confirmed by Saisho et al. (10) who performed a computed-tomography based 
retrospective study on 1886 adult patients. Furthermore, PS is associated with 
several benign and malignant diseases, such as cystic fibrosis, chronic pancreatitis, 
steroid therapy, Shwachman-Diamond syndrome, pancreatic pseudohypertrophia, 
Johanson-Blizzard syndrome, viral infection, and pancreatic duct obstruction 
(11-14). Pancreatic steatosis also increases the risk of postoperative fistulas in 
pancreatic surgery and promotes dissemination and lethality of pancreatic cancer 
(15,16).
In the liver, accumulation of triglycerides in the absence of excess of alcohol use 
and other chronic liver diseases has been defined as nonalcoholic fatty liver 
disease (NAFLD). After exclusion of secondary causes (eg, steatogenic medication), 
a strong association exists between NAFLD, insulin resistance, and the metabolic 
syndrome (17,18).  As a consequence of the increasing prevalence of obesity, 
NAFLD is becoming the most common cause of chronic liver disease.19 It ranges 
from simple hepatic steatosis through nonalcoholic steatohepatitis (NASH) to liver 
cirrhosis and increased risk for developing hepatocellular carcinoma (20). Simple 
hepatic steatosis is of minor clinical importance because less than 5% develops 
end-stage liver disease (21). However, in patients with NASH, characterized by 
lobular inflammation and ballooning degeneration of hepatocytes, approximately 
20% develops cirrhosis, liver failure, and/or hepatocellular carcinoma (21). Some 
authors introduced the entity nonalcoholic fatty pancreas disease (NAFPD) for PS, 
thereby suggesting a possible relation between NAFLD and NAFPD/PS (22,23). 
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However, an association of NAFLD and PS has never been demonstrated in larger 
cohort studies. The objective of this study was to analyze this relation between PS/
NAFPD and NAFLD. 
mAterIAls And metHods
In this retrospective study, autopsy material of the pancreas and the liver of 
deceased patients admitted to the VU University Medical Centre, Amsterdam, the 
Netherlands, was collected and reviewed. Patients of 18 years and older were 
included (24). Exclusion criteria were (1) features consistent with hepatic or 
pancreatic disease collected from medical files, (2) major abdominal surgery in 
patient’s medical history: major gastrointestinal surgery (small intestinal surgery, 
Billroth surgical intervention, Roux-en-Y anastomosis, hepatobiliary, and pancreatic 
surgery due to possible aspecific lymphocytic infiltration of liver tissue), (3) 
documented history of excessive alcohol intake (≥21 drinks per week for men and 
≥14 drinks per week for women), and (4) severe postmortem changes that hampered 
histological features. The aim of this study was to evaluate the relation between 
obesity-related NAFLD and PS; therefore, (5) patients who used steatogenic 
medication (eg, methotrexate, highly active antiretroviral therapy, amiodarone, and 
glucocorticoids (25) or with unknown previous use of medication were excluded.
Histopathological study
Autopsy material was assessed by an experienced hepatobiliary histopathologist 
(EB) and 2 research fellows (MS and EG), all blinded for patients’ clinical and 
laboratory data. Only 1 liver slide and 1 pancreas slide were available per patient. 
Unfortunately, it was not known where in the liver and the pancreas these samples 
were taken. Different scoring systems were used for the liver and the pancreas.
liver
Hepatic steatosis and inflammation were graded according to the NAFLD activity 
score (NAS) (24). Slides were stained with hematoxylin and eosin sand assessed 
regarding the presence of macrovesicular steatosis (0-3), lobular inflammation 
(0-2), hepatocellular ballooning (0-2), and fibrosis (0-4). The sum of individual 
grades, excluding fibrosis, represents NAS. In addition, the overall amount of 
hepatic steatosis (macrovesicular and microvesicular) was scored (0-3).
Pancreas
Because there is no evidence-based scoring system for PS, our research group 
developed a new grading system: the PL score (article under submission). This 
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grading system emphasizes the distribution of intralobular, interlobular, and total 
pancreatic fats. In our validation process, we have found a high interrate variability 
(kappa 0.89) and a low intrarater variability (kappa, 0.10). Therefore, all pancreatic 
slides were scored by 1 panel (MS, EG, and EB). With this system, the quantity of 
adipocytes per microscopic pancreas compartment (interlobular and intralobular) 
was graded according to 5 separate groups: 0, 0% to 7% adipocytes; 1, 8% to 14%; 
2, 15% to 25%; 3, 26% to 50%; and 4, greater than 51%. When grading total amount 
of fatty infiltration (interlobular and intralobular), an additional group was added: 5, 
greater than 75%. In addition, the presence of lymphocytes was noted.
Clinical data
From (electronic) medical files and autopsy reports, clinical and biochemical data 
were collected in a central database. Collected clinical data consisted of sex, BMI, 
age, blood pressure, history of alcohol and tobacco abuse, and medical history, in
particular cardiovascular, liver, and gastroenterological diseases, diabetes mellitus, 
and cause of death. Body mass index was calculated from the data noted in 
autopsy reports. Biochemical data, such as viral serologic data (eg, hepatitis B and 
C antibodies), autoimmune serologic data (antinuclear factor, smooth muscle 
antibodies, and mitochondrial antibodies), and storage diseases (iron and copper 
studies), were collected. The use of steatogenic medication and medication used 
in patients with the metabolic syndrome (eg, antihypertensive, antidiabetic, and 
lipid-lowering medication) within the last 12 months were noted.
statistical Analysis
Univariate ordinal logistic regression was used to test the relation between ordinal 
histological parameters. Binary parameters were analyzed by binary logistic 
regression. Multivariate analysis (forward stepwise ordinal regression) was 
performed to correct for BMI and sex. A P ≤ 0.05 was considered to be statistically 
significant. Results are presented as ordinal regression coefficients (B) and P 
values. All analyses were performed using SPSS software version 15 for Windows 
(SPSS, Chicago, Ill).
Patient Characteristics
In total, more than 900 autopsies were performed in the VU University Medical 
Center from January 2005 till December 2007. In this period, 598 autopsies were 
performed on clinical patients of the VU University Medical Center. Of these 
patients, 415 met the inclusion criteria and were enrolled in this study. Eventually, 
335 subjects were excluded predominantly because of inferior quality of the 
histological material due to postmortem changes or absence of histological 
material. Six patients were excluded because of major abdominal surgery: 2 
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Whipple operations, 1 Roux-en-Y anastomosis, 1 Billroth II anastomosis, 1 hepatitis 
e causa ignota after small intestinal surgery, and 1 right extended hemihepatecto-
my. Thirty-four patients were excluded because they used steatogenic medication. 
Thirty-six patients had an unknown medication history and were therefore excluded. 
Characteristics of 80 eligible patients are summarized in Table 1. There were no 
patients with cryptogenic cirrhosis.
results
In Table 2, the scores for liver and pancreatic fats are given for all patients. Almost 
half of the patients had steatosis of the liver. Nonalcoholic steatohepatitis was 
observed in the minority of patients with steatosis, although the density of lobular 
infiltrates was generally low. Fibrosis was uncommon and, if present, of minor 
degree. Pancreatic lipomatosis was found in most patients. This consisted mainly 
of interlobular fat accumulation. Pancreatic fibrosis was uncommon. No pancreatic 
inflammatory infiltrates were identified.
Pancreatic and Hepatic relations 
Several statistically significant correlations between histopathologically determined 
pancreatic and hepatic fats could be found (Table 3). Significant relations were 
found between pancreatic interlobular and hepatic macrovesicular fats (B, 0.377; 
Table 1   Patients’ characteristics (mean ± sd or number of cases (%))
     Patients  (n = 80)
Male sex 42 (53%)
Age of death 68 ± 14
BMI (kg/m2) 26 ± 5
NAFLD (including NASH) 37 (46%)
NASH 3 (4%)
Cause of death:
Cardiovascular 49 (61%)
Gastro-enterologic 2 (3%)
Malignancy 14 (17%)
Other 15 (19%)
Abbreviations: BMI = body mass index,  NAFLD = non-alcoholic fatty liver disease,  NASH = non-alcoholic 
steatohepatitis
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Table 2   Histopathologic analysis [amount (percent %)]
Patients
liver Macrovesicular
steatosis
0 46 (58)
1 21 (26)
2 9 (11)
3 4 (5)
Lobular inflammation 0 62 (78)
1 16 (20)
2 2 (2)
3 0 (0)
Hepatocellular ballooning 0 77 (96)
1 3 (4)
2 0 (0)
Fibrosis 0 74 (93)
1A 0 (0)
1B 0 (0)
1C 5 (6)
2 1 (1)
3 0 (0)
4 0 (0)
Pancreas Intralobular steatosis 0 20 (25)
1 33 (41)
2 12 (15)
3 11 (14)
4 4 (5)
Interlobular steatosis 0 12 (15)
1 26 (33)
2 14 (17)
3 15 (19)
4 13 (16)
Intralobular fibrosis 0 59 (74)
1 14 (17)
2 7 (9)
Interlobular fibrosis 0 65 (81)
1 12 (15)
2 3 (4)
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P = 0.03) and NAS (B, 0.377; P = 0.03) and between total pancreatic and hepatic 
macrovesicular fats (B, 0.340; P = 0.04) and NAS (B, 0.348; P = 0.03).
However, pancreatic intralobular fat was not related to hepatic steatosis (Fig. 1). 
Histological features of NASH (eg, hepatocyte ballooning and lobular inflammation) 
were not related to PS.
multivariate Analysis
Body mass index was significantly related to hepatic macrovesicular fat (B, 0.172; 
P = 0.001), total fat (B, 0.134; P = 0.008), and NAS (B, 0.18; P = 0.001; Fig. 2). It was 
not related to lobular infiltration (B, 0.054; P = 0.35) or hepatocellular ballooning 
(B, 0.025; P = 0.84). The relation of BMI and pancreatic fat was present for intralobular 
fat (B, 0.119; P = 0.01), interlobular fat (B, 0.152; P = 0.002), and total fat (B, 0.155; 
P = 0.001; Fig. 2). No significant relation between pancreatic and hepatic fats could 
be demonstrated when a correction for BMI was performed performed by multi- 
variate analysis. This phenomenon was shown to be present disregarding the 
distribution of pancreatic fat (Table 4). (data not shown). When corrected for age, 
sex, and BMI, no significant relation between hepatic and pancreatic fats could be 
found (Table 4).
Correction for age or sex did not statistically affect the relation of pancreatic and 
hepatic fats. Remarkably, male subjects failed to show a significant relation on all 
variables, whereas female subjects inclined to statistical significance on most 
variables. Correction for BMI did not change this distinction.
Table 3   Relations between liver and pancreas histology [ordinal regression 
coefficients (p-values)]
Pancreas liver
Total fat Macro - 
vesicular fat
lobular 
infiltration
Ballooning NAS
Intralobular fat 0.149
(0.425)
0.209
(0.276)
0.095
(0.682)
0.493
(0.297)
0.219
(0.250)
Interlobular fat 0.318
(0.053)
0.377
(0.026)
0.191
(0.341)
0.466
(0.317)
0.377
(0.025)
Total fat 0.298
(0.056)
0.340
(0.035)
0.213
(0.270)
0.639
(0.188)
0.347
(0.031)
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Cut off Points
When dividing PS into percentiles, a cutoff point of 15% of total pancreatic fat was 
statistically significantly related to hepatic macrovesicular fat (B, 1.027; P = 0.04), 
total fat (B, 1.161; P = 0.02), and NAS (B, 1.056; P = 0.03; Fig. 3). Furthermore, a 
similar cutoff point of 15% of total pancreatic fat was related to the diagnosis NAFLD 
(B, 1.148; P = 0.02). In patients with NASH, a cutoff of 25% of intralobular pancreatic 
fat was significantly associated with this diagnosis (B, 2.708; P = 0.04). However, 
total pancreatic fat was not related to NASH.
Figure 1   Relation of PS and hepatic NAS with SEM
The relation of PS (A, intralobular; B, interlobular; C, total) with hepatic NAS. Intralobular PS is not related 
to hepatic NAS; interlobular and total PS do. P value is calculated by ordinal logistic regression. NAS, 
NAFLD activity score. 
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Table 4   Relation between NAFLD en PL after correction for BMI, age and gender
Relation between
Pancreatic and Hepatic
Normal Corrected for
BMI Gender Age BMI, 
Gender, 
Age
Intralobular fat Macrovesicular fat 0.276 0.840 0.207 0.253 0.716
Total fat 0.425 0.985 0.324 0.451 0.985
NAS 0.250 0.942 0.154 0.248 0.763
Interlobular fat Macrovesicular fat 0.026 0.485 0.039 0.017 0.582
Total fat 0.053 0.469 0.081 0.050 0.724
NAS 0.025 0.459 0.040 0.019 0.596
Total fat Macrovesicular fat 0.035 0.710 0.046 0.022 0.784
Total fat 0.056 0.626 0.079 0.051 0.879
NAS 0.031 0.602 0.041 0.024 0.697
Figure 2   Relation between BMI and PS/NAFLD
The relation of BMI with NAS and total PS. Both relations are statistically significant (P = 0.001 and P = 0.001, 
respectively).
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dIsCussIon
This is the first histopathological study focusing on the relation of NAFLD and PS. 
In imaging studies, Tushuizen et al. (9) using MR spectroscopy and Schwenzer et 
al.(26) using MR imaging could not demonstrate a relation between pancreatic and 
hepatic fats. Unfortunately, both studies lacked power owing to low numbers of 
included patients (N = 36 and N = 17, respectively). In our study, pancreatic and 
hepatic tissues of 80 deceased patients were reassessed and graded according to
the generally accepted NAS and a newly developed PL score to find relations 
between NAFLD and PS.
relations of Pancreatic and Hepatic fats
From our analyses using the criterion standard (ie, histologic examination), a 
relation between various types of hepatic and pancreatic fats could be clearly 
demonstrated. Especially, a cutoff of more than 15% total pancreatic fat seemed to 
be significantly correlated with NAFLD. In particular, pancreatic fat was more 
significantly related to macrovesicular hepatic fat than to total hepatic fat. This 
suggests different pathophysiological mechanisms of macrovesicular and 
microvesicular fats, consistent with available data from other publications (27). 
Nonalcoholic fatty liver disease was stated to be associated with macrovesicular fat 
caused by accumulation of triglycerides, whereas microvesicular steatosis is 
caused by mitochondrial dysfunction due to, for instance, toxins.
Body mass Index, Insulin resistance, and sex
Significant relations between PS and NAFLD disappeared when BMI correction in 
the multivariate analysis was performed. Therefore, this study provides evidence 
that BMI is involved in the pathogenesis of pancreatic and hepatic fats. Possibly, 
insulin resistance is involved because a strong relation between obesity and nsulin 
resistance has been shown (28). Insulin resistance influences peripheral lipolysis, 
thereby increasing the portal flux of fatty acids, which is suggested to be the “first 
hit” in NAFLD (29). In addition, in an overfed status, adipocytes produce inadequate 
amounts of adipocytokines (eg, leptin, adiponectin, and tumor necrosis factor α), 
causing further peripheral and hepatic insulin resistance, resulting in increased 
hepatic fatty acid accumulation accumulation (30-33). Whether mechanism(s) 
associated with fatty acids hepatic influx are similar in PS is questionable. 
Interestingly, in contrast to NAFLD, PS was not related to features of the metabolic 
syndrome (P = 0.38), which can be explained by the studies’ retrospective fashion 
and its accompanied missing clinical data. Another controversial argument is the 
presence of adipocytes in pancreatic parenchyma in comparison with lipid droplets 
in liver tissue.
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Differences in sex regarding visceral fat and serum triglycerides have been 
demonstrated by many studies. In female patients, this correlation is more 
significant than in male patients (34). Nielsen et al.(35) hypothesized that the export 
of free fatty acids (FFAs) derived from visceral lipolysis to the liver is more 
pronounced in female patients. Another study demonstrated only in female patients 
the significant correlation of insulin resistance and visceral fat (36). These findings 
are in accordance with this study, where a sex correction in a multivariate analysis 
only showed a significant correlation between PS and NAFLD in female subjects.
Pancreatic Cellular lipotoxicity and overt t2dm
This study demonstrates a trend of overt T2DM and quantity of total PS (P = 0.092). 
These findings confirm results of recent reports demonstrating the deleterious 
effects of the accumulation of FFAs on A-cell function and the development of 
T2DM. In murine models (Zucker diabetic fatty rats), male animals who were fed a 
standard diet represented significantly more hyperglycemia and FFA when 
compared with their female counterparts (37-39). Administration of peroxisome 
proliferator-activated receptor-F agonists in mice on a high-fat diet decreased 
pancreatic islet cell triglyceride content and consequently improved insulin 
secretion (40).  Proposed mechanisms by which FFA causes damage to A-cell 
dysfunction are effects on insulin biosynthesis, preproinsulin gene expression, and 
expression of uncoupling proteins (5,41). Whether these data can be translated to 
humans needs to be clarified.
Hypothesis
We hypothesize that BMI and associated insulin resistance play an important role 
in pancreatic adipocyte infiltration, causing PS. In addition, insulin resistance (due 
to a high BMI) causes peripheral lipolysis, thereby increasing the flux of fatty acids 
to the liver (29). Lipolysis in the pancreatic adipocytes further increases the portal 
flux of fatty acids. As a consequence, hepatic insulin resistance and NAFLD 
develop. This implies that PS precedes NAFLD. Because this is not a prospective 
study, conclusions regarding the chronological order of appearance cannot be 
drawn.
limitations
Some limitations of this study need to be noted. Owing to its retrospective fashion, 
some important data are missing, undermining the statistical power. In addition, 
fibrosis in histological liver samples could not be accurately assessed because no 
Gieson staining was performed. Numbers of patients with NASH were low and 
statistical analysis to demonstrate possible relations between NASH and PS 
therefore impaired. Another limitation is the presence of 1 histological slide per 
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patient and the concomitant potential for sampling error because pancreatic and 
hepatic fats can be irregularly distributed (34,42). Further research for unraveling 
PS’s pathophysiological mechanism and clinical consequences on the long-term is 
warranted.
Conclusions
Pancreatic steatosis is a relatively new clinical entity that remains to be clarified yet. 
Fatty liver and fatty pancreas are related especially in women, but the relationship 
seems to be mediated by general obesity. Therefore, using the name NAFPD can 
be justified owing to the coexistence with NAFLD. Whether NAFLD and PS are 
caused by similar mechanisms needs to be further investigated.
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CHAPTER 7
ABstrACt 
More research is now focused on pancreatic steatosis. Multiple definitions, clinical
associations and synonyms for pancreatic steatosis are described in the literature 
and can be confusing. The integration and comparison of several studies 
concerning this topic is therefore challenging. In the past, pancreatic steatosis was 
considered an innocuous condition, a bystander of many underlying diseases 
(such as congenital syndromes, hemochromatosis and viral infection). However, 
evidence that pancreatic steatosis (strongly associated with obesity and the 
metabolic syndrome) has a role in type 2 diabetes mellitus, pancreatic exocrine 
dysfunction, acute pancreatitis, pancreatic cancer and the formation of pancreatic 
fistula after pancreatic surgery is emerging. This Review focuses on the different 
etiological factors and the clinical consequences of pancreatic steatosis.
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IntroduCtIon
The incidence of overweight and obesity is increasing each decade. the current 
prevalence of obesity in the USA is 33.8% and in western Europe is approximately 
20% (1,2). Obesity (BMI >30) is associated with several serious diseases –metabolic 
syndrome, cardio vascular disease and cancer– which makes obesity a major public 
health issue (3–5) moreover, obesity causes fatty infiltration of organs, such as the 
liver (non alcoholic fatty liver disease [NAFLD] or nonalcoholic steato hepatitis 
[NASH]), striated muscle, heart and pancreas (6,7). The latter condition, pancreatic 
steatosis, was first described in 1933 by Ogilvie (8). In his human post mortem study 
he observed 9% pancreatic fat in lean individuals versus 17% pancreatic fat in obese 
individuals. Olsen et al.(9) reported that the amount of pancreatic fat increases 
significantly with age (P <0.05) and Stamm(10) found significantly more type 2 
diabetes mellitus and severe generalized atherosclerosis in patients with >25% fat in 
their pancreas (P <0.01) (9,10). The introduction of imaging techniques such as ultra-
sonography, CT and MRI, confirmed the associations of pancreatic steatosis with 
obesity and type 2 diabetes mellitus (11–15). However, obesity is not a pre requisite 
for pancreatic steatosis, as the disease also occurs in non-obese individuals (that is, 
patients with cystic fibrosis, iron overload, viral infections, chemo therapy and chronic 
alcohol abuse) (16–22). Currently, research on pancreatic steatosis focuses on 
several different topics, such as its association with type 2 diabetes mellitus, acute 
pancreatitis, pancreatic cancer and the formation of pancreatic fistula.
To date, the ‘true’ incidence of pancreatic steatosis is unknown owing to a lack of 
clear definitions and research. this review summarizes available literature on the 
topic of pancreatic steatosis and reports the current knowledgeof this condition. 
Potential clinical consequences and future research directions are also described. 
revIew CrIterIA
A PubMed search was performed using the following search terms: “pancreatic 
steatosis”, “pancreatic lipomatosis”, “NAFPD”, “fatty pancreas”, “pancreatic fat”, 
“pancreatic fatty replacement” and “pancreatic fatty infiltration”. The search was 
limited to English, Dutch or German articles; human as well as animal studies were
accepted. This search retrieved a total of 159 articles and the abstracts were 
carefully scanned for their clinical relevance; 84 papers were excluded from this 
Review (in 53 papers pancreatic steatosis was not the main topic of discussion, 26 
papers did not discuss the consequences of pancreatic steatosis and five abstracts 
with corresponding articles could not be retrieved). Additionally, articles were 
selected according to our own expertise on the topic.
124
CHAPTER 7
nomenClAture
Several synonyms of ‘pancreatic fat accumulation’ are reported in the literature, 
including: pancreatic lipomatosis, pancreatic steatosis, fatty replacement, fatty 
infiltration, fatty pancreas, lipomatous pseudohypertrophy and nonalcoholic fatty 
pancreas disease (naFPD) (9,21,23–27). Unfortunately, researchers use the above-
mentioned terms with several different clinical and histological identities and the 
integration and comparison of several studies concerning this topic is therefore 
challenging. After reviewing the literature on pancreatic steatosis, we formed the 
following concept (detailed below) on the condition and will use the nomenclature 
for pancreatic steatosis as outlined in table 1 throughout this review. In our opinion, 
pancreatic steatosis, pancreatic lipoma tosis and fatty pancreas are general terms 
that can be used for all forms of pancreatic fat accumulation. Steatosis is a general
term for parenchymal intra cellular fat accumulation (28) and pancreatic steatosis 
would therefore describe accumulation of fat in islet cells or acinar cells (29). 
However, in the literature this term is also used for fat accumulation in adipocytes 
(30). We therefore believe pancreatic steatosis can be used for the description of all 
kinds of pancreatic fat accumulation. In our opinion, ‘fatty replacement’ must be 
reserved for cases in which damage to pancreatic acinar cells has led to their death 
(such as viral infection or pancreatic duct ligation), which then results in their 
replacement in the pancreas by adipocytes (31). Fatty replacement has been 
stated as being irreversible (26), whereas fatty infiltration (pancreatic infiltration of 
adipocytes caused by obesity (32) is possibly reversed by weight reduction and 
appropriate medications, such as troglitazone (33,34). Fatty infiltration, a relatively 
old term, will probably be replaced by the term NAFPD (25). However, we propose 
that the term NAFPD should be reserved for pancreatic steatosis in association with 
obesity and metabolic syndrome as this disease subtype is crucially different from 
pancreatic steatosis associated with congenital syndromes. Pancreatic lipomatosis 
is used as a synonym for fatty replacement of the exocrine tissue and fatty infiltration; 
therefore, we believe pancreatic lipomatosis can be used as a general term concerning 
pancreatic steatosis (26,35) whether pancreatic lipomatosis must be distinguished 
from lipomatous pseudo hypertrophy is unclear. Some investigators employ the 
latter term for the condition when the pancreas is enlarged (uniformly or focally), the 
exocrine system is replaced by fat, and when no association can be found with 
obesity (23,36) However, pancreatic steatosis also enlarges the pancreas, which 
can be uniform or focal, and is not always related to obesity (14,37). We therefore 
believe that lipomatous pseudohypertrophy is an extreme variant of pancreatic fat 
accumulation and is therefore not a different clinical subtype in its own right.
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dIAGnosIs
Small amounts of pancreatic fat accumulation are common and are not associated 
with clinical signs and symptoms (31). By contrast, a substantially increased 
amount of pancreatic steatosis may be related to different clinical syndromes (type 
2 diabetes mellitus, exocrine insufficiency, pancreatic cancer). Pancreatic steatosis 
is usually detected by abdominal imaging techniques and incidentally reported by 
the radiologist during clinical workup for several disorders, or during autopsy. 
Histology in histological examinations, an increased number of pancreatic adipocytes 
will be found in pancreatic tissue (Figure 1) (32).
Table 1   Common nomenclature and proposed definitions for pancreatic steatosis
Nomenclature Definition in literature Proposed definition
Pancreatic Fatty replacement of exocrine General term for pancreatic
lipomatosis tissue;(26) fatty infiltration (35) fat accumulation
Pancreatic Fat accumulation in islet or acinar General term for pancreatic
steatosis* cells;(29) fat accumulation inpancreatic 
adipocytes (30)
fat accumulation
Fatty pancreas General term for pancreatic fat General term for pancreatic
accumulation fat accumulation
Lipomatous Enlarged pancreas; exocrine Extreme variant of
pseudohypertrophy systemisreplacedwithadipocytes; not 
associated with obesity (23)
pancreatic fat accumulation
Fatty replacement* Death of acinar cells with Death of acinar cells with
subsequent replacement with subsequent replacement
Adipocytes (31) with adipocytes
Fatty infiltration Infiltration of adipocytes owing Infiltration of adipocytes
to obesity (32) owing to obesity
Nonalcoholic fatty Increased fat in the pancreas (25)
Pancreatic fat accumulation
pancreas disease* in association with obesityand 
metabolic syndrome
Nonalcoholic fatty Pancreatitis owing to pancreatic fat Pancreatitis owing to
steatopancreatitis* Accumulation (25,110) pancreatic fat accumulation
*Suggested terms that should be made standard definitions.
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The amount of steatosis can be quantified using a subjective scoring system 
(25,31,38), as no scoring system for pancreatic steatosis has been validated in 
patients yet, our study group has developed and validated the Pancreatic lipo matosis 
score (M.M. Smits and E.J.M. van Geenen, unpublished work). A more objective 
method for measuring the amount of fat in the pancreas is morphometric analysis, a 
computer assisted technique that exactly calculates the amount of pancreatic fat 
based on the area highlighted during micro scopy (39). Some evidence exists that 
pancreatic fat accumulation is unevenly distributed in the pancreas (with fatty 
replacement being more severe at the anterior aspect of the pancreas) and 
consequently sampling errors can occur during histological grading of pancreatic 
steatosis in pancreatic biopsies (40). with immunohistochemistry or electron 
microscopy, intracellular lipid accumulation can be shown in exocrine parenchyma 
and islet cells (12,32,41). Moreover, lee and colleagues (12) showed that intra cellular 
lipid accumulation precedes adipocyte infiltration. unfortunately, the current 
nomenclature for pancreatic fat accumulation makes no distinction in the accumulation 
of triglycerides in parenchymal or adipocytal tissue. Walters and coworkers (31) 
demonstrated that leukocyte infiltration accompanies pancreatic steatosis. However, 
Mathur et al.(25) and our study group7 were not able to reproduce these findings.
Figure 1   Histological findings of pancreatic steatosis
On microscopy, a surplus of adipocytes can be found within the pancreas (arrow). Hemotoxylin and eosin 
stain. Original magnification ×50.
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Imaging techniques
As histological examination requires a biopsy, pancreatic steatosis is most often 
found using imaging techniques. using ultrasonography, steatosis in the pancreas 
presents as a hyperechogenic pancreas (11,42). It must be kept in mind that, 
especially in obese patients, the pancreas is not always (completely) visible with 
abdominal ultrasonography techniques. Furthermore, pancreatic fibrosis is also 
hyperechogenic on abdominal ultrasonography, which virtually excludes this 
imaging technique as a screening tool for lipid deposition in the pancreas (42,43). 
When ultrasonography is applied for the detection of pancreatic steatosis, the 
kidney or the liver can be used as reference point; an echogenity of the pancreas 
higher than the liver or kidney could indicate pancreatic steatosis, while an 
echogenity similar to retroperitoneal fat implies the highest amount of pancreatic 
steatosis (44,45). 
A complete steatotic pancreas will show as having the same density as adipose 
tissue using abdominal CT (14). The amount of pancreatic steatosis on CT can be 
measured using Hounsfield units, correlated to the spleen. as a steatotic pancreas 
will be hypodense on CT images (Figure 2), the amount of Hounsfield units compared 
to the spleen will be negative. No cutoff points for pancreatic steatosis on CT have 
been defined yet. The CT scan can be performed with or without intravenous 
contrast (46,47) and exposure to radiation with this technique hampers its use in 
research. 
Several MRI methods are capable of measuring lipids in the pancreas, such as 
in-phase, opposed-phase and spectral– spatial excitation techniques (15,48). On 
T1weighted and T2weighted sequences, a steatotic pancreas will show as being 
(slightly) hyper intense compared with the liver (49), while opposed-phase sequences 
show a reduction in signal intensity in steatotic pancreases (47,50). Short time 
inversion recovery (stir)weighted sequences will retrieve a value of null in steatotic 
pancreases (a null value in stir-weighted sequences is characteristic of fat) (49). 
With the use of magnetic resonance spectroscopy (MRS), the amount of ectopic 
triglycerides can be quantified noninvasively (13). In 2010, Lee and colleagues (12) 
showed an almost identical distribution of triglycerides in the exocrine and 
endocrine pancreas. MRS measurements of triglycerides in the whole pancreas 
can therefore be used as a surrogate marker for islet triglycerides. Furthermore, Hu 
et al.(51) reported that the three-dimensional Iterative Decomposition with echo 
asymmetry and least squares estimation (IDEAL)MRI method was superior to MRS 
in the measurement of pancreatic fat (51). 
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Using endoscopic retrograde cholangiopancreatography, severe pancreatic steatosis 
can present with ductal obstruction that resembles pancreatic carcinoma (52). 
However, pancreatic steatosis can be distinguished from pancreatic carcinoma by 
its abrupt obstruction in the main pancreatic duct with smooth tapering (52).
Although CT and MRI are useful techniques for detecting pancreatic steatosis, their 
use is hampered by lack of research, and the detection limit for pancreatic steatosis 
using these methods is unknown. Additionally, no papers reported cutoff points for 
clinical symptoms, or sensitivity and specificity for the detection of pancreatic 
steatosis with these imaging techniques. Future research must focus on these 
matters and comparative trials are needed to conclude which technique is superior 
for detecting pancreatic steatosis. For now, the ‘gold standard’ for detecting 
pancreatic steatosis remains histology and biochemical measurements, but MRS is 
almost equivalent to histology and biochemical measurements for in vivo use.
etIoloGY
As mentioned in the introduction, obesity is strongly associated with pancreatic 
steatosis (8–10,25,44,53–57). Obesity results in adipocytes infiltrating the pancreas 
Figure 2   CT scan of pancreatic steatosis
A steatotic pancreas (arrow) will appear hypodense compared with the spleen (arrowhead) on CT scan 
images. Courtesy of T. L. Bollen, St Antonius Hospital, The Netherlands.
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(32). Moreover, increasing age has been associated with an increase in the levels 
of pancreatic steatosis (9,39). In childhood and adolescence the amount of fat 
increases linearly with the volume of the pancreatic parenchyma (39).  However, in 
adulthood the amount of fat increases independently of the amount of pancreatic 
parenchyma. Obesity and age are not the only causes of pancreatic steatosis. 
various syndromes and diseases are associated with the disease, as discussed 
below.
Congenital syndromes
Pancreatic fat replacement has been associated with a number of congenital 
syndromes, such as cystic fibrosis (18,58–69), shwachman–Diamond syndrome 
(49,70–74), Johanson–Blizzard syndrome (75), and heterozygous Carboxylesterli-
pase mutations (35 ). These syndromes also share pancreatic exocrine insufficiency 
as a symptom. in cystic fibrosis, mucous plugs obstruct the pancreatic ductules, 
thereby leading to damage and death of pancreatic parenchyma with subsequent 
exocrine dysfunction. It has been hypothesized that the empty spaces are then 
filled up with adipocytes (31). In the other congenital syndromes
the cause of pancreatic steatosis is still unknown.
hemochromatosis
In hemochromatosis, iron overloading occurs in the cells of the reticuloendothelial 
system. When the iron storage capacity of the reticuloendothelial system reaches 
its limit, iron is stored in the parenchyma of other organs (most often in the heart, 
liver, skin and endocrine organs such as the pancreas). Iron overload in the 
pancreas causes exocrine and endocrine dysfunction, pancreatic fibrosis and fat 
replacement (76). Lin et al.(17) have presented a patient with transfusion-depen-
dent myelodysplastic syndrome who developed pancreatic fat replacement after 
numerous blood transfusions and consequent iron overload. This observation was 
confirmed by the development of pancreatic steatosis in patients with transfusion-
dependent α-thalassemia major (77,78). Iron overload has been hypothesized to 
cause fatal damage to the pancreatic parenchyma, which is replaced by adipose 
tissue (fatty replacement). Toxic agents or medications in many articles, the 
relationship between pancreatic steatosis and Cushing syndrome or steroid therapy 
is stated (26,31,52,79). However, no statistical analysis was performed in the original 
1966 paper by Walters (31) that identified severe pancreatic steatosis in patients 
who were treated with cortisone or its analogues. In a case report, Makay et al.(19) 
presented an individual with pancreatic steatosis after neoadjuvant chemotherapy 
with gemcitabine. Additionally, in 2009, rosiglitazone has been shown to exacerbate 
pancreatic fat infiltration (80).
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other factors
Pancreatic fat replacement is related to pancreatic duct obstruction and can be 
induced by viral infections (for example, infection with reoviruses) (16,31,81,82). 
Duct obstruction leads to necrosis of the acinar cells, with fat replacement within 48 
h. Hepatic disease has also been suggested to be a cause of pancreatic steatosis 
(26,37,79). Currently, only case reports of patients with chronic hepatitis B and liver 
cirrhosis underpin this hypothesis (31,36,83). Furthermore, pancreatic steatosis 
has been associated with malnutrition and has been observed in a patient with 
kwashiorkor (84). However, its clinical relevance in association with this form of 
malnutrition is unknown. In patients with AIDS, pancreatic steatosis can also be 
found in association with low BMI, hypo-albuminosis and acinar atrophy (85). 
Chehter and colleagues (85) hypothesized that AIDS leads to protein-energy 
malnutrition, which then leads to pancreatic changes, as seen in individuals with 
kwashiorkor.
ClInICAl ConsequenCes
metabolic syndrome and diabetes mellitus
Obesity is associated with the metabolic syndrome (or syndrome X), which consists 
of hypertension, low plasma HDl cholesterol levels, hypertriglyceridemia, impaired 
glucose regulation and abdominal obesity (86). Obesity also causes fat infiltration 
of organs such as the liver, striated muscle, heart and pancreas (6). Consequently, 
NAFLD is strongly associated with the metabolic syndrome, and some clinicians 
suggest that it must be part of the definition of this disorder (87). This suggestion is 
supported by the fact that pancreatic steatosis, related to obesity, is associated 
with the metabolic syndrome (44) and NAFLD (7).
The association of insulin resistance with the metabolic syndrome is the cornerstone 
of the pathogenesis of type 2 diabetes mellitus. Type 2 diabetes mellitus occurs 
when pancreatic β cell dysfunction leads to impaired  nsulin secretion in the context 
of insulin resistance (88).
The pathogenesis of β cell dysfunction is still unclear, but glucotoxicity and 
lipotoxicity have been proposed to have a role (for more information see the review 
by van Raalte et al.89). In animal models, triglyceride overload in pancreatic β-cells 
leads to lipotoxicity and lipoapoptosis (90). The increased pancreatic triglyceride 
levels observed in NAFPD have been hypothesized to reflect an increased amount 
of triglycerides in pancreatic β cells, which then causes β cell dysfunction (12). 
Another hypothesis is that intrapancreatic adipocytes have a negative paracrine 
effect on β cells. However, one can also postulate that NAFPD and type 2 diabetes 
mellitus are both just consequences of obesity, and that NAFPD is not involved in
the pathogenesis of type 2 diabetes mellitus.
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7Pancreatic steatosis is present in the prediabetic phase and the amount of pancreatic fat increases before type 2 diabetes mellitus occurs (12,13). Moreover, in 
patients with impaired fasting glucose and impaired glucose tolerance, pancreatic 
fat is negatively associated with insulin secretion (P <0.03), which suggests that β 
cell Dysfunction is present in these individuals (55). This finding was confirmed by 
Tushuizen et al.29 who found a negative correlation between NAFPD and β cell 
function in nondiabetic individuals (P <0.01) (29). A notable relationship between 
NAFPD and diabetes was not observed, a finding that has been confirmed by 
Saisho and colleagues (39). Moreover, data from van der Zijl and coworkers shows 
no relationship between NAFPD and hyperglycemic clamp-derived secretion 
parameters (91,89). In their 2010 review, van Raalte et al.89 conclude that current 
evidence suggests that pancreatic steatosis is innocuous and is probably not a 
cause of lipotoxicity in pancreatic β cells (89), a conclusion shared by Szendroedi
and colleagues (92). We agree with these researchers that there is insufficient 
evidence available to define a causal relationship between NAFPD and type 2 
diabetes mellitus— the inactive role of naFPD in the pathogenesis of type 2 diabetes 
mellitus is still to be proven, or indeed refuted, by further research.
exocrine dysfunction
It is widely known that >90% of pancreatic exocrine tissue must be destroyed 
before exocrine dysfunction occurs (93). In 1976, Savvina concluded that even 
massive pancreatic fat replacement (only 10% of exocrine parenchyma remaining) 
does not cause exocrine dysfunction (94). By contrast, Dupont et al.(95) 
hypothesized that the reduction of pancreatic enzymes is an early phenomenon in 
pancreatic lipomatosis. the researchers stated that pancreatic lipomatosis is the 
second most common cause of pancreatic insufficiency in childhood. Indeed, in a 
few childhood syndromes (cystic fibrosis, shwachman– Diamond syndrome and 
Johanson–Blizzard syndrome) exocrine dysfunction and pancreatic steatosis often 
coexist, as described earlier. The literature on exocrine dysfunction in pancreatic 
steatosis is scarce, apart from a few case reports; no series have been reported 
(14,78,96,97).
More research considering the degree and influence of pancreatic steatosis on the 
exocrine pancreas is therefore needed. If exocrine dysfunction occurs, patients 
present with chronic diarrhea, fatty stools, weight loss and/or general symptoms of 
malabsorption. Furthermore, imaging studies have reported a pancreas completely
replaced by fat (14,78,96,97).In theory, fat droplet accumulation in acinar cells 
could cause exocrine insufficiency in pancreatic steatosis (12,32,41). However, to 
date, this mechanism has not been confirmed. Pancreatic adipocytes could have 
negative paracrine effects on acinar cells, thereby decreasing the exocrine function 
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of acinar cells. On the other hand, pancreatic steatosis could result from an 
underlying disease causing death of acinar cells and subsequent fatty replacement, 
which eventually could lead to pancreatic exocrine insufficiency.
Acute pancreatitis
Obesity is related to the severity of acute pancreatitis (98,99). Zyromski and 
colleagues(100) showed that obese mice develop more severe pancreatitis after 
cerulean hyperstimulation than lean mice. Furthermore, obesity is associated with 
developing organ failure,(101) local complications,(102) a longer hospital stay (103) 
and even increased mortality in patients with pancreatitis (99,104). Frossard and 
coworkers(105) defined five hypotheses regarding the causal relationship between 
obesity and acute pancreatitis. One hypothesis is that hepatic dysfunction 
associated with obesity might enhance the systemic inflammatory response. 
Another hypothesis is that pancreatic microcirculation in obese patients is reduced, 
increasing the risk of ischemic injury. Also, obesity restricts the inspiratory capacity, 
leading to ventilation or perfusion mismatch and subsequent hypoxemia. Another 
link between obesity and acute pancreatitis could be that necrosis and inflammation 
is often located in pancreatic fat. When the amount of pancreatic fat increases 
because of obesity, it is reasonable to postulate that the severity of an attack of 
acute pancreatitis would subsequently increase. of interest is the hypothesis that 
the increased amount of pancreatic fat (NAFPD) associated with obesity causes a 
more severe episode of acute pancreatitis. Adipose tissue can be regarded as an 
endocrine organ, secreting adipokines, chemokines and cytokines (collectively 
called adipocytokines) (106). In obesity, an imbalance in these adipocytokines 
causes a general inflammatory state (106,107) and this imbalance in hormone 
levels has been associated with NAFLD and atherosclerosis (106,108). It is plausible 
that pancreatic adipocytes could introduce an inflammatory milieu in the pancreas, 
making this organ more susceptible to pancreatitis. In support of this hypothesis, 
an increased amount of pancreatic toxic fats and inter leukin 1α and tumor necrosis 
factor (cytokines that are associated with the initiation of pancreatic inflammation)
(109) has been observed in obese mice (25,100). The condition of pancreatitis 
owing to NAFPD has been termed non alcoholic steatopancreatitis (NASP) by Pitt 
and his group (25,110). This concept is analogous to the development of NASH in 
patients with NAFLD. Currently, our group is employing a CT-based study to 
elucidate a relationship between pancreatic steatosis and the severity of acute 
pancreatitis. Preliminary data in a patient population with predicted severe acute 
pancreatitis (n = 105) demonstrates a significant relationship between pancreatic 
steatosis (measured as pancreatic Hounsfield units corrected by the splenic 
Hounsfield units) and Ct severity index (P <0.03; van Geenen and  Bollen, unpublished 
work).
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Pancreatic cancer
Obesity has been associated with multiple types of cancer, such as endometrial, 
renal cell, breast, colon and esophageal cancer (5,111,112). Evidence that obesity is 
also linked to pancreatic cancer is increasing (113,114), as pancreatic steatosis is 
related to obesity, NAFPD has been hypothesized to be involved in the development 
of pancreatic cancer (25). Zyromski and colleagues (115) have shown that the 
adipocyte mass is markedly greater in pancreatic tumors of obese mice than in 
lean mice. This observation has been confirmed in human pancreatic cancer (H. a. 
Pitt, unpublished work). These data suggest a role for pancreatic adipocytes in the 
development of pancreatic cancer. NAFPD has also been suggested to cause 
pancreatic cancer via NASP, a concept analogous to NAFLD, which can cause 
hepatic cancer via NASH and hepatic cirrhosis. Various investigators are convinced 
that pancreatic steatosis is associated with chronic pancreatitis, however, no 
original article to support this relationship can be found (26,52,96).
Most patients with pancreatic cancer have substantial pancreatic fibrosis. However, 
whether this pancreatic fibrosis has been caused by NASP, after which pancreatic 
cancer develops, or whether pancreatic cancer causes the fibrosis owing to duct 
obstruction is unknown. We believe there is insufficient evidence to support the 
theory of NASP as a precursor of pancreatic adenocarcinoma. In patients with 
pancreatic cancer, pancreatic steatosis promotes dissemination and increases the 
lethality of the disease (30). Also, it has been theorized that duct obstruction 
associated with pancreatic cancer can cause pancreatic steatosis (116–119). 
Evidence to support this theory was presented by Walters in 1966 in a study on 40 
rats (31).
Pancreatic fistula
The risk of developing pancreatic fistula after pancreatoduodenectomy is increased 
when the pancreatic consistency is soft (37). Mathur et al.(38) were the first to report
a study on the relationship between pancreatic steatosis and pancreatic fistula. In 
their retrospective case– control study, they found that presence of pancreatic fat 
significantly increased the risk of developing pancreatic fistula (P <0.001). These 
findings were confirmed by later studies (54,56,120). One study showed that 
individuals with 10% fatty tissue in the pancreas have significantly increased risk of 
developing pancreatic fistula (P <0.0003) (56). Whether pancreatic steatosis 
causes this increase in pancreatic fistula by softening the pancreatic tissue is 
unclear. Lee et al.(120) concluded that pancreatic consistency is related to the 
amount of pancreatic fat. However, other studies found pancreatic consistency to 
be related to pancreatic fibrosis and not pancreatic fat (54,56). Moreover, 2010 data 
conclude that pancreatic steatosis is a more reliable risk factor for the development 
of pancreatic fistula than a soft pancreas (54).
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Pancreatic transplantation
In pancreatic transplantation, obesity of the transplant recipient increases the risk 
of dehiscence, intra-abdominal infection and gangrene, but does not influence 
allograft failure (121). Obesity in the transplant donor increases the risk of technical 
surgical failure, but in successful transplantations the risk of allograft failure is 
unchanged (122). In 2004, Nghiem et al.(123) ‘defatted’ a pancreas of a donor with 
a high BMI and transplanted it successfully. This intervention could potentially 
reduce the amount of technical failure observed during pancreatic transplantation. 
in addition, isolation of pancreatic islet is a technique used in islet transplantation, 
and a high BMI and pancreatic steatosis has been shown to increase the yield of 
islet isolation (124,125).
Pancreatic hyperenzymia
In an unknown disorder called ‘pancreatic hyperenzymia’, hypersecretion of 
pancreatic enzymes in the absence of pancreatic disease exists.126,127 Cavallini 
and colleagues(126) describe a relationship between pancreatic steatosis (hyper-
echogenic pancreas on ultrasonography) and hyperamylasia in their study population. 
However, in a MRI-based study, no relationship between hypersecretion
of pancreatic enzymes and pancreatic steatosis was demonstrated (127).
ConClusIons
Many different terms to describe pancreatic fat accumulation are used interchange-
ably. Uniform definitions regarding different forms of pancreatic fat accumulation 
are needed to aid the comparison and design of future studies. We propose to use 
pancreatic steatosis as a general term for pancreatic fat accumulation; the term 
NAFPD must be reserved for fat accumulation in association with obesity. Pancreatic 
fatty replacement is an adequate term for when acinar death leads to replacement 
with adipocytes in the pancreas. In pancreatic fat replacement, pancreatic steatosis is 
probably an ‘innocent bystander’. this scenario is most likely the case in pancreatic 
exocrine dysfunction, hemochromatosis, viral infection and some congenital 
syndromes (Figure 3). in pancreatic fat infiltration (owing to obesity, also called 
naFPD), the role of pancreatic steatosis is less clear. NAFPD has been suggested 
to have a role in type 2 diabetes mellitus, acute pancreatitis, pancreatic cancer and 
the formation of pancreatic fistula after pancreatic surgery (Figure 3). Unfortunately, 
current evidence to support these theories is insufficient. Future research must 
focus on pancreatic steatosis, and NAFPD in particular, to examine the multiple 
associations and underlying pathophysiology of these diseases.
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Figure 3   Etiological factors and consequences of pancreatic steatosis
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CHAPTER 8
ABstrACt
Introduction: Obesity is widely regarded as a risk factor for poor outcome in acute 
pancreatitis.  Indeed, several recent meta-analyses on obesity in acute pancreatitis 
show an increased relative risk for local complications, systemic complications, 
and death, but did not take into account the predicted severity of disease. In several 
conditions, other than pancreatitis, a so called “obesity paradox” has been 
described meaning that certain subgroups of obese patients in fact have an 
improved outcome. In the current study we examined whether the obesity paradox 
exists in acute pancreatitis and (central) overweight/obesity, is associated with an 
increased risk of complications and mortality in patients with predicted severe 
acute pancreatitis. 
Methods: In the current post-hoc analysis of a observational, multicenter study we 
included patients with a primary episode of predicted severe acute pancreatitis 
from a larger cohort of patients enrolled in a previous randomized clinical trial. 
Criteria for predicted severe acute pancreatitis were based on APACHE score ≥8, or 
Imrie score ≥3, or CRP >150 mg/L within 72 hours after onset of symptoms. The 
primary endpoint was mortality. Secondary endpoints were morbidity and intensive 
care unit (ICU)-admission. Anthropometric assessment included body mass index 
(BMI), CT measurements including hip and waist diameters /circumferences (WC), 
and calculation of the WC/BMI.
Results: 144 patients with predicted severe acute pancreatitis were evaluated. 
Multivariable analysis showed an association between mortality and high WC/BMI 
(OR 10.0, 95% C.I. 1.89-52.7), and a lower BMI (OR 0.84, 95% C.I. 0.71-0.99). For 
morbidity, multivariable analysis showed an association with a higher WC/BMI (OR 
11.5 95% C.I. 2.07-63.8),  CTSI (OR 9.81, 95% C.I.: 3.22-29.2) and a lower BMI (OR 
0.79, 95% C.I.: 0.66-0,94). 
Conclusion: This is the first study to show that the “obesity paradox” also exists in 
patients with predicted severe pancreatitis; obese patients suffering from a 
predicted severe attack of acute pancreatitis have a better outcome than non-obese 
patients, unless a patient has central obesity.
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IntroduCtIon
The prevalence of overweight and obesity is increasing rapidly worldwide. In 1996, 
13.3% of the US population had a body mass index (BMI) of >30. In 2005, this 
already doubled to nearly 25% 1. In Europe, overweight affects 30-70% of the adult 
population and 10-30% is obese2. In China the prevalence of overweight and 
obesity in children and adolescence increased from 1992 to 2002 by 22.8 and 7.1%, 
respectively3.  Traditionally, overweight is defined as a body mass index (BMI) > 25 
kg/m2 and obesity by a BMI >30kg/m (WHO-definition) 2.Overweight and obesity 
are major risk factors for a wide range of chronic diseases, among them metabolic 
syndrome, NASH, type II diabetes, cardiovascular disease, and various cancers 
including colorectal, breast and pancreatic cancer4. 
Increasing evidence indicates that central obesity (or abdominal adiposity) is a 
better predictor than BMI in predicting the outcome of cardiovascular disease and 
several metabolic abnormalities4-7. Alternative measurements of obesity, focusing 
on central obesity are: waist circumference (WC), waist/hip ratio (W/H), waist/height 
ratio and intra-abdominal fat-area8. Recent studies have shown that WC adjusted 
for BMI is strongly and positively associated with overall mortality9. It has been 
suggested that adjusted-WC acts as a surrogate measure for intra-abdominal 
fatness10.
Obesity has long been regarded as a risk factor for poor outcome in severe acute 
pancreatitis. Indeed, several recent meta-analyses on obesity in acute pancreatitis 
showed a relative risk of 4.3 for local complications, 2.0 for systemic complications, 
and 2.1 for death 11-15. However, the incidence of acute pancreatitis is  increased in 
obese patients and hence results in a proportional  increase and relative over-rep-
resentation of obese patients with acute pancreatitis14. In the aforementioned 
meta-analyses no stratification was applied with regard to the predicted severity of 
acute pancreatitis, which is associated with an increased mortality. However, in 
several conditions, other than pancreatitis, a so called “obesity paradox” has been 
described meaning that certain subgroups of obese patients in fact have an 
improved outcome16-19. In the current post-hoc analysis of a large observational 
multicenter study, we examined whether (central) overweight/obesity, is associated 
with an increased risk of complications and mortality in patients with predicted 
severe acute pancreatitis. 
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metHods
study population and design
This study evaluated a subset of patients with predicted severe acute pancreatitis 
from a larger cohort of patients enrolled in the Dutch randomized clinical trial on 
probiotic prophylaxis in acute pancreatitis: the PRObiotics in PAncreatitis TRIAl 
(PROPATRIA)20. For this observational study an experienced abdominal radiologist 
peformed additional abdominal CT-measurements on existing PROPATRIA study CT 
sets including hip and waist diameters (and calculated hip and waist circumferences), 
ventral and dorsal subcutaneous fat layer, Hounsfield measurements of the liver, 
spleen and pancreas. 
The PROPATRIA study included adult patients with a primary episode of predicted 
severe acute pancreatitis of all causes. Acute pancreatitis was defined as abdominal 
pain with serum amylase and/or lipase levels elevated to at least three times the 
institutional upper limit of normal. Criteria for predicted severe acute pancreatitis 
were: a) an Acute Physiology, Age and Chronic Health Evaluation (APACHE)-II 
score ≥814, or b) Imrie score ≥315, or c) C-reactive protein (CRP) >150 mg/L16 within 
72 hours after onset of symptoms. Between March 2004 and March 2007, 296 
consecutive patients with predicted severe acute pancreatitis were enrolled in 8 
university medical centers and 7 major teaching hospitals. The current observational 
study included patients from PROPATRIA diagnosed with acute pancreatitis from 
March 2004 till March 2006. Exclusion criteria were: 1. No digital abdominal CT-scan 
available (inaccurate anthropometric measurements), 2. incomplete abdominal CT- 
scans (pelvic region not included), 3. no acute pancreatitis (alternative diagnosis).
treatment protocol
Patients were treated according to a fixed treatment protocol20. This consisted of 
nasojejunal enteral feeding with a probiotic preparation or placebo according to 
treatment allocation, administered within 72 hours after onset of symptoms for a 
maximum of 28 days. Antibiotic prophylaxis in necrotizing pancreatitis was not 
allowed. Physical examination and laboratory measurements were performed daily. 
Contrast-enhanced CT was performed routinely 7-10 days after admission, and the 
CT-severity index was determined21.  Patients with infected necrotising pancreatitis 
were treated with percutaneous drainage and/or operative intervention according 
to decision of the treating physician. In case of acute biliary pancreatitis (defined in 
a former study)22, the decision to perform endoscopic retrograde cholangiopan-
creatography (ERCP), with or without papillotomy, was left to the treating physician. 
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endpoints
The primary and secondary endpoints were mortality and overall complications 
during admission and 90-day follow-up after admission (Box1). All complications 
were weighted equally; multiple complications in the same patient were considered 
as one endpoint. Organ failure was defined asPaO2 <60 mmHg despite FiO2 of 
30%, or the need for mechanical ventilation (pulmonary insufficiency); serum 
creatinine >177 mmol/L after rehydration or need for hemofiltration or hemodialysis 
(renal failure), and systolic blood pressure <90 mmHg despite adequate fluid 
resuscitation or need for vasopressor support (cardio circulatory insufficiency), 
adapted from the Atlanta classification23.  Multi-organ failure was defined as failure 
of two or more organ systems on the same day. Secondary endpoints were intensive 
care unit (ICU)-admission and ICU-admission time.
Anthropometric measurements
Patients’ weight and height were noted on admission. The body mass index (BMI) was 
calculated as: the patients’ weight/(height)2 in kg/m2. Anthropometric measurements 
were performed on transverse slides of abdominal CT-scans at two regions: the 
waist (umbilical level) and hip (spina iliaca anterior superior level or anterior superior 
iliac spine) (Fig 1a and b). In order to estimate the waist and hip circumference (WC 
Box 1   Definitions of complications included in endpoint and overall 
complications
- Pancreatic necrosis: pancreatic non-enhancement on contrast enhanced CT 
scan performed 7-10 days after admission.
-  Infected pancreatic necrosis: positive fine needle aspiration culture of 
peripancreatic fluid or positive culture of necrosis removed during first surgical 
intervention.
-  Bacteremia: positive blood culture: for bacteria that are usual non-pathogens 
like coagulase-negative staphylococci at least two samples had to be positive.
- Infected ascites: bacteria detected in aspirate of intraperitoneal fluid or 
abdominal fluid sampled during surgical exploration. 
-  Pneumonia: coughing, in combination with dyspnea, chest film showing 
infiltrative abnormalities, or lowered arterial blood gas with positive sputum 
culture. If on the intensive care unit a positive endotracheal culture is 
mandatory. 
-  New onset organ failure: initial (for the first time) onset of organ failure.
148
CHAPTER 8
and HC), the shape of a cross-sectional plane of the body was considered an 
ellipse by approximation. The circumference at the waist and hip regions were 
respectively determined at the umbilical and the spina iliaca superior anterior levels. 
The lateral and ventral-dorsal diameters were measured at the waist and hip region. 
The circumference of the waist and hip was calculated by approximation by the first 
formula of Ramanujan (1914), a simplification of a first degree integral (Figure 2). 
The waist to hip ratio (W/H) was subsequently determined by the calculated waist-
circumference (WC) divided by the calculated hip circumference (HC). WC adjusted 
for BMI (WCBMI) is calculated as WC minus the calculated WC (WCcalc), or 
mathematically: WCBMI = WC - WCcalc. The WCcalc is determined via linear 
regression of the WC versus the BMI in the study population10. An alternative WC 
adjusted for BMI is introduced by our study group in order to obtain a more practical 
parameter to accurately estimate intra-abdominal fatness. This parameter is 
calculated by the WC to BMI ratio (cm/kg/m2). The WC/BMI and BMI were divided 
into 4 percentiles: 0-25%, 25-50%, 50-75% and 75-100%. Each group was analyzed 
and mortality rates were compared to the remainder groups. The ventral and dorsal 
subcutaneous (s.c.) fat layers were measured para-umbilical at the waist in cm 
(figure 1a and b).
Figure 1   Anthropometric measurements (a and b)
a Umbilical region
b  Anterior superior iliac 
spine region
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data collection
Local physicians completed the case-record forms prospectively. An independent 
data monitor performed an onsite cross-check of at least 10% of the individual 
patient data. One experienced radiologist (TLB) and gastroenterologist (EVG), 
blinded for treatment and clinical outcome, reevaluated all CTs for the presence 
and extent of pancreatic necrosis, CT-severity index (CTSI) and anthropometric 
measurements. Before any analysis and blinded for treatment, two investigators 
(HCvS and MGHB) checked all data on baseline characteristics and primary or 
secondary endpoints with primary source data. Analyses were performed only after 
agreement was reached on all endpoints.
statistical analysis
Analyses for the current study were performed according to a pre-established 
analysis plan using SPSS version 17.01 (SPSS, Chicago, IL, USA).
Continuous data are presented as mean (±SD) and in case of skewed distributions 
as median (range). Univariable analysis of continuous variables was performed 
with binary logistic regression and logistic regression (ANOVA). Proportions were 
compared by the Fisher’s exact test. Multivariable logistic regression analysis was 
used to adjust for possible confounders. All baseline variables with a p-value 
smaller than 0.200 were entered in a model as covariables. Backward stepwise 
regression was used to exclude variables with P > 0.05.
results
A total of 211 patients with predicted severe acute pancreatitis were evaluated for 
inclusion. Sixty-seven patients were excluded because of an alternative diagnosis 
(n=3), incomplete abdominal CT-scans (n=4), or hardcopy abdominal CT-scan 
only (n=60), leaving 144 patients for final analysis (Figure 3). The anthropometric 
Figure 2   Circumference calculation of an ellipse
Ramanujan’s first approximation formula:
P=π [3(a+b)-√(3a+b)x(a+3b)]
P = circumference
a = radius of longest radius (1/2 x diameter)
b = radius of shortest radius (1/2 x diameter)
b
a
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data, etiology, age and sex are listed in table 1. The BMI was not noted in 32 patients. 
From this missing group, 8 patients died, resulting in a mortality of 25%. In 7 patients 
the hip region was not scanned. Linear regression of the WC (in cm) and BMI (in kg/
m2) resulted in the following equation in our population: calculated WC (WCcalc) = 
1.719 x BMI +53.36. The WC corrected for BMI (WCBMI) was calculated by the 
equation: WCBMI = WC – (1.719 x BMI + 53.36). 
morbidity
The different complications and their relation with anthropometric parameters are 
listed in table 2. The CTSI and WC/BMI were significantly related to the overall 
morbidity in patients with predicted severe acute pancreatitis (OR 5.31, 95%C.I.: 
2.74-10.28 and OR 2.76, 95%C.I.:1.10-6.97) and to all complications including 
infectious complications, necrotizing pancreatitis, infected pancreatic necrosis, 
new onset organ failure and multiple organ failure. The ventral-dorsal umbilical 
waist diameter and WC/BMI are significantly related to new onset organ failure and 
multiple organ failure. The ventral-dorsal hip diameter and the ventral- dorsal 
umbilical waist diameter were significantly related to infected complications.
With multivariable logistic regression, the CTSI, BMI and WC/BMI were included. 
Separate multivariable analysis for BMI and WC/BMI were performed with the CTSI, 
since the WC/BMI and BMI are related. (Table 4). BMI showed an inverse relation to 
the morbidity rate (OR 0.79, 95% C.I.:0.66-0.94) whereas a higher WC/BMI and 
CTSI were significantly associated with higher morbidity rates (OR 11.5 and 9.81, 
95%C.I.: 2.07-63.8 and 3.22-29.8).  
Figure 3   Patient inclusion flowchart
Predicted severe acute pancreatitis  
analyzed in PROPATRIA 
(March 2004-March 2006)
(n=211)
66 patients excluded: 
2 pancreatic cancer
1 chronic pancreatitis
4 incomplete scan
60 hardcopy CT-scan
Patients included with predicted severe 
acute pancreatitis (n=144)
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mortality
Univariable analysis revealed four parameters significantly associated with mortality 
(Table 3). Among patients who used a probiotic 16.9% of them died compared with 
4.1% in the placebo group (OR 4.75, 95%C.I.: 1.28-17.62). A higher CTSI and WC/
Table 1   Patient characteristics
Mean/ 
frequency
range Standard 
deviation
Missing 
data
Percentiles (%)
1)<25, 2) 25-50
3) 50-75, 4) >75
Male (%) 59.7 0
Age (year) 58.3 24-88 15.4 0
Probiotics( %) 49.3 0
BMI (kg/m2) 28.3 16.5-51.4 5.77 32 <25,  25-26.8
26.9-30.7, >30.7
Mortality(%) 10.4 0
Morbidity or mortality (%) 50.7 0
Morbidity (%) 41.7 0
CTSI (points) 4.64 0-10 2.54 0
ICU admission (%) 29.9 0
ICU admission (days) 4.95 0-89 13.39 0
Biliary cause (%) 38.2 0
Umbilical waist diameter 
v-d (cm)
27.876 18.0-47.4 4.52 0
Umbilical waist diameter 
lateral (cm)
36.41 21.1-57.2 4.88 0
Umbilical waist 
circumference (cm)
102.06 67.39-149.32 13.27 0
wC/BMI (cm/kg/m2) 3.67 2.01-4.98 0.45 32 <3.40, 3.40-3.68
3.69-3.93, >3.93
wCBMI (cm) 0.01 -40.6-23.79 8.57 32
Hip diameter v-d (cm) 27.3 18.3-41.3 4.06 7
Hip diameter lateral (cm) 38.04 23.9-55.5 4.98 7
Hip circumference
(cm)
104.19 72.46-144.53 11.88 7
waist hip ratio (cm) 0.98 0.77-1.23 0.06 7
Ventral s.c. fat (cm) 2.61 0.8-13.6 1.55 1
Dorsal s.c. fat (cm) 6.18 2.6-11 1.62 0
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BMI were related to a higher mortality (OR 1.28, 95%C.I.:1.06-1.55 and OR 13.02, 
95%C.I.:2.52-67.4). Additionally, a higher BMI was associated with a lower mortality 
(OR 0.84, 95%C.I.:0.71-0.98). 
In the multivariable logistic regression the following parameters were included 
(univariable analyses p< 0.200): admission age, probiotics, CTSI-score, WC/BMI, 
BMI, WCBMI, and s.c. ventral fat layer. Since the parameters WC/BMI and WCBMI 
were directly related to the BMI, separate multivariable analyses for BMI, WC/BMI, 
WCBMI and WC combined with BMI were performed (Table 4). A lower BMI and a 
higher WC/BMI were significantly associated with mortality (OR 0.84 and 9.97, 
95%C.I: 0.71-0.99 and 1.89-52.7, Table 4). A separate insertion of the BMI and WC 
(instead of WC/BMI) in the multivariable logistic regression resulted in a significant 
relation of the two parameters with mortality (OR 1.1 and 0.70, table 4). 
Table 3   Mortality versus (anthropometric) parameters
Variable Average mortality
yes / No
p-value OR 95% C.I.
Gender (m/f) 10.5 / 10.3 0.982 0.99 0.33-2.94
Admission age (year) 65 / 57.4 0.082 1.03 1.00-1.07
Probiotics (%) 16.9 / 4.1 0.012 4.75 1.28-17.62
CTSI (points) 6.27 / 4.45 0.012 1.28 1.06-1.55
BMI (kg/m2) 24.8 / 28.7 0.031 0.84 0.71-0.98
Biliary cause
(yes/no)
12.4 / 7.27 0.332 1.80 0.54-5.96
Umbilical waist diameter v-d (cm) 28.8 / 27.8 0.621 1.03 0.92-1.14
Umbilical waist diameter lateral (cm) 37.0 / 36.3 0.400 1.05 0.94-1.17
Umbilical waist circumference (cm) 104.3 / 101.8 0.485 1.01 0.98-1.05
WC/BMI (cm/kg/m2) 4.09 / 3.63 0.020 13.02 2.52-67.4
WCBMI (cm) 4.18 / -0.45 0.081 1.08 0.99-1.17
Hip diameter v-d (cm) 27.6 / 27.2 0.696 1.03 0.90-1.17
Hip diameter lat (cm) 38.9 / 37.0 0.495 1.04 0.93-1.16
Hip circumference (cm) 106.1 / 104.0 0.529 1.01 0.97-1.06
Waist hip ratio 0.99 /0.98 0.274 0.004 0.000-82.9
Ventral s.c. fat (cm) 2.12 / 2.67 0.154 0.63 0.33-1.20
Dorsal s.c. fat (cm) 6.02 / 6.19 0.692 0.93 0.67-1.32
s.c. = subcutaneous
v-d= ventral-dorsal
OR = odds ratio
C.I. = confidence interval
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The BMI percentiles divided over 4 groups versus mortality are presented in Graph 1. 
The curve has an inverted J-shape, with a significantly increased mortality between 
the group 1 and the rest (0-25% percentile vs. 25-100%, P=0.05). For the WC/BMI 
Table 4   Multivariable analysis on primary and secondary endpoints
Endpoint Variable p-value OR (95% C.I.)
Morbidity CTSI
WC/BMI
Separate analyses
BMI
WCBMI
0.000
0.005
0.008
0.193
9.81 (3.22-20.2)
11.5 (2.07-63.8)
0.79 (0.66-0.94)
1.07 (0.97-1.18)
Mortality WC/BMI
Separate analyses
BMI 
WCBMI
wC and BMI analysis
BMI
WC
0.007
0.039
0.077
0.011
0.049
10.0 (1.89-52.7)
0.84 (0.71-0.99)
1.08 (0.99-1.17)
0.70 (0.53-0.92)
1.10 (1.00-1.20)
Graph 1   BMI percentiles versus mortality risk: inversed J-shape
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these results are shown in Graph 2; patients in group 1 are less likely to die in predicted 
SAP (0% versus 13.3%, p=0.039), whereas patients in group 4 have an increased 
mortality rate compared to the rest of the groups (25% versus 4.8%, p=0.002). 
ICu-admission and duration of stay
ICU-admission and duration of the ICU-admission (stay) were significantly related 
to an increased CTSI, ventral-dorsal umbilical waist diameter and WCBMI (Table 5). 
A biliary cause of the acute pancreatitis was significantly protective against 
ICU-admission compared to a non-biliary cause (p=0.037; 23% versus 44%).
dIsCussIon
This to our knowledge is the first study to investigate the effect of the BMI and other 
anthropometric parameters on the course of an attack of predicted severe acute 
pancreatitis. The major findings of this study are: 1) a lower BMI is associated higher 
mortality and morbidity rates, and 2) a higher WC/BMI and WC are associated with 
higher morbidity and mortality rates. In other words: obese patients suffering from 
a predicted severe attack of acute pancreatitis have a better outcome than 
non-obese patients, unless a patient has central obesity.
In a recent meta-analysis including eight prospective studies, obesity (defined as 
BMI >30 kg/m2) was associated with a significant increased mortality in patients 
Graph 2   WC/BMI percentiles versus morbidity and mortality risk
The x-axis contains the mortality rate (%) and the Y-axis contains the percentiles of WC/BMI.
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with acute pancreatitis (OR 3.81; 95% C.I. 1.22-11.83) 13. However, obesity was also 
associated with a significant increased predicted severity of the pancreatitis (OR 
2.48; 95% C.I. 1.34-4.60). These findings suggest that in obese patients the 
incidence of predicted severe acute pancreatitis is increased, which in turn is 
associated with higher mortality. I n the aforementioned studies and meta-analysis 
however, predicted disease severity was not accounted for, which makes it 
Table 5   ICU-admittance/stay versus anthropometric parameters
Variable ICU-admittance
P-value
OR (95% C.I.)
Average: yes vs no
ICU stay (days)
P-value
R2 / F
Gender (m/f):% 0.138 0.062
Admission age 0.792 0.616
Probiotics (yes/no: %) 0.102 0.076
CTSI (points) 0.000
1.56 (1.32-1.85)
6.5 / 3.8
0.000
0.147 / 24.5
BMI (kg/m2) 0.176 0.959
Biliary cause
(yes/no: %)
0.037
0.46 (0.22-0.96)
23% / 44%
0.861
Umbilical waist diameter v-d (cm) 0.043
1.09 (1.003-1.177)
29.1 / 27.4
0.000
0.083 / 12.81
Umbilical waist diameter lateral (cm) 0.806 0.958
Umbilical waist circumference (cm) 0.244 0.082
WC/BMI (cm/kg/m2) 0.007
4.36 (1.49-12.8)
3.87 vs 3.60
0.094
WCBMI (cm) 0.021
1.07 (1.01-1.14)
3.15 / -1.14
0.003
0.077 / 9.19
Hip diameter v-d (cm) 0.181 0.084
Hip diameter lat (cm) 0.987 0.267
Hip circumference (cm) 0.499 0.113
Waist hip ratio 0.645 0.546
Ventral s.c. fat (cm) 0.892 0.958
Dorsal s.c. fat (cm) 0.907 0.511
158
CHAPTER 8
impossible to discern the true influence of obesity and/or abdominal fatness on 
morbidity and mortality.
The outcome of our multivariable analysis is in line with recent ICU-studies which 
found a relationship between increased BMI and decreased mortality. A recent 
meta-analysis16 concluded that obesity in patients admitted to a ICU showed a 
trend towards a lower mortality, but longer hospital stay16. We could not confirm a 
relationship between BMI and ICU-stay. However, a significant relation between 
central obesity (WCBMI and ventral-dorsal umbilical diameter) and the ICU-stay was 
found (p=0.003 and p<0.001, table 5). In a large ICU study, underweight was 
associated with an increased mortality (OR 1.19 95% C.I.: 1.08-1.32), whereas 
overweight, obesity and severe obesity was not associated with a significant 
increase or decrease in mortality17. A similar trend of decreased mortality in 
overweight patients compared with underweight and normal weight patients was 
reported in studies concerning recovery post-surgically and also in acute and 
chronic heart failure18.  This observation, also known as “the obesity paradox”, 
states that an inverted J-shape curve exists between mortality and obesity (as 
shown in Graph 1.). This theory has recently been confirmed by a German study 
reporting an increased hospital mortality rate in underweight patients who were 
post-operatively admitted at the ICU compared with normal weight patients (17,8% 
versus 11.1%, p=0.006)19. Notably, in that study overweight and obesity were 
associated with a lower mortality rate (p=0.047)19, but mortality increased in very 
obese patients (HR = 0.3, 95% CI = 1.06-8.48, P = 0.039)19.
Several explanations for the obesity paradox (inversed J-shaped survival curve) 
have been proposed. The three most prominent are smoking as confounder, 
co-existence of an occult disease or so-called reverse causation24,  and the fact 
that BMI, its numerator being composed of both fat and fat-free mass, does not 
adequately represent the  effect of fat mass on mortality rates25. 
In order to discriminate between muscle and fat mass induced weight several 
anthropometric parameters are used. For instance, intra-abdominal obesity, which 
is more prominent in obese patients, can be quantified by: WC, WHR and visceral 
adipose tissue (VAT). In a Mexican study in 88 patients, patients with android fat 
distribution and higher waist circumference are at greater risk for developing severe 
AP26. The same study group reported a stronger correlation between the umbilical 
WC and the development of SAP than parameters like BMI, minimum WC, 
waist-to-hip ratio and waist-to-thigh ratio27. More evidence pointing towards to the 
abdominal fat theory was provided by Yashima et al28. In their multi-variable analysis 
only volume of visceral adipose tissue (VAT) was strongly and negatively correlated 
to the course of an attack of acute pancreatitis. Other parameters, such as: BMI, 
subcutaneous adipose tissue, and WC (L2-L3 region), failed to reach statistical 
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significance. These findings are in line with our study, in which WC/BMI was 
significantly related to mortality in patients with predicted SAP. 
Physiologic mechanisms for the protective effect of a higher BMI have been 
suggested, including the ability of adipose tissue to counteract higher levels of 
circulating inflammatory markers such as tumor necrosis factor, as well as increased 
nutritional and metabolic reserves29-31. In our study the multivariable analysis showed 
a significant inversed relation between BMI, mortality and morbidity, which could be 
related to the above mentioned theory. However, the individual complications (Table 
2) and overall morbidity (multivariate) were significantly associated with an increased 
abdominal waist diameter (ventral-dorsal umbilical waist diameter, WCBMI, WC/BMI), 
which suggests a negative effect of abdominal fat on overall morbidity.
Childers and colleagues propose an additional explanation32. They hypothesize 
that with obesity the mortality rates increase in the absence of major injuries or 
other diseases and mortality rates decrease in the presence of certain major 
injuries or other diseases. This hypothesis explains the inversed-J-shaped survival 
curve between BMI and mortality rates in our multivariable analysis 32 and the 
increased incidence of predicted severe acute pancreatitis in obese patients in the 
meta-analyses 13.
This study introduces the WC/BMI as a measure for central fatness. Separate 
multivariable analysis in which the WC was added to the BMI and rest of the 
parameters resulted in significant relations of both parameters with mortality (table 4). 
In other words: an increased WC/BMI results in additive and more powerful prediction 
of mortality than both parameters alone. 
Definitions of Mortality, morbidity and ICU duration of stay were prospectively 
defined in this study cohort. Also the abdominal CT timing was prospectively 
defined and therefore, this study almost equals the quality of a prospective trial. A 
nationwide multicenter trial almost excludes local biases and represents a 
representative cross-section of the Dutch severe acute pancreatitis population. 
There are several limitations of this study. First, the umbilical waist circumference 
was not measured on admission, but calculated using abdominal CT-scans by 
estimation of an elliptical shape. Second, from 32 patients the BMI was not 
retrievable from the case-record files (CRF. Third, smoking status, diabetes, and 
race were not noted in the CRFs and hence could not be accounted for. Finally, no 
information on the fat free mass and visceral adipose tissue (VAT) was available in 
this cohort.
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In conclusion, this is the first study showing that the “obesity paradox” or an inverted 
(nadir) relationship between BMI and mortality rates exists in patients with a 
predicted severe acute pancreatitis. Furthermore, we confirm results from studies 
in patients with other criticall illnesses that also in predicted severe pancreatitis 
abdominal obesity is associated with an increased mortality and morbidity. This 
leads to the conclusion that obese patients suffering from a predicted severe attack 
of acute pancreatitis have a better outcome than non-obese patients, unless a 
patient has central obesity. Future (randomized) studies on acute pancreatitis 
should also stratify for (central) obesity, beside other well-known confounders. 
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ABstrACt
Objectives: Smokers are at risk for pancreatic cancer (PC) and other pancreatic 
diseases. Cigarette smoking also aggravates the risk of PC in patients with 
hereditary and chronic pancreatitis (CP) and results in a higher incidence of acute 
pancreatitis and relapses in CP. Both PC and CP are characterized by a progressive 
fi brosis. Recently, two studies on rats reported that tobacco smoking is associated 
with chronic pancreatic inflammation with fibrosis and scarring of pancreatic acinar 
structures. In this study, we aimed to confirm a relationship between cigarette 
smoking and pancreatic fibrosis (PF) in humans.
Methods: In this retrospective study, pancreatic and liver tissue acquired during 
autopsy was collected and analyzed. PF was scored by assessing severity of 
intralobular, extralobular, and total PF: grade 0 (normal or mild; 0 – 25 % PF), grade 
1 (moderate; 25 – 50 % PF), and grade 2 (severe; > 50 % ). Information on smoking 
habits was extracted from (electronic) medical records.
Results: Of 900 autopsies performed from January 2005 to December 2007, a 
minority of patients ( n = 111) met all inclusion criteria for analysis. Grade 2 – 3 total 
PF and intralobular PF was significantly more present in smokers vs. “ never-smokers” 
(total: 42.9 vs. 26.5 % , P = 0.027 and intralobular: 39.3 vs. 15.6 % , P = 0.013), 
whereas no differences could be found between never-smokers and ex smokers 
and between ex-smokers and smokers. When we took into account interlobular PF, 
no differences between all groups were observed. No relationship between PF and age 
( P = 0.893), body mass index ( P = 0.707), and pancreatic lipomatosis ( P = 0.916) 
was observed.
Conclusions: To our knowledge, no study in humans had studied the effect of 
tobacco smoking on pancreatic tissue. We have demonstrated for the first time that 
current cigarette smoking is associated with total PF – specifically, intralobular PF – 
as compared with nonsmokers.
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IntroduCtIon
Smoking tobacco exerts several eff ects in humans, including a pronounced 
carcinogenic effect on several organs. There is strong epidemiological evidence for a 
dose-dependent relationship between cigarette smoking and pancreatic cancer (PC).
Cigarette smokers have a two- to threefold risk of developing PC compared with 
nonsmokers, and the risk remains higher for up to two decades aft er cessation of 
smoking (1 – 7). Pipe and cigar smokers have a lower risk of developing PC than 
cigarette smokers, with a relative risk between 0 and 2.1 (8,9). To date, no statistical
relationship between passive smoking and the development of PC has been 
reported in the literature (4,10). Additionally, no relationship between smokeless 
tobacco and PC was observed in a recent meta-analysis (relative risk 1.03, 95 % 
confidence interval 0.71 – 1.49) (11).
Cigarette smoking is an independent risk factor in the development of and 
progression to chronic pancreatitis (CP) (12,13), and it results in a higher incidence 
of acute pancreatitis and relapses in CP (14 – 17). Smokers and patients with 
chronic and hereditary pancreatitis are at higher risk for PC (18,19). Furthermore,
cigarette smoking increases the risk of the development of PC in patients with 
hereditary CP (15,20,21). The risk of smoking for the (progressive) development of 
PC and CP can be explained by the fact that CP is a precancerous condition.
Therefore, it can be assumed that tobacco smoking induces chronic pancreatic 
inflammation as a trigger for PC development.
Recently, more evidence for the theory that smoking induces chronic pancreatic 
inflammation was provided by two rat studies that investigated the effect of tobacco 
smoke inhalation on the pancreas. The investigators concluded that tobacco 
smoking is associated with chronic pancreatic inflammation with fibrosis, scarring 
of pancreatic acinar structures, and suppression of glutathione peroxidase activity 
(22,23).
To our knowledge, no previous study in humans had investigated the effect of smoking 
on pancreatic tissue. In this study, we aimed to confirm a relationship between 
cigarette smoking and pancreatic fibrosis (PF) and / or inflammation in humans.
metHods
In this retrospective study, autopsy material consisting of pancreas and liver tissue 
from deceased patients at the VU University Medical Centre, Amsterdam, the 
Netherlands, was collected and analyzed. Patients 18 years and older were included 
( 24 ). Exclusion criteria were as follows: (i) features consistent with hepatic or 
pancreatic disease as reported in medical records, (ii) a history of major abdominal 
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or gastrointestinal surgery (including small intestinal surgery or Billroth, Roux-en-Y 
anastomosis, Hepato-biliary, or pancreatic surgery because of possible hepatic / 
pancreatic lymphocytic infiltration), (iii) documented history of excessive alcohol 
intake ( ≥α21 drinks / week for men and ≥α14 drinks / week for women), (iv) severe 
postmortem changes that hampered histology, and (v) no documented smoking 
history.
Histopathology
Pancreatic tissue obtained during the autopsy was processed in a standard manner 
and stained with hematoxylin / eosin. All slides were evaluated under a light 
microscope (magnification ×100). The slides were assessed by an experienced 
hepatobiliary histo-pathologist (EB) and two research fellows (MS and EG), all 
blinded for patients ’ clinical and laboratory data. Discrepancies were discussed.
PF was scored with the pancreas fi brotic score. Th is score emphasizes a 
subdivision between intralobular, extralobular and total PF: group 0 (normal or mild 
PF: < 25 % PF), group 1 (moderate PF: 25– 50% PF), and group 2 (severe PF: > 
50%). Pancreatic lipomatosis was graded using the pancreatic lipomatosis score 
(PLS). This grading system emphasizes the distribution of intralobular, interlobular, 
and total pancreatic fat. The quantity of adipocytes per microscopic pancreas 
compartment (inter- and intralobular) was graded as follows: 0: 0 – 7 % adipocytes, 
1: 8– 14%, 2: 15– 25%, 3: 26– 50%, and 4: > 51%. For the purpose of grading the 
total amount of fatty infiltration (inter and intralobular), a fifth group was added: > 
75%. In addition, the presence of lymphocytes was noted.
statistical analysis
To compare group characteristics, we used analysis of variance for continuous 
variables. Univariate ordinal logistic regression was used to test the relationship 
between ordinal histological parameters. Binary parameters were analyzed by 
binary logistic regression. Multivariate analysis (forward stepwise ordinal regression) 
was performed to correct for age, body mass index, and gender. A P value ≤α0.05 
was considered statistically significant. Results are presented as ordinal regression 
coefficients (B) and P values. All analyses were performed using SPSS soft ware 
version 17 for Windows (Chicago, IL).
Clinical data
Clinical and biochemical data were collected from electronic medical records and 
autopsy data. Anthropometric data comprised gender and body mass index. The 
medical data encompassed age, blood pressure, history of alcohol use, and 
smoking habits. Past history with respect to smoking; cardiovascular, liver, and 
gastroenterological diseases; and diabetes mellitus was noted. Smoking behavior 
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was noted as (i) “ actual smoker, ” a cigarette, cigar, or pipe smoker at the time of 
death; (ii) “ ex-smoker, ” quit smoking within the 10 years before death; and (iii) “ 
never-smoker, ” never smoked tobacco. Additionally, the cause of death was 
recorded.
results
Patient characteristics
More than 900 autopsies were performed in the VU University Medical Center from 
January 2005 to December 2007. During this period, 598 autopsies were performed 
on clinical patients of the VU University Medical Center. Of these patients, 415 met 
the inclusion criteria and were considered for this study. Of these, 259 subjects 
were excluded because of inferior quality of the histological material due to post- 
mortem changes ( n = 42), absence of pancreatic and / or liver histological material 
(n = 88, cerebral autopsy only), known liver and / or pancreatic disease (n = 41 
respectively n = 28), alcohol abuse ( n = 29), or more than one reason (n = 31). 
Six patients were excluded because they had had major abdominal surgery: two 
Whipple operations, one Roux-Y-en anastomosis, one Billroth II, one hepatitis e. causa 
ignota (e.c.i.) after small intestinal surgery, and one right extended hemi-hepatectomy. 
Thirty-nine patients were excluded because no smoking history could be retrieved. 
Ultimately, 111 patients were eligible for analysis. Patient characteristics are shown 
in Table 1.
Table 1   Patient characteristics
Never smoked Ex-smokers Actual smokers 
(n=64) (n =19) (n =28) P value 
Gender (men) 31 (48 % ) 8 (42 % ) 19 (68 % ) NS 
Age ± s.d. 66.1± 15.9 67.4 ±9.2 64.6 ± 13.5 NS 
BMI± s.d. 26.0 ± 4.5 28.5 ±6.2 24.5 ±5.0 NS 
Case of death 
Cardiovascular 35 (55 % ) 5 (26 % ) 19 (68 % ) 0.006 
Gastrointestinal 1 (2 % ) 1 (5 % ) 1 (4 % ) NS 
Malignancy 15 (23 % ) 8 (43 % ) 4 (14 % ) 0.034 
Other 12 (20 % ) 5 (26 % ) 4 (14 % ) NS 
BMI, body mass index; NS, not significant. Ex-smokers: quit smoking within the past 10 years.
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smoking status, age, BmI, and pancreatic lipomatosis vs. Pf
All the smokers and ex-smokers smoked cigarettes; none of the patients used 
smokeless tobacco. Because pack-years were not (accurately) noted in the medical 
records, no statistical calculations on this aspect could be performed.
The smoking status and PF grades are listed in Table 2 . For statistical analysis, PF 
was divided into two groups: group 1 (normal –mild PF) and group 2 (moderate – 
severe PF). Significantly more moderate – severe total PF was observed in the 
actual-smokers group vs. the never-smoked group (42.9 vs. 26.5 % , P = 0.027, 
Figure 1 ), whereas no significant difference in total PF was observed between the 
never-smokers vs. ex-smokers and ex-smokers vs. actual smokers ( P = 0.47 and 
0.32, respectively). Focusing on intralobular PF, the differences between the 
different smoking statuses were more pronounced ( Figure 2 ): smoking vs. never- 
smoker (39.3 vs. 15.6 % , P = 0.013), ex-smoker vs. never-smoker ( P = 0.122), and 
smoker vs. ex-smoker ( P = 0.589). In the light of interlobular fibrosis, no statistical 
differences were observed between smokers vs. never-smoker, ex-smoker vs. 
neversmoker, and smoker vs. ex-smoker ( P = 0.754, 1.00, and 1.00, respectively). 
No relationship between PF and age ( P = 0.893), body mass index ( P = 0.707), 
and total pancreatic lipomatosis ( P = 0.916) was observed. The intralobular 
pancreatic lipomatosis was significantly inversely correlated with the total PF ( P = 
0.034). The inverse relationship between intralobular lipomatosis and intralobular 
fibrosis was even more pronounced ( P = 0.014). Interestingly, no pancreatic 
inflammatory infiltrates were identified.
Table 2   Smoking status vs. pancreatic Fibrosis
Never Smoked
(n =64) 
Ex-Smokers
(n =19) 
Actual Smokers
(n =28) 
Intrafibrosis Normal 54 (84 % ) 13 (68 % ) 17 (60.7 % ) 
Moderate 8 (12.5 % ) 4 (21.1 % ) 8 (28.6 % ) 
Severe 2 (3.1 % ) 2 (10.5 % ) 3 (10.7 % ) 
Interfibrosis Normal 55 (85.9 % ) 16 (84.2 % ) 23 (82.1 % ) 
Moderate 7 (10.9 % ) 3 (15.8 % ) 4 (14.3 % ) 
Severe 2 (3.1 % ) 0 (0 % ) 1 (3.6 % ) 
Total fibrosis Normal 47 (73.4 % ) 12 (63.2 % ) 16 (57 % ) 
Moderate 15 (23.4 % ) 6 (31.6 % ) 10 (35.7 % ) 
Severe 2 (3.1 % ) 1 (5.3 % ) 2 (7.1 % ) 
Ex-smokers: quit smoking within the past 10 years
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Figure 1   Smoking status vs. total pancreatic fibrosis (PF)
Figure 2  Smoking status vs. intralobular pancreatic fibrosis (PF)
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dIsCussIon
To our knowledge, this is the fi rst study on PF in humans in relation to their smoking 
status. Overall, cigarette smokers had a significantly increased incidence of total 
PF compared with non smokers, consistent with the fi ndings of two animal studies.
The first study that reported a relationship between pancreatic inflammation / 
fibrosis and smoking was performed in rats. The animals were exposed to either a 
high or low dose of environmental tobacco smoke twice a day for 12 weeks, after 
which an increase in pancreatic extracellular matrix among a decreasing number of 
acinar structures and infiltrating cells was detected (23). The second study, also in 
rats, reported inflammatory cell infiltration and ductal hyperplasia in pancreata after 
12 weeks of exposure to cigarette smoke (22).
The relationship between smoking and the development of PF is a major element in CP, 
PC (25 – 27), postoperative pancreatic anastomotic leakage (28,29), and pancreatic 
exocrine insufficiency after a Whipple procedure (29,30). Two observational studies 
reported a significant relationship between cigarette smoking and pancreatic 
exocrine insufficiency (31,32). Cigarette smokers have significantly lower insulin 
levels and higher glucose levels compared with nonsmokers (31); PF could be a 
causative factor in this observation. Kim et al. (33) provided some evidence for this 
theory by reporting a relationship between activated pancreatic stellate cells (PSCs) 
and progression of islet fibrosis in type 2 diabetes.
limitations of the study
This study has several limitations inherent to retrospective review of medical 
records, such as incomplete documentation (e.g., missing charts or unrecoverable 
or unrecorded information), difficulty in interpreting information found in the 
documents (e.g., owing to use of jargon and acronyms or unclear photocopies or 
microfiche), problematic verification of information and difficulty in establishing 
cause and effect, and variance in the quality of information recorded by medical 
professionals. Therefore, this study is more susceptible to documentation bias, 
selection bias, and potential confounders. One of the major limitations of this study 
was the lack of accurate information on smoking behavior of the deceased patients. 
Basic data regarding the number of pack-years and daily consumption of cigarettes 
were not noted in the autopsy reports or patient charts. Most Dutch citizens start to 
smoke between the ages of 14 and 25 years, with an average starting age of 15; the 
lifelong average of cigarette use is 15 cigarettes per day (source: Statistics 
Netherlands, http://www.CBS.nl , 18 December 2010). Considering the average 
age in our groups ( ~ 65 years), the estimated number of pack-years was more 
than 30 in our smokers group. The ex-smoker count in our study was low, which 
resulted in underpowered analysis concerning PF in this group.
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Potential fibrosis inhibitors have been reported in animal studies, including AT1 
antagonists (angiotensin-converting enzyme inhibitors) (34,35), AT2 agonists (AT1 
inhibitors, by not blocking AT2) (35), statins (36), and cyclooxygenase-2 inhibitors 
(37). In rat models, the nonsteroidal anti-inflammatory drug naproxen induced PF 
(38). Interestingly, Rothenbacher et al. (32) observed a decreased incidence of 
pancreatic exocrine insufficiency in patients taking angiotensin-converting enzyme 
inhibitors, possibly due to antifibrotic effects of angiotensin-converting enzyme 
inhibitors on the pancreas. These studies suggest that drugs can infl uence the 
PSCs. However, considering the fact that evidence on this subject is derived mainly 
on laboratory and animal studies, the possible consequences of these drugs on 
human PF are not known.
With regard to histology, there are three major limitations to the present study: (i) no 
information about the samples ’ location in the pancreas, (ii) estimated quantification 
of PF, (iii) no additional PF staining, and (iv) no information about postmortem 
sampling time. The exact sample location was not known in our study. We assumed 
that the distribution of PF is uniform, but the actual PF pattern with respect to 
location in the pancreas is not known. However, in a study in rats, Wittel et al. (23) 
reported that cigarette smoke – induced pancreatic lesions were distributed 
throughout the entire gland without a greater prevalence in one specific area.
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The scoring of the pancreas fibrosis was performed via estimation, which is subjective. 
However, many pathological scores that are based on estimation of quantity (for 
instance, the non-alcoholic-steatohepatitis (NASH) score (24) and other PF scoring 
studies (30) are used in scientific papers and clinical practice. This study used hema- 
toxylin/eosin staining for the quantification of PF. Fibrosis could easily be detected 
and quantified by estimation (see Figure 3). Because all slices were quantified in this 
manner, the (in)accuracy of estimating the amount of PF was consistent.
To date, no paper has reported the optimal postmortem sampling time for the 
pancreas. Only one letter to an editor suggested that the optimal sampling time is 
within 7 h ( 39 ). However, we do not know whether the scoring of fibrosis is 
negatively influenced by the sampling time, nor do we know the effect of the 
presence of fibrosis on the quality of the sample. Therefore, we think this is an 
interesting question that needs further investigation. To minimize this postmortem 
sampling time bias, we excluded all pancreatic samples for which there were signs 
of autolysis of the ductal epithelium, which resulted in exclusion of 42 specimens.
Figure 3   Hematoxylin and eosin – stained histology of the pancreas with respect to 
pancreatic fi brosis and lipomatosis
(a) normal histology, (b) interlobular fibrosis, (c) intralobular fibrosis, and (d) pancreatic lipomatosis.
a
c
b
d
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Hypothesis
The key player in PF is the PSC. PSCs, which are located in the interacinar spaces, 
account for ~ 4 % of all pancreatic cells in the healthy pancreas (26). PSCs exhibit 
limited proliferation and are characterized by the presence of vitamin A – containing 
fat droplets and absence of α-smooth muscle actin expression (26,40– 42). PSCs 
are activated by both internal stimuli (cytokines and growth factors produced by 
tumor cells, inflammatory cells, or injured resident cells) and external stimuli 
(oxidative stress, hyper glycemia, and alcohol) (26,40– 44). Aft er stimulation, PSCs 
phenotypically transform into myofibroblast-like cells that proliferate at high rate, 
lose the retinoid-containing fat-droplet synthesis ability, and produce large amounts 
of extracellular matrix proteins (mainly collagen type 1, laminin, and fibronectin) 
(41,42). Activated PSCs are capable of migration and phagocytosis (26), and they 
stimulate PC cell growth, angiogenesis, and desmoplastic reaction of PC (40,45). 
Hypothetically, oxidative stress induced by cigarette smoke and tobacco 
components could result in activation of the PSCs, which eventually results in PF, 
as our study suggests. Interestingly, in this study, the amount of intralobular, but not 
inter lobular, PF correlated significantly with cigarette smoking, which could be 
explained partly by the periacinar anatomical position of the PSCs.
In conclusion, cigarette smoking induces PF (mainly intralobular) in humans. This 
study provides additional evidence for the theory that smoking induces chronic 
pancreatic inflammation. Given that PF is associated with nearly all benign and 
malignant pancreatic diseases, smoking behavior should be accounted for in all 
studies and clinical practice when pancreatic disease is a potential confounder, 
and patients with pancreatic diseases should be encouraged to quit smoking.
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This thesis addresses studies concerning acute and chronic inflammation of the 
pancreas. The first part of the thesis contains studies regarding the diagnosis, 
treatment and incidence of acute biliary pancreatitis and azathioprine induced 
acute pancreatitis. The second part concerns the influence of obesity and smoking 
on the   clinical course of pancreatitis and morphological aspects on the pancreas. 
Part 1 Biliary and drug induced pancreatitis
In (chapter 1) an update is given concerning the etiology and diagnosis of acute 
biliary pancreatitis. Establishing a biliary etiology in acute pancreatitis is clinically 
important because of the potential need for invasive treatment, such as endoscopic 
retrograde cholangiopancreatography (ERCP) or a subsequent laparoscopic cho-
lecystectomy. The etiology of acute biliary pancreatitis (ABP) is multifactorial and 
complex. A diagnosis of a biliary etiology in acute pancreatitis is supported by both 
laboratory and imaging investigations. An increased serum level of alanine amino-
transferase (>1.0 μkat/l) is associated with a high probability of gallstone pancreatitis 
(positive predictive value 80–90%). Confirmation of choledocholithiasis is most 
accurately obtained using endoscopic ultrasonography or magnetic resonance 
cholangiopancreatography.
In (chapter 2) an evaluation of the treatment of acute biliary pancreatitis is given. A 
systematic review of previous meta-analyses and guidelines on ERCP in ABP was 
performed. There is consensus in both the meta-analyses and guidelines that 
ERCP is indicated in case of ABP with coexistent cholangitis and/or persistent 
cholestasis. By exception of the first meta-analysis, all included studies agreed that 
there is no place for early ERCP in predicted mild ABP. Consensus is lacking 
regarding the role of early ERCP in predicted severe ABP as 3 of the 8 meta-analysis 
and 1 of the 11 guidelines do not advice this strategy. Routine early ERCP in 
predicted severe ABP is recommend in 6 of the 11 guidelines. Indication of an 
endoscopic sphincterotomy is not well defined in meta-analyses and guidelines. 
In the light of the somewhat confusing and in part conflicting recommendations 
found in (chapter 2) we investigated the opinion and attitude of Dutch gastroenter-
ologists toward the application of (early) ERCP in the clinical management of ABP 
by means of a nationwide survey (chapter 3). In this survey, the vast majority of 
Dutch gastroenterologists attest to a role for ERCP in ABP, but indications when to 
perform ERCP, its timing, and the application of ES vary greatly and are not always 
in line with the Dutch or other published national guidelines. The results of this 
survey highlight the need for additional comparative randomized studies to define 
the role of (early) ERCP in ABP.
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(Chapter 4) addresses the different treatment options for preventing recurrent 
attacks of acute biliary pancreatitis (RABP) including conservative treatment, 
 cholecystectomy, ES, and combinations of these options. From the observational 
literature data it can be concluded that ES is as effective in reducing RABP as 
 cholecystectomy but inferior in reducing mortality and overall morbidity. The 
combination of ES and cholecystectomy seems superior to either of the treatment 
methods alone. A prospective randomized clinical trial comparing ES plus chole-
cystectomy with cholecystectomy alone is needed.
In (chapter 5) the cumulative incidence and patient characteristics of thiopurine-
induced acute pancreatitis in IBD patients is evaluated. Several reports suggest an 
increased rate of adverse reactions to azathioprine in patients with Crohn’s disease. 
The cumulative incidence of thiopurine-induced acute pancreatitis in Crohn’s 
disease equaled that of ulcerative colitis (UC) (2.6% vs. 3.7%) and this did not differ 
from vasculitis patients (2.6% vs.1.9%). In the IBD group, 100% of thiopurine- induced 
acute pancreatitis patients were women, whereas in the vasculitis group the two 
observed thiopurine induced acute pancreatitis cases (n = 2 of 2) concerned were 
men (P = 0.012). In this study, the alleged higher cumulative incidence of thiopurine 
induced acute pancreatitis in Crohn’s disease compared with vasculitis or UC patients 
was not confirmed. 
Part 2  Clinico-morfological studies on pancreatic lipomatosis and 
pancreatic inflammation
Obesity and insulin resistance cause fatty infiltration of many organs, including 
the pancreas (pancreatic steatosis [PS]) and the liver (nonalcoholic fatty liver 
disease [NAFLD]). In (chapter 6) we observed a relation between interlobular and 
total pancreatic fat with the NAFLD activity score, in patients without steatogenic 
medication. When corrected for body mass index (BMI), no relation could be 
found. Total pancreatic fat was a significant predictor for the presence of NAFLD 
but not for NASH. Presence of intralobular pancreatic fat was related to 
nonalcoholic steatohepatitis (NASH). This chapter demonstrates a relationship 
between NAFLD and PS, and, intralobular pancreatic fat and NASH. This 
relationships seem to be mediated by general obesity. The clinical significance of 
pancreatic steatosis is reviewed in (chapter 7). Multiple definitions, clinical 
associations and synonyms for pancreatic steatosis are described in the literature 
and can be confusing. In the past, pancreatic steatosis was considered an 
innocuous condition, a bystander of many underlying diseases (such as 
congenital syndromes, hemochromatosis and viral infection). However, evidence 
that pancreatic steatosis (strongly associated with obesity and the metabolic 
syndrome) has a role in type 2 diabetes mellitus, pancreatic exocrine dysfunction, 
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acute pancreatitis, pancreatic cancer and the formation of pancreatic fistula after 
pancreatic surgery is emerging. 
In (chapter 8 ) the relation between (central) obesity and predicted severe acute 
pancreatitis is studied. Via a post-hoc analysis of a observational, multicenter study 
we included patients with a primary episode of predicted severe acute pancreatitis 
from a larger cohort of patients enrolled in a previous randomized clinical trial. 
Multivariable analysis showed an association between mortality and high waist 
circumference (WC)/BMI (OR 10.0, 95% C.I. 1.89-52.7), and a lower BMI (OR 0.84, 
95% C.I. 0.71-0.99). For morbidity, multivariable analysis showed an association 
with a higher WC/BMI (OR 11.5 95% C.I. 2.07-63.8) and CTSI (OR 9.81, 95% C.I.: 
3.22-29.2) and a lower BMI (OR 0.79, 95% C.I.: 0.66-0,94). With regard to ICU 
duration of stay, univariable analysis revealed an association between the CTSI 
(p<0.0001), ventral-dorsal umbilical waist diameter (p<0.0001) and the WC 
corrected for BMI (p=0.003). This is the first study to show that the “obesity 
paradox” also exists in patients with predicted severe pancreatitis. Mortality in 
obese patients with predicted severe pancreatitis is only higher as compared to 
non-obese patients when they suffer from central overweight. Whereas mortality in 
obese patients without central overweight is lower.
In chapter 9 we investigate the effect of tobacco smoking on pancreatic inflammation 
and fibrosis. Smokers are at risk for pancreatic cancer (PC) and other pancreatic 
diseases. Cigarette smoking also aggravates the risk of PC in patients with hereditary 
and chronic pancreatitis (CP) and results in a higher incidence of acute pancreatitis 
and relapses in CP. Both PC and CP are characterized by a progressive fibrosis. In 
this retrospective study, we aimed to confirm a relationship between cigarette 
smoking and pancreatic fibrosis (PF) in humans, via pancreatic tissue acquired 
during autopsy. PF was scored by assessing severity of intralobular, extralobular, 
and total PF: grade 0 (normal or mild; 0-25% PF), grade 1 (moderate; 25-50% PF), 
and grade 2 (severe; >50%). Grade 2-3 total PF and intralobular PF was significantly 
more present in smokers vs. “never-smokers” (total: 42.9 vs. 26.5%, P=0.027 and 
intralobular: 39.3 vs. 15.6%, P=0.013), whereas no differences could be found between 
never-smokers and ex-smokers and between ex-smokers and smokers. 
future PersPeCtIves
Acute bilairy pancreatitis and drug induced pancreatitis
The role of an early ERCP in the treatment of predicted severe acute biliary 
pancreatitis will be investigated in the new APEC-trial (Acute Bilary Pancreatitis; 
early ERC/ES versus conservative treatment), that will start in the end of 2012. This 
trial will be coordinated by the Dutch Pancreatitis Study Group. In the RABP-study 
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(a follow-up study of the APEC: Recurrent Acute Biliary Pancreatitis Study) the rates 
of recurrent acute bilairy pancreatitis and other bilairy events will be studied in the 
cholecystectomy versus cholecystectomy /ES versus ES group (patients unfit for 
surgery). The outcome of this study will bring about the need of an updated biliary 
pancreatitis guideline. (New) Guideline adherence can be tested in the future via an 
questionnaire.
The literature on drug induced pancreatitis is scarce. Thiopurine induced pancreatitis 
seems to be an idiosyncratic reaction. However, after an e-mail correspondence 
with Professor Sachar (Mount Sanai Medical Center, New York), a dose dependent 
relationship seems to exist. He described a young male patient with Crohn disease 
(CD), who developed thiopurine induced pancreatitis after increasing the dosage of 
6-MP. Re-challenge resulted in the same clinical picture. Additionally, in my IBD- 
praxis, I observed a similar case (young male, CD, acute pancreatitis after dose 
increase of 6-MP). Further investigation, in terms of genetic susceptibility, interval 
between drug initiation and development of pancreatitis and the presence or absence 
of thiopurine induced pancreatitis in 6-TG users will give us a more detailed picture 
of this disease.
Clinico-morfological studies on pancreatic lipomatosis and 
pancreatic inflammation
Pancreatic steatosis is a relatively new clinical entity. Little is known about its 
pancreatic distribution. A radiological and pathological study would give an insight 
in this topic or further studies. Normal value’s of pancreatic steatosis and its relation 
to other syndromes and diseases are barley known. Case finding studies would be 
very welcome to define the quantity of steatosis in relation to certain diseases. The 
role of abdominal fat in relation to survival and morbidity in acute pancreatitis is 
getting clearer. However, more research in terms of fat-distribution, nutritional status, 
smoking behavior in relation to morbidity and mortality in acute pancreatitis is need.
The role of smoking and pancreatic diseases is clearly underlined in the last years. 
However, exact mechanism of inflammation, fibrosis (pancreatic stellate cel activation) 
genetic susceptibility and its clinical consequences, such as: pancreatic insufficiency, 
operative outcome (after Whipple: peri-operative and long term morbidity and 
mortality), are unknown. 
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nederlAndse sAmenvAttInG
InleIdInG
Een aanval van een acute alvleesklierontsteking (acute pancreatitis) komt in de 
wereld voor met een aantal van 5-80 per 100.000 inwoners per jaar (jaarlijkse 
incidentie).  In Nederland is deze jaarlijkse incidentie 19 per 100.000 inwoners per 
jaar. Tussen de 3 en 10.7 procent van de patiënten met een aanval van een acute 
pancreatitis sterft er tussen de 3 en 10.7%. Helaas blijft het sterfte percentage de 
laatste 4 decennia stabiel. De twee meest voorkomende ooraken van acute 
pancreatitis (70-80% van alle oorzaken)zijn galwegstenen en alcohol. Andere 
oorzaken zijn: buiktrauma, ischemie, chirurgie, ERCP, pancreaskanker, anatomische 
varianten van het galwegsysteem/pancreas, autommuun ziekten, hyperlipidemie, 
drugs, geneesmiddelen, infecties, genetisch en idiopathisch. Het geslacht is sterk 
geassocieerd met het risico op een aanval van acute pancreatitis. Mannen krijgen 
vaker een alcoholische pancreatitis en vrouwen vaker een galsteen (of biliaire) 
pancreatitis.
oPBouw vAn Het ProefsCHrIft
Het proefschrift bestrijkt gebieden in de pancreatologie:
1. Klinische studies naar biliaire en geneesmiddel geïnduceerde acute pancreatitis
2. Clinico-morfologische studies naar pancreasvervetting en pancreasverbind-
weefseling/ontsteking.
deel 1  Klinische studies naar biliaire en geneesmiddel geinduceerde 
acute pancreatitis
Hoofdstuk 1
Het vaststellen van een biliaire etiologie in acute biliaire pancreatitis (ABP) is van 
klinisch belang, omdat ere en potentiele behandeling kan plaats vinden met een 
ERCP. De etiologie van een ABP is multifactorieel en complex.  De passage van 
kleine galblaassteentjes of sludge (zandachtig gruis), door de uitgang van de 
galwegen naar de 12-vingerige darm lijkt belangrijk voor de pathogenese. Andere 
factoren lijken ook hun steentje bij te dragen, zoals: anatomische varianten (inductie 
van biliopancreatische reflux), gal en pancreassap exclusie van de 12-vingerige 
darm (duodenum), en genetische factoren. De diagnose van een ABP wordt 
ondersteund door laboratoriumwaarden en beeldvorming. Een verhoogd serum 
ALT van meer dan 1μkat/l is geassocieerd met een hoge kans op een biliaire vorm 
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van pancreatitis (positieve predictieve waarde van 80-90%). De bevestiging van 
galwegstenen wordt het meest accuraat gedaan met een endo-echo of MRCP.
Hoofstuk 2
Verschillende gerandomiseerd studies hebben de rol van een ERC en endo- 
scopische sphincterotomie (ES) bestudeerd in ABP.  In dit hoofdstuk worden de 
uitkomsten van verschillende meta-analysen en richtlijnen naast elkaar gelegd 
om te bekijken of er een internationale conscensus is m.b.t .de behandeling van 
acute biliaire pancreatitis. Doormiddel van een systematische review (en de 
 PRISMA-richtlijnen) wordt er een literatuur search gehouden. Uit deze review kwam 
naar voren dat er consensus was over de behandeling van patiënten met een ABP 
en cholangitis en blijvende cholestase, heirbij is een snelle ERCP/ES geïndiceerd. 
In vormen van voorspeld milde ABP wordt op 1 meta-analyse na, geadviseerd om 
de patiënt conservatief te behandelen. In het geval van een voorspeld ernstige 
ABP zijn de uitkomsten en aanbevelingen van meta-analysen en richtlijnen sterk 
verdeeld.
Hoofdstuk 3
In hoofdstuk 4 bestuderen we de opinie en attitude van de Nederlandse endoscopist/ 
MDL-arts, aangaande de behandeling van ABP: vroege ERCP/ES versus een 
conservatieve aanpak. Via een enquête onder al de MDL-artsen (n=283, respons 
ratio van 52%) kwam naar voren dat 96.6% van de MDL-artsen een rol zag 
weggelegd voor een vroege ERCP bij de behandeling van ABP. Veertien procent 
van de ondervraagde gaf zelfs aan altijd een ERCP/ES te verrichten bij een ABP. De 
rest van de groep gaf aan, onder bepaalde voorwaarden een ERCP te verrichten, 
zoals: gedilateerde galweg (95%), galwegstenen (72%), cholangitis (87%), geelzucht 
(59%), ampullaire steen (68%), en bij een voorspeld ernstige ABP (35%). De helft 
van de ondervraagden vonden een ERCP binnen 24 uur na opname of klachten het 
beste tijdstip voor een ERCP. In 55% van de gevallen, waarbij er een ERCP wordt 
verricht,  wordt er zo wie zo een ES verricht, zonder duidelijke reden. Deze enquête 
laat zien dat de overgrote meerderheid geloofd in een vroege ERCP/ES bij ABP. 
Echter, de timing, indicatie en applicatie van een ES zijn niet altijd in overeenkomst 
met de Nederlandse richtlijnen. Deze studie geeft aan dat er eendduidelijkere 
studies en richtlijnen op dit vlak gewenst zijn. 
Hoofdstuk 4
Een hernieuwde aanval van een ABP (HABP) kan worden voorkomen dor een gal-
blaasverwijdering (de bron van galsteen aanmaak). Sinds de introductie van de 
ERCP/ES, zijn er verschillende series die een gelijkwaardige preventie beschrijven 
m.b.t. het voorkomen van een HABP in vergelijking met een galblaasverwijdering.
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In hoofdstuk 4 reviewen we de verschillende behandelingsopties aangaande de 
preventieve behandeling voor het tegengaan van een HABP, zoals een conservatieve 
therapie, galblaasverwijdering, ERCP/ES en combinaties van beide opties. De 
uitkomsten waren als volgt: een galblaasverwijdering en ERCP/ES waren superieur 
t.o.v een conservatieve behandeling in het voorkomen van HABP. Echter een gal-
blaasverwijdering geeft ook bescherming tegen galsteen/blaas gerelateerde 
complicaties. Observationele studies laten zien dat een combinatie van een gal-
blaasverwijdering en ERCP/ES een lagere aantal HABP geven dan een van de 
modaliteiten alleen. Het is noodzakelijk deze strategie uit te zoeken in een 
prospectieve gerandomiseerde studie.
Hoofdstuk 5
In hoofdstuk 5 onderzoeken we of de bewering van verschillende studies of de 
kans op een thiopurine geïnduceerde pancreatitis hoger is in patiënten met M. 
Crohn (CD) dan in patiënten met een colitis ulcerosa (CU) of vasculitis (VA). Door 
middel van een retrospectieve studie met data uit 3 ziekenhuizen (241 patienten 
met CD en CU, 108 patienten met VA). De cumulatieve incidentie van thiopurine-
geinduceerde acute pancreatitis verschilde niet tussen de CD en UC groep (2.6% 
vs 3.7%). Ook de was de cumulatieve incidentie van patienten met CD of UC niet 
verschillend van de VA-patienten. Er bestond een duidelijke vrouwelijke predominantie 
bij de thiopurine geïnduceerde pancreatitis bij IBD patiënten. Terwijl in de VA groep 
er alleen maar mannen met een thiopurine geïnduceerde pancreatitis waren. 
deel 2  Clinico-morfologische studies naar pancreasvervetting en 
pancreasverbindweefseling/ ontsteking.
Hoofdstuk 6
Overgewicht en insuline resistentie zorgen voor een vettige infiltratie van meerdere 
organen, zoals: pancreas (pancreatische steatose-PS) en lever (nonalcoholic fatty 
liver disease-NAFLD). Doormiddel van een post-mortum studie op 80 patiënten 
worden de coupes van de lever en het pancreas bestudeerd op de vervettings-
graad. De interlobulaire en totale vervetting graad van het pancreas zjn gerelateerd 
aan de aanwezigheid van NAFLD. De intralobulaire vervettingsgraad was 
gerelateerd aan de aanwezigheid van non-alcoholic steato-hepatitis (NASH). Dit is 
de eerste studie in de literatuur, die een relatie tussen NASH en PS laat zien.
Hoofdstuk 7
De verschillende definities en associaties van/met klinische entiteiten en PS worden 
onderzocht in een pubMed search. Vroeger dacht men dat PS een “onschuldige 
voorbijganger” was. Echter, met de huidige associatie van PS met het metabool 
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syndroom, hemochromatose, virale infecties, exocriene pancreas insufficiëntie, 
acute pancreatitis, pancreas kanker en ontstaan van fistels na pancreas chirurgie, 
lijkt PS niet meer zo onschuldig.
Hoofdstuk 8
Zoals boven beschreven, lijkt het erop dat overgewicht leidt to een ernstiger verloop 
van een aanval et acute pancreatitis. Dit blijkt uit meerdere studies en meta-analysen. 
Echter, obese mensen hebben een hogere incidentie van acute pancreatitis, wat 
leidt tot een over-representatie van obese patiënten in een acute pancreatitis cohort. 
Verder is het percentage voorspeld ernstige acute pancreatitis hoger bij obese dan 
bij niet obese patiënten, hetgeen automatisch leidt tot een over- representatie van 
ziekere patiënten in de obesitas-groep, waardoor het lijkt dat het obees zijn 
gecorreleerd is aan een slechtere overleving bij patiënten met een acute pancreatitis. 
In studies met kritisch zieke patiënten komt juist naar voren dat obese mensen juist 
beter overleven dan magere of mensen met een normaal postuur. Worden ze ernstig 
obese kan neemt de sterfte kans weer toe. Dit fenomeen wordt de omgekeerde 
J-curve (overleving versus BMI) of Obesity-Paradox genoemd. In hoofdstuk 8 wordt 
via een post-hoc analyse van een observationele, multicenter studie, waarbij er 
alleen patiënten met een ernstige pancreatitis worden geincludeerd, gekeken of een 
hoog BMI en andere antropometrische waarden leiden tot een grotere morbiditeit 
en mortaliteit. Bij 144 patiënten met een voorspeld ernstige pancreatitis kwam uit 
de multivariabele analyse naar boven dat de sterfte kans toenam bij patiënten met 
een normaal of laag BMI en een hoge buikomvang gerelateerd aan de BMI (WC/
BMI, afgeleide van abdominaalvet). Uit deze studie kun je concluderen dat een 
hoog BMI leidt tot minder kans op sterfte bij obese patiënten met een voorspeld 
ernstige pancreatitis, tenzij de patiënten een centrale (abdominale) obesitas hebben.
Hoofdstuk 9
Rokers hebben meer risico op het krijgen van pancreas kanker, exocriene en 
endocriene pancreas insufficiëntie, chronische pancreatitis en acute pancreatitis. 
Zowel pancreas kanker als chronische pancreatitis hebben pancreas fibrose als 
gezamenlijke uiting van inflammatie. Twee ratten studies hebben een verband laten 
zien tussen pancreas fibrose/ inflammatie en roken. In hoofdstuk 9 bestuderen we 
het rookgedrag in relatie tot de pancreasfibrose d.m.v. een post-mortum studie. 
De pancreasfibrose werd gescoord (kwantitatief d.m.v. schatting) in relatie tot het 
rookgedrag. In 111 patienten werd dit onderzoek verricht, waarbij het opviel dat 
matig-ernstige totale fibrose en intra-lobulaire fibrose vaker voorkwam bij rokers 
dan bij niet rokers (totaal: 42.9 vs. 26.5 % , P = 0.027 and intralobular: 39.3 vs. 15.6 
% , P = 0.013). Dit is de eerste humane studie die een relatie tussen pancreas 
fibrose en het rookgedrag legt.
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Vooraleer personen specifieker te danken, Vang ik met een  
allesomVattende dank aan, Voor iedereen in mijn omgeVing die  
me de afgelopen jaren heeft gesteund en/of moeten lijden  
aan aandachttekort, kribbigheden en soortgelijke uitingen/ 
omstandigheden. oftewel: “DAnk AAn AllEn DIE zICh gEmEEnD 
gEDAnkT TE moETEn voElEn. ook DIE DAT nIET voElEn, mAAr WEl 
gEDAnkT bEhorEn TE WorDEn, DAnk!”
Beste Chris, door je creatieve en avontuurlijke geest, blijf je een collega met een 
enorm enthousiastmerende houding, die warmte, oprechtheid en collegialiteit uitstraalt. 
Ik ben je ongelofelijk dankbaar dat je me aannam voor de opleiding tot MDL-arts en 
me alle vrijheid gaf om aan een proefschrift te werken. Je “out of the box denken” 
en daarbij ver voor de troepen uit lopen, werkte bij mij stimulerend en gaf me een 
bevrijdend gevoel. Een gevoel van een vrije geest! 
Beste Marco, je toomloze inzet, geduld, creativiteit, empathie, scherpe kritiek, 
fijnzinnige adviezen en steun, die je me de afgelopen jaren hebt gegeven, zijn van 
onschatbare waarde geweest voor het tot stand komen van dit proefschrift en de 
positie die ik heden ten dage bekleed. Ik ben onder de indruk van de “Realpolitik” 
die jij bedrijft. Ik hoop nog veel projecten met je te kunnen afronden!
Beste, Donald. Dank voor je kritische beschouwingen en analyses, aangaande 
patiëntenzorg en wetenschap, tijdens en na mijn opleiding. Zonder je motiverende 
aanwezigheid was dit proefschrift onderhevig aan uitstelregelingen geweest. Ik ga je 
missen in het Oosten van het land. Kom gerust een keer (rook) uitblazen op de hei!
Beste Thomas, het is een genoegen om met je te werken. Dankzij je interesse, inzet, 
kennis/kunde, gezelligheid en doorzettingsvermogen kon ik hoofdstuk 8 schrijven. 
Gelukkig brengt onze samenwerking nog een mooie publicatie! Beste Hjalmar en 
Marc, dank voor jullie kritische blik, creatieve ideeën en lessen in de statistiek. Jullie 
professionaliteit, gedrevenheid, kennis en kunde is voor mij en vele anderen een 
voorbeeld.  
Beste Tim en Mark, zonder jullie was de vervetting van het pancreas nog een illusie, 
de fibrose in rook opgegaan, nu is het een feit geworden. Dank voor jullie gezellige en 
196
ADDENDUM
positieve inzet voor een gezamenlijk project dat uiteindelijk eindigde in 2 artikelen.
Beste Adje, gaag wil ik je bedanken voor onze samenwerking. Je compositielessen 
m.b.t .het schrijven van een artikel staan nog in mijn geheugen geschreven! 
Natuurlijk dank ik je ook voor de fantastische opleiding, die je me hebt meegegeven 
in en na de VU-tijd.
Beste Maarten, met geduld en humor bracht je me de beginselen van de EUS en 
advanced endoscopy bij. Ik ben je ontzettend dankbaar dat je me deze bagage 
hebt meegegeven en gegund. Hopelijk komen er nog vele congressen, waarbij we 
onze schoenen laten warmlopen voor de mooie zaken in het leven!
Beste Hans, als opleider was je stimulerend, geestig en warm. Dankzij je bevlogen- 
heid ben ik kunnen gaan starten met dit proefschrift. Beste Dimitri, dank voor je 
geduldige lessen in de beginselen van het “schuiven”, later enthousiasmeerde je 
me om endomucosale resecties te gaan leren. Natuurlijk denk ik nog aan de lange 
schuifdagen en dat we met buikpijn van het lachen de tent verlieten.
Beste Mike, als begenadigt endoscopist, clinicus en levensgenieter heb ik veel 
steun aan je gehad tijdens de academische MDL-vorming. Klinkende wijze woorden 
werden als door een berg weerkaatst.
Beste (ex)-maten van de maatschap interne/MDL van het ziekenhuis Bronovo. Ik 
heb genoten van mijn lidmaatschap in het netste ziekenhuis van Nederland. Beste 
Jan, Yvo, Tom, Nir, Egbert-Jan, en Edith, dank zij jullie vertrouwen in dit project en 
de tijd die ik er vrij voor kreeg, kon ik dit proefschrift afronden. Dank voor jullie steun 
toen ik er alleen voorstond!  Beste “pensioenado’s”, alhoewel jullie de pensioenge-
rechtigde leeftijd hebben, doet jullie enthousiasme, energie, kennis en humor aan 
een andere decade denken. Sjoerd, je ongelofelijke internoide diepgang maakt 
nog immer indruk op me, je hebt me de beschouwende kant van het vak laten 
reuken, proeven en doen toepassen. Beste, Jan, dank voor je luisterend oor en 
welgemeende adviezen. Je sprankelend frisse aanwezigheid, gaven kleur aan de 
donderdag! Speciaal wil graag Max Schrijver bedanken. Al die keren dat je waarnam, 
me geduldig de kunst van het canuleren en Haagse politiek bijbracht, staan nog 
immer in mijn geheugen gegrift.
Beste Dick, Lex, Frits en Juda, door jullie kritische interesse ontstond de APEC- 
studie, welke via het Rijn-Ijsselland genootschap werd uitgebreid via een GUTCLUB 
collaboratie naar een landelijke studie. Lex, dank voor je adviezen. Mede hierdoor 
had ik de gelegenheid om in de ULB-keuken mee te kijken! 
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Beste Frans Mol, ontzettend bedankt voor je steun en geloof in mij. Zonder jou was 
ik nooit in Leipzig beland en zeer waarschijnlijk nooit een MDL-arts geworden.
Beste Jan Haus, dank voor het bij brengen van de grondbeginselen van de chirurgie 
en wetenschap. Je bent een sociaal bewogen, stimulerende opleider. Ondanks 
deze fijne tijd heb ik Leipzig vaarwel gezegd. Hopelijk, respecteer je mijn overstap 
naar de MDL en kunnen we samen verder met onderzoek naar een prachtig orgaan! 
Beste Theo van Vroonhoven, graag dank ik je voor je wijze lessen. Je doorzettings-
vermogen, ambities, fenomenale klinische/ chirurgische inzichten en betrokkenheid 
bij de patiënt zijn nog immer een voorbeeld en maatstaf voor me. 
Lieve Pa en Ma, zonder jullie onvoorwaardelijke steun en bagage, die jullie me hebben 
(mee)gegeven, was me dit nooit gelukt. “Repraesentat commodis”!
Lieve opa en oma, dank voor jullie steun, interesse en mooie kaft van dit proefschrift. 
Ik besef maar al te goed dat ik bevoorrecht ben om jullie allen nog om mij heen te 
hebben! Beste Anne-Lies, dank voor je hulp bij het inscannen.
Lieve Antoinette,  ik dank voor je begrip, steun, liefde en wijsheid. Zonder jou bleef 
het proefschrift een gedachtespinsel zonder einde. Je schonk me vrijheid, rust en 
begrip, en het hoogst haalbare voor een man op deze aarde: pappa worden! Lieve 
Quinten en Xavier, pappa heeft genoten van jullie tekensessie’s op zolder. Jullie 
brachten kleur aan de zonderlinge dagen en gaven me kracht om door te gaan!
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Na zijn opleiding werd hij maatschapslid van de afdeling MDL in het Bronovo 
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